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 Colorectal cancer is a leading cause of cancer-related death, particularly in developed 
countries. In Singapore, colorectal cancer has emerged as the top malignancy in the 
population. Epidemiological and experimental studies have shown the negative 
correlation between high dietary fiber intake and incidence of this disease. It was 
discovered that butyrate, derived from the anaerobic fermentation of indigestible fiber, is 
responsible for the protective effects of fiber in colorectal cancer prevention. 
Physiological concentrations of butyrate promote proliferation in normal colonic 
epithelial cells but induce cell maturation via promoting growth arrest, differentiation 
and/or apoptosis in colorectal cancer cells. Our earlier work had shown that butyrate 
initiates growth arrest and apoptosis in HCT-116 cells at 24h treatment. To better 
understand the ‘blueprint’ of butyrate’s chemopreventive role in this disease, we used an 
integrated proteomics approach to identify the proteins and cellular processes involved 
during the maturation of butyrate-treated colorectal cancer cells.  
 Firstly, we performed 2-dimensional difference gel electrophoresis (2-D DIGE) of 
24h butyrate-treated HCT-116 cells to identify protein targets of butyrate that are 
involved in the initiation of growth arrest and apoptosis. To delve deeper into the 
proteome, we pre-fractionated the cell lysate using heparin affinity chromatography prior 
to 2-D DIGE. A combination of this enrichment step with overlapping narrow range IPGs 
(pH 4-7 and pH 6-11) in 2-D DIGE resulted in the detection of 46 differentially 
expressed spots. Twenty-four of these were identified by MS analyses, five of which 
were shown to be isoforms of heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). 
 viii
Three of the isoforms of hnRNP A1 with Mr of 38kDa were down-regulated while two 
with Mr ≈ 26kDa were up-regulated. These represent phosphorylated isoforms of hnRNP 
A1 as verified by immunoblotting with anti-phosphotyrosine and anti-phosphoserine 
antibodies. Using 2-DE, subcellular fractionation and western blot analyses, we further 
showed that full-length hnRNP A1 underwent down-regulation, cleavage and 
cytoplasmic retention upon butyrate treatment. These indicate that modulations of hnRNP 
A1 may play a role in the initiation of growth arrest and apoptosis in cancer cells by 
butyrate. 
Secondly, in order to understand the progression of cell maturation induced by 
butyrate, we performed quantitative proteomics using iTRAQ, a stable isotope labeling 
methodology that enables multiplexing of 4 samples, for a temporal study of butyrate 
treatment. In addition, cICAT which selectively tags cysteine-containing proteins was 
used, and the results complemented that obtained from the iTRAQ strategy. These 
‘bottom-up’ multiplexed proteomics approaches coupled to a high-throughput 2-D LC 
MALDI-TOF/TOF MS platform identified several proteins refractory to separation by 
2-DE. Selected protein targets were validated by real-time PCR and western blotting. A 
model was proposed to illustrate our findings from this temporal analysis of 
butyrate-responsive proteome which uncovered several integrated cellular processes and 
pathways involved in growth arrest, apoptosis, and metastasis. These signature clusters of 
butyrate-regulated pathways are potential targets for novel chemopreventive and 
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Chapter 1    INTRODUCTION 
 
1.1 COLORECTAL CANCER (CRC) 
1.1.1 Epidemiology of CRC – High Incidence Rate 
Colorectal cancer (CRC) is a malignancy that affects the large intestine, 
particularly the colon and rectum. CRC is the third most common cancer in both men and 
women, and is one of the top leading causes of cancer-related death worldwide. About 1 
million new cases of CRC are reported annually. This accounts for almost 10% of 
cancers in the world. In addition, CRC has a high mortality rate; approximately 500,000 
deaths are reported annually (Kamangar et al., 2006; Figure 1.1). 
The prevalence of CRC is found to correspond to the socioeconomic affluence of 
the population. This is reflected in the incidence rate of CRC in developed countries, 
which is 4-fold higher than that in developing countries. In the developed countries, CRC 
is a prevalent disease with a cumulative lifetime risk of 5% and a 5-year mortality rate of 
50%. In 2006, approximately 140,000 new cases were diagnosed in the United States and 
more than 50,000 CRC-associated deaths were reported (Jemal et al., 2006). In Singapore, 
there has been a dramatic increase in the incidence rate of CRC during the last few 
decades. CRC is currently the most commonly diagnosed malignancy in Singapore (Lee 
et al., 2007). Undoubtedly, CRC has become a major public health burden both locally as 
well as worldwide. Thus, it is imperative to develop new preventive and therapeutic 




1.1.2 Low Survival Rate of Patients with Late Stage CRC 
Clinical evidence clearly showed that early detection and removal of precancerous 
adenomatous polyps (abnormal outgrowth of colonic mucosal lining) can significantly 
reduce the incidence and mortality rates of CRC (Winawer, 2005). The detection of CRC 
at an early stage (T1N0M0, Stage A; see Section 1.1.3 for the staging system) allows the 
attainment of a 5-year survival rate of more than 90% for patients with localized tumour. 
However, due to the asymptomatic nature of CRC during the development of the 
adenomas, about 50% of the CRC patients are likely to progress to metastatic disease 
before being diagnosed. Indeed, approximately 75% of the newly diagnosed patients are 
already at the advanced stage (Stage IV) and their 5-year survival rate is reportedly only 
5% (Rougier and Mitry, 2003). The high mortality rate of CRC is largely due to the 
extensive metastatic spread of colorectal cancer cells, with secondary hepatic tumour 
being the most common occurrence. Even upon curative surgery and adjuvant 





Figure 1.1 Worldwide incidence and mortality of cancers, according to the cancer 
site and sex. CRC is the third most common malignancy, after lung and stomach cancer, 
in both men and women worldwide (Reproduced from Kamangar et al., 2006; reprinted 
with permission of American Society of Clinical Oncology). 
 
1.1.3 Staging Systems for CRC 
Cancer staging estimates the degree of tumour penetration and spread, and is used 
to determine the best treatment regimen for each patient. The TNM system (Fleming et 
al., 1997) and Duke’s classification (Dukes, 1932), which rely on the histopathological 
patterns of the tumours, are the most commonly used staging systems for CRC (Table 1.1 
and 1.2). Other staging systems for CRC include the Astler-Coller system (Astler and 
Coller, 1954) and the Gunderson-Sosin modification of Astler-Coller system (Gunderson 
and Sosin, 1974). The TNM system was introduced by the American Joint Committee on 
 4
Cancer (AJCC) and is mainly based on the size and degree of invasion of the primary 
tumour (T), extent of lymph node involvement (N) and degree of metastasis (M). The 
Duke’s staging system is grouped into 4 categories viz. Stage A, B, C and D, and its 
classification basis is similar to the TNM system (Table 1.1 and 1.2).  
The staging of tumour is also used as a prognostic indicator for cancer patients. 
Individuals with localized primary tumours (Stage I; T1-2, N0, M0) are mostly curable 
with 5-year survival rates of more than 90%, whereas those with the involvement of 
lymph nodes have survival rates as low as 30%. Patients at the advanced stage with 
metastatic spread of the tumour (Stage IV) have a 5-year survival rate of only 5% (Table 
1.1). Hence, those patients at the advanced stage with invasive and metastatic neoplasia 
(Stage IV or D) have a much poorer prognosis, i.e. lower survival rate than those at the 
early stage (Stage I or A) (O'Connell et al., 2004). Unfortunately, as discussed, due to the 
asymptomatic nature of this cancer, the number of CRC patients diagnosed at the 












Table 1.1 The TNM staging system (AJCC). The TNM staging system is largely based 
on the size and degree of invasion of the primary tumour (T), extend of lymph node 
involvement (N) and degree of metastasis (M) (Source: Adapted from Wolpin et al., 
2007). 
 
TNM Stage Description 
T - Size, degree of invasion of primary tumour 
  
T0 No tumour 
Tis Tumour in situ 
T1 Invasion through submucosa into lamina propria 
T2 Invasion into the muscularis propria 
T3 Invasion through the muscularis propria 
T4 Invasion of surrounding structures or with tumour cells on the free external surface of the bowel 
  
N - Involvement of lymph nodes 
  
N0 No lymph nodes involved 
N1 One to three nodes involved 
N2 Four or more nodes involved 
  
M - Degree of metastasis 
  
M0 No metastasis 
M1 Presence of metastasis 
  
AJCC TNM 5-Year Survival Rate 
0 Tis, N0, M0 100% 
I T1, N0, M0, or T2, N0, M0 >90% 
IIA T3, N0, M0 60-85% 
IIB T4, N0, M0 60-85% 
IIIA T1-2, N1, M0 55-60% 
IIIB T3-4, N1, M0 35-42% 
IIIC Any T, N2, M0 25-27% 
IV Any T, Any N, M1 5-7% 
 6
Table 1.2 The modified Duke’s classification system for CRC. Similar to the TNM 
system, the Duke’s classification is mainly based on the degree of invasion of the primary 
tumour, involvement of lymph nodes, and degree of metastasis. There is a higher 
incidence but lower survival rates for patients at the advanced stages than those at the 
early stages (Source: Adapted from Bosman, 1995). 
 
Modified 




Tumour is limited to the muscular 
mucosa and submucosa of the bowel 
wall 
15% >90% 
    
B Tumour invades through the intestinal wall 35% 70% 
    
B1 Cancer extends into but not through 
the muscularis propria. 
  
    
B2 Cancer extends through the muscle but 
does not involve lymph nodes. 
  
    
C Involvement of lymph nodes 50% <30% 
    
C1 Cancer is contained within the 
confines of the bowel wall and 
involves lymph nodes. 
  
    
C2 Cancer extends through the bowel 
muscle wall and involves lymph nodes
  
    
D Cancer has metastasized to organs 
such as the liver, bone or lung 
10% 5-10% 









1.1.4 Screening Tools for CRC Diagnosis 
Early detection and surgical removal of colorectal precancerous polyps provide a 
better prognosis. The use of various screening tools for CRC, such as the fecal occult 
blood testing (FOBT), double contrast barium enema (DCBE), flexible sigmoidoscopy 
and colonoscopy, improved the diagnosis rate of CRC and thus helped to reduce the 
mortality rate of CRC (Winawer et al., 1993; Towler et al., 1998; Thiis-Evensen et al., 
1999). Although biannual FOBT reduced about 20% of CRC-related mortality, this 
detection method was also reported to have low specificity and/or low sensitivity. Serum 
carcinoembryonic antigen (CEA), the broadly used colon tumour serum prognostic 
marker, also suffered from frequent false positives and false negatives (Kahlenberg et al., 
2003). Flexible sigmoidoscopy decreased 60% of CRC-associated death, and 
sigmoidoscopy followed by colonoscopy can reduce up to 80% of CRC incidence. 
However, the discomfort and risks associated with the invasive screening tools used in 
sigmoidoscopy and colonoscopy, such as pain, perforation and bleeding are intolerable to 
many asymptomatic average-risk individuals. This has resulted in a low response from 
the public to the screening programs. 
Although CRC is a treatable disease, it relies on an effective and routine 
population screening program for early diagnosis to improve the survival rate of patients. 
Furthermore, counseling and specialized screening programs are required for high risk 
groups with hereditary colorectal disorders. A current diagnostic challenge for the clinical 
management of CRC is to design better screening methods or identify novel diagnostic 
and prognostic biomarkers that are of high specificity and sensitivity. 
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1.1.5 Etiology of CRC – Hereditary or Sporadic Disease 
Etiologically, CRC is primarily classified as inherited, e.g. familial adenomatous 
polyposis (FAP) and hereditary nonpolyposis colon carcinoma (HNPCC), or sporadic 
disease. Inherited CRC is responsible for about 20% of this disease whereas sporadic 
CRC accounts for 80% of the cases (Burt, 1996). While inherited CRC is largely caused 
by genetic perturbations, sporadic CRC is influenced by both genetic and environmental 
factors. 
High-risk symptoms of patients with inherited CRC include diagnosis under the 
age of 45, presence of multiple colonic malignancies, and a family history of colonic or 
extracolonic cancer. These individuals, who have low survival rates, carry germline 
genetic mutations that accelerate the initiation and progression of CRC (Chung, 2000). 
The life-time risk of developing CRC for individuals with first-degree and/or 
second-degree relatives who are CRC patients is 20%, and reaches 80% to 100% in FAP 
and HNPCC patients. 
Inherited CRC has been well characterized for developmental and genetic 
alterations associated with tumour progression (Gayet et al., 2001). Genetic alterations 
tend to arise from activation of oncogenes, inactivation of tumour suppressors or 
disruption of the mismatch repair system. Notably, genetic lesions that disrupt the 
homeostatic balance among cellular proliferation, differentiation and apoptosis are the 
key causes of colorectal carcinogenesis (Ilyas et al., 1999; Calvert and Frucht, 2002). For 
example, mutational modifications in hallmark genes including APC, K-Ras, p53, BRAF, 
SMAD4, PIK3CA and TGFBR2, are found to disrupt growth signaling pathways or 
genomic stability and promote colorectal carcinogenesis. 
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Generally, there are two major processes involved in the development of CRC. 
The first involves mutation of specific genes in the adenoma-carcinoma sequence; the 
second involves genome instability in the microsatellite instability pathway. Through a 
series of accumulated mutations in hallmark genes including adenomatous polyposis coli 
(APC), deleted in colorectal cancer (DCC), p53 and K-Ras, CRC develops from a benign 
polyp or adenoma in the gastrointestinal tract to a dysplastic lesion and then to malignant 
tumour (Fearon and Vogelstein, 1990). APC functions in the regulation of cellular 
proliferation via the WNT signaling pathway. Mutation or deletion of the tumour 
suppressor activities of APC promotes hyperproliferation of the colonic epithelium. More 
than 90% of FAP individuals carry germline mutations in the tumour suppressor APC. 
Subsequently, mutations in oncogene K-Ras and tumour suppressor p53 result in their 
activation and loss of function, respectively. K-Ras functions in cell growth and survival 
in the mitogen-activated protein kinase (MAPK) pathway, whereas p53 plays a major 
role in inhibiting angiogenesis, and triggering apoptosis in response to DNA damage. 
This molecular and histological transformation from a normal mucosa to invasive tumour 
spans over 10-20 years, and this process is known as the adenoma-carcinoma sequence. 
This pathway is commonly found in FAP patients and is characterized by the appearance 
of numerous adenomatous polyps that become cancerous if they are not surgically 
removed.  
Besides FAP, HNPCC (or Lynch syndrome) is the other main group of familial 
CRC cases. A majority of the HNPCC patients possesses germline mutations (loss of 
activity) in DNA mismatch repair genes, most frequently in MSH2, MLH1, MLH6 and 
PMS2. The inactivation of the DNA mismatch repair system causes the inability to 
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recognize and repair base-pair mismatches during DNA replication. This results in a 
further disruption of genome integrity. Genomic instability, i.e. inability to maintain 
fidelity of genomic sequence, accelerates the accumulations of genetic and epigenetic 
alterations which promote the initiation and progression of CRC. This pathway is known 
as the microsatellite instability pathway. Genomic instability in CRC comprises of 
microsatellite instability (MSI), chromosomal instability (CIN) and chromosomal 
translocations (Stoler et al., 1999; Grady, 2004). 
Sporadic CRC, which constitutes 80% of CRC cases, may be caused by genetic 
factors (Burt, 1996). Inactivation of APC and mismatch repair genes, which occurs in 
patients with inherited CRC, is also found in sporadic CRC patients who have no 
evidence of inheritance disorders. However, sporadic CRC is largely caused by 
environmental factors. As discussed, epidemiological studies have shown that the 
incidence of CRC reflects socioeconomic affluence of the population. There is an up to 
25-fold variation in the prevalence of CRC worldwide; the incidence rate of CRC in 
developed countries is greater than that in developing countries (Kamangar et al., 2006). 
Most of this geographical variation is caused by risk factors associated with lifestyle 
practices, such as physical activities and types of dietary habits. Indeed, clinical and 
experimental evidence have strongly implied that dietary factors contribute greatly to the 
etiology of CRC. 
 
1.1.6 Colorectal Carcinogenesis: Disruption of the Cell Maturation Pathway 
  The colonic cell maturation pathway is inevitably perturbed in colorectal 
carcinogenesis. The highly proliferative colonic mucosa undergoes a cell maturation 
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pathway during the self-renewal process. The renewal of colonic tissues involves 
well-controlled cellular differentiation and apoptosis which is crucial for the maintenance 
of intestinal tract homeostasis. In a normal colonic cell maturation pathway, the cells 
differentiate into functional intestinal cells, undergo senescence or die by apoptosis 
(programmed cell death). In the course of neoplastic transformation, mutations in growth 
control genes, such as oncogenes and tumour suppressors, result in uncontrolled cellular 
proliferation, failure to differentiate and/or abnormal pattern of cell death (Fearon and 
Vogelstein, 1990). The progression from precancerous polyps to malignant colorectal 
tumours implicates the disruption of the colonic cell maturation pathway. Understanding 
the mechanism of CRC carcinogenesis, in particular the perturbation of the colonic cell 
maturation pathway will certainly help to identify valuable diagnostic markers and 
therapeutic targets that can prevent the onset of CRC or block its progression. 
 
1.1.7 Clinical Management of CRC using Chemotherapy 
  Surgical resection of premalignant lesions by endoscopical polypectomy is the 
mainstay curative treatment for CRC patients with localized tumour (Duke’s A or TNM 
stage I). No adjuvant therapy is required for these individuals. Although a large number 
of CRC patients at Duke’s C or D stage with metastasis disease would likely die of 
recurrent cancer within 5 years of post-surgery (Rougier and Mitry, 2003), there is 
evidence that patients do benefit from post-operative adjuvant therapies, which lengthen 
their survival time and improve their quality of life. 
Chemotherapy is the main treatment for patients with advanced CRC. For almost 
four decades, 5-fluorouracil (5-FU) was the only anti-cancer drug available for CRC 
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patients. 5-FU acts on neoplastic cells by inhibiting thymidylate synthetase, the 
rate-limiting enzyme in pyrimidine nucleotide synthesis. Due to the low response rate to 
5-FU treatment in most CRC patients, several advancements in adjuvant chemotherapy 
have been introduced to reduce CRC recurrence and improve patient’s survival rate 
(Wolpin et al., 2007). For example, capecitabine is an oral fluoropyrimidine carbamate 
prodrug of 5-FU that has a better absorption rate in the GI tract than 5-FU. Other progress 
in chemotherapy for CRC includes the addition of bimodulating agent leucovorin (LV) to 
5-FU treatment. The current chemotherapy for metastatic CRC incorporates irinotecan (a 
topoisomerase I inhibitor) or oxaliplatin (a platinum compound) into the 5-FU/LV 
regimen and has been giving encouraging results. Irinotecan acts via inhibiting 
topoisomerase I leading to single stranded DNA breakages whereas oxaliplatin forms 
cross-linking DNA adducts to impair DNA replication in the cancer cells. 
With an increasing understanding of tumour biology, several ‘targeted’ 
anti-cancer drugs that act on cancer-associated proteins have been developed for clinical 
trials. Novel ‘targeted’ biologic drugs such as bevacizumab (Avastin) and cetuximab 
(Erbitux) have been approved for chemotherapy in advanced CRC patients, and they 
target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor 
(EGFR) respectively (Van Custem et al., 2006). Both VEGF and EGFR are involved in 
metastasis-associated pathways and are reportedly up-regulated in advanced CRC 
patients. ‘Targeted’ anti-cancer drugs have also been successfully used in combination 
chemotherapy for CRC patients. Hence, the development and incorporation of novel 
efficacious molecular-targeted therapeutic agents hold great promise in the clinical 
management of CRC patients. 
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Despite improvements in the efficacy of anti-cancer drugs, there is still a poor 
prognosis for late stage CRC patients. Moreover, there are many cytotoxic 
chemotherapies that destroy normal and neoplastic cells indiscriminately, and/or cause 
adverse side-effects such as gastrointestinal damage or cardiovascular toxicity. The 
development of more efficient and nontoxic chemotherapeutic agents is required to 
improve the quality of life and prolong the survival of CRC patients. 
 
1.1.8 Chemoprevention – A Better Strategy for CRC? 
With the existing lack of effective detection tools for early diagnosis and 
chemotherapeutic drugs for advanced CRC patients, administration of chemopreventive 
agents is an appealing strategy for this prevalent disease. Chemoprevention refers to the 
use of natural or synthetic agents to block, reverse, delay or prevent the onset, 
development or recurrence of malignant transformation (Gustin and Brenner, 2002; 
Greenwald et al., 2002). The long period (10 to 20 years) of CRC progression certainly 
provides a great opportunity for therapeutic interventions. There is a compelling need to 
search for potent chemopreventive agents that targets only cancer cells, but spares normal 
cells, to lower the prevalence of CRC (Arber and Levin, 2005). The elucidation of the 
underlying mechanism of these agents’ actions will facilitate the discovery of novel 
therapeutic targets and monitoring of anti-cancer drug’s responses. 
Various chemical agents have been found to induce transformed cells to undergo 
growth arrest or express differentiated phenotypes via activation of the appropriate 
cellular pathways. The identification of these pathways and their associated proteins 
could serve as leads for drug development. The observations that many of the 
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transformed cells respond to various cell cycle blockage, differentiation or apoptotic 
stimuli have suggested the possibility of using these stimuli as potential chemopreventive 
drugs (Marks et al., 2000; Okuno et al., 2004). Several compounds are shown to prevent 
the onset of polyps and halt the progression of CRC. For example, nonsteriodal 
anti-inflammatory drugs (NSAIDs) have been demonstrated to possess chemopreventive 
properties against CRC.  
 
1.1.9 Chemopreventive Agents for CRC 
NSAIDs e.g. aspirin and cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib, 
are promising chemopreventive agents that are shown to reduce the incidence of CRC 
and CRC-related death (Spychalski et al., 2007; Rostom et al., 2007). Aspirin is a 
nonselective NSAID that inhibits both COX-1 and COX-2 which are enzymes in the 
prostaglandin biosynthetic pathway. In particular, the expression level of COX-2 is 
up-regulated by pro-inflammatory cytokines and tumour promoters. The increased 
expression of COX-2 found in many cancers, including colon, liver, and lung, promotes 
angiogenesis and inhibits apoptosis in the tumour. Thus, COX-2 is found to be an 
attractive target for chemotherapy especially for colon cancer whereby chronic 
inflammation is one of the risk factor. Unfortunately, consumption of NSAIDs is found to 
be associated with adverse cardiovascular events and gastrointestinal hemorrhage. These 
side-effects have limited the usage of NSAIDs in average – risk individuals. 
Other examples of chemopreventive compounds with known efficacy against 
CRC include folate, calcium, selenium, vitamins (A and D), antioxidants and dietary 
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fibers. Interestingly, these compounds can be easily obtained from the diet or as 
supplemental medications. 
 
1.1.10 Dietary Habits Play a Crucial Role in CRC 
 The colonic mucosa is constantly exposed to various luminal contents. Increased 
consumption of diet containing red meat, preserved meat, animal saturated fats and 
alcohol was shown to promote tumour formation (Willett, 2000; Ferguson et al., 2004). 
These foods contain or generate mutagens, such as the N-nitroso compounds in preserved 
meat, and heterocyclic amines and polycyclic aromatic hydrocarbons from cooked meat. 
High intake of animal fats induced excretion of bile acids which can be converted to 
carcinogenic secondary and tertiary bile acids. Alcohol is converted to the carcinogen 
acetaldehyde by alcohol dehydrogenase 3 (ADH3) enzyme.  
On the other hand, intake of minerals, vitamins and indigestible fibers has been 
associated with a reduced incidence and growth of colorectal tumour (Howe et al., 1992; 
Greenwald et al., 2002; Bingham et al., 2003). Various “cancer blocking” or “cancer 
suppressing” agents in the diet have been identified (Manson et al., 2000). Other 
examples of dietary substances with potential chemopreventive properties include green 
and black tea polyphenols, curcumin, phenethyl isothiocyanate, lycopene and soy 
isoflavones. In general, modulation of dietary habits can be used as a chemopreventive 





1.1.11 Dietary Fibers Reduces the Risk of CRC 
 Though CRC develops from multiple genetic lesions, environmental factors, 
especially dietary habits, have a strong influence on this disease. Despite contradictory 
reports on the association of dietary fibers and CRC, several studies have strongly shown 
that high intake of fiber-rich foods reduces the incidence and growth of CRC (Howe et al., 
1992; Williams et al., 1999; Gill and Rowland, 2002; Key et al., 2002; Peters et al., 2003; 
Bingham et al., 2003). Burkitt (1971) was the first to suggest that bowel cancer and other 
diseases of the bowel can be prevented by high intake of fiber-rich diets. Three large 
prospective epidemiologic studies demonstrated that low-fiber diets exacerbate the risk of 
developing adenomas and hyperplastic polyps, whereas high intake of dietary fibers was 
inversely associated with the incidence of CRC (Howe et al., 1992; Bingham et al., 2003; 
Larsson et al., 2005). Howe et al. (1992) conducted a combined analysis of 13 
case-control studies from populations with different colorectal cancer rates and dietary 
practices, and reported a protective effect of fibers on CRC. The European Prospective 
Investigation into Cancer and Nutrition (EPIC) study that involved 520,000 individuals 
from 10 European countries strongly illustrated the protective role of dietary fibers in 
reducing the risk of CRC (Bingham et al., 2003). The EPIC study showed that in 
populations with low intake of food fibers, doubling of total dietary fiber intake could 
reduce the risk of CRC by 40%. Nonetheless, the molecular mechanisms underlying how 
alimentary fibers exert anti-carcinogenic effects on CRC are still poorly characterized.  
 
1.2 BUTYRATE 
1.2.1 Production of Butyrate from Dietary Fibers in the Colon 
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Dietary fibers are unabsorbable plant components consisting of mainly non-starch 
polysaccharides and non-polysaccharides, such as celluloses, hemicelluloses and pectins. 
It is believed that intake of dietary fibers reduces the risk of CRC in part by binding 
putative carcinogens so that their concentration in the large intestine is lowered. In 
addition, since dietary fibers increase fecal bulking, the intestinal transit time is shortened 
which will enable putative carcinogens to be egested more quickly. 
Notably, a wealth of studies has shown that short-chain fatty acids (SCFAs), 
particularly the 4-carbon butyrate (structural formula = CH3CH2CH2-COOH) which is 
derived from the colonic fermentation of indigestible carbohydrates, is responsible for the 
chemopreventive properties of a fiber-rich diet (Cummings, 1981; Cummings and 
Macfarlane, 1991; Van Munster and Nagengast, 1993; Barnard and Warwick, 1993; 
McIntyre et al., 1993; Heerdt et al., 1994; Scheppach et al., 1995; Hill, 1995; Hassig et 
al., 1997; Perrin et al., 2001). SCFAs, including butyrate, acetate and propionate, are 
formed when undigested fibers, resistant starch and other saccharides are fermented by 
anaerobic saccharolytic microflora in the large bowel (D’Argenio and Mazzacca, 1999). 
The different type and degree of fermentability of the fibers affect the composition of 
SCFAs produced in the colon. For example, the fermentation of wheat bran was found to 
produce a high concentration of butyrate (McIntyre et al., 1993). The same study also 
showed that butyrate produced from intake of such insoluble fibers protected against 
colon cancer. During carbohydrate fermentation, two molecules of acetyl CoA are 
required to form acetoacetyl CoA for butyrate production. Acetoacetyl CoA is then 
converted to butyryl CoA via the intermediates β-hydroxybutyryl CoA and crotonyl CoA. 
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Subsequently, butyrate is formed from butyryl CoA via butyrate kinase or butyryl 
CoA:acetate CoA transferase (Pryde et al., 2002; Louis et al., 2007). 
Butyrate is absorbed in the colon and metabolized by the colonic epithelial cells 
as an energy source (Cummings et al., 1987). After absorption, most of the butyrate is 
metabolized via β-oxidation in mitochondria to provide up to 80% of respiratory fuel for 
cellular proliferation in normal colonocytes (Roediger, 1982; Ardawi and Newsholme, 
1985; Scheppach, 1994). The main products of butyrate metabolism in the colonic 
epithelium are ketone bodies (acetoacetate and β-hydroxybutyrate), carbon dioxide and 
water. Butyrate that is not metabolized is transported by the hepatic portal vein to the 
liver. 
The production of butyrate in colon strongly influences the turnover rate of 
normal colonic epithelium. Butyrate exists in the colon lumen at 2-10mM (Cummings, 
1981) as a physiological survival factor for the maintenance of a healthy colonic mucosa 
(Luciano et al., 1996; Hass et al., 1997; Wachtershauser and Stein, 2000). The formation 
of butyrate in the colon results in colonic acidification which reduces the solubility of 
free bile acids and inhibits the transformation of primary bile acids to tumourigenic 
secondary bile acids (Wong et al., 2006). Intriguingly, butyrate has been demonstrated to 
exert potent chemotherapeutic effects on various cancer cells. 
 
1.2.2 Butyrate Mediates Cell Maturation in Colon Cancer Cells 
 Butyrate is avidly absorbed by the colonocytes via passive diffusion of its 
undissociated form (in the distal colon), counter-transport with bicarbonate (apical end of 
colonocytes) or paracellular diffusion of its anionic form (in the proximal colon) 
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(Velazquez et al., 1997). The monocarboxylate transporter (MCT1) protein localized on 
the luminal membrane of colonocytes was found to play an important role in transporting 
butyrate into the colonic cells (Ritzhaupt et al., 1998). Interestingly, Ritzhaupt and 
coworkers also showed that the expression of MCT1 is lower in colonic carcinomas 
compared to normal colonic tissues. Hence, the down-regulation of MCT1 expression 
during colon carcinogenesis corresponded to its role in importing butyrate to maintain 
colonic mucosa homeostasis (Daly et al., 2005; Cuff et al., 2005; Thibault et al., 2007). 
Likewise, SLC5A8 which belongs to the Na(+)/glucose co-transporter gene family  was 
recently shown to mediate the entry of butyrate into colonic epithelial cells and this 
supports the role of this plasma membrane transporter as a potential tumour suppressor 
(Ganapathy et al., 2005; Gupta et al., 2006). 
  Whilst butyrate serves as a major energy source for normal colonocytes (Roediger, 
1982), in vivo and in vitro studies have shown that at physiological concentrations, this 
natural occurring SCFA modulates a variety of fundamental cellular processes in cancer 
cells (Barnard and Warwick, 1993; Heerdt et al., 1994; Hague et al., 1995; Miller, 2004). 
Millimolar concentrations of butyrate mediate cell maturation in cancer cells via the 
induction of growth arrest at G0/G1 phase (Coradini et al., 2000), followed by the 
reappearance of phenotypic markers of differentiation (Augeron and Laboisse, 1984; 
Whitehead et al., 1986; Gamet et al., 1992; Spira and Carducci, 2003), and/or stimulation 
of apoptotic cascades (Hague et al., 1993; Heerdt et al., 1994; Hague and Paraskeva, 
1995; Heerdt et al., 1997; McBain et al., 1997) in various cancer cells, including  
hepatoma (Yamamoto et al., 1998; Ogawa et al., 2004), pancreatic (Farrow et al., 2003), 
breast (Soldatenkov et al., 1998), prostrate (Kuefer et al., 2004), and colorectal cancer 
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cells (Barnard and Warwick, 1993; Augenlicht et al., 1995; Hague et al., 1995; Velcich et 
al., 1995; Mandal et al., 1997;). These biological effects are particularly crucial in 
colorectal cancer treatment as colonic transformation is characterized by perturbations of 
cellular proliferation, differentiation and apoptosis (Ilyas et al., 1999), and the resultant 
aberrant cell division and/or cell death (Fearon and Vogelstein, 1990; Bedi et al., 1995). 
Furthermore, butyrate is a natural byproduct in the colon that has no adverse effects on 
normal colonocytes. Hence, butyrate acts as a natural physiological regulator of healthy 
colonic mucosa. 
 
1.2.3 Butyrate Acts as a Chemopreventive and Chemotherapeutic Agent 
Butyrate is a remarkable chemopreventive and chemotherapeutic agent as it is 
able to reverse malignancies and at the same time to serve as a key source of energy for 
normal colonic epithelial cells (Hill, 1995; Hass et al., 1997). Butyrate was also found to 
suppress the growth of carcinogen-induced colorectal tumours in animal models 
(McIntyre et al., 1993; D’Argenio et al., 1996; Medina et al., 1998; Bauer-Marinovic et 
al., 2006). For example, McIntyre et al. (1993) illustrated an inverse association between 
the colon tumour size and luminal butyrate concentration in rat models. Likewise, 
Medina et al. (1998) showed that intracecal administration of butyrate halted the growth 
of 1, 2-dimethylhydrazine (DMH)-induced tumours in rats. 
Butyrate also represses intestinal inflammation and assists in mucosal repair in 
inflammatory conditions (D’Argenio and Mazzacca, 1999). A long-standing history of 
inflammatory bowel disease (IBD), e.g. Crohn’s disease and ulcerative colitis (UC), is 
one of the risk factors for the onset of CRC. In addition to its protective role in neoplastic 
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conditions, insufficient production of butyrate correlated with the incidence of Crohn’s 
disease and UC. The anti-inflammatory property of butyrate has been demonstrated, such 
as the inhibition of TNF-α – induced inflammatory responses and cytokine-induced 
NFκB activation. On a similar note, butyrate is currently undergoing clinical trials for 
IBD (Scheppach et al., 1992; Galvez et al., 2005).  
Butyrate exists as an important natural constituent of the luminal content, and thus 
has been purported to be a potential non-toxic chemopreventive and chemotherapeutic 
agent in cancer treatment, such as for CRC (Velazquez and Rombeau, 1997; Chen et al., 
2003). This has initiated several notable research in identifying proteins and pathways 
that contributed to the mechanism underlying butyrate’s anti-cancer effects (Siavoshian et 
al., 1997; Archer et al., 1998a), particularly in its protective role against CRC. These 
butyrate-responsive proteins and pathways could serve as potential targets for novel 
anti-cancer drugs. 
 
1.2.4 Butyrate is a HDAC inhibitor (HDACi) 
Studies have shown that cellular exposure to butyrate resulted in a range of 
changes in the nucleus, including hyperacetylation of histones (Riggs et al., 1977; Sealy 
and Chalkley, 1978), DNA hypermethylation and high-mobility group modifications (de 
Haan et al., 1986), all of which led to modulation of gene expression. Although the 
molecular mechanism of butyrate’s multifunctional actions is not fully understood, 
butyrate is known to inhibit histone deacetylases (HDACs) resulting in remodeling of 
chromatin architecture and regulation of gene expression (Marks et al., 2000; Hinnebusch 
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et al., 2002). Indeed, butyrate’s role as a HDAC inhibitor (HDACi) contributes to its 
anti-cancer effects. 
The equilibrium between histones acetylases (HATs) and HDACs, which 
acetylate and deacetylate histones respectively, determines chromatin structure, and 
regulates gene expressions and downstream biological processes (Wolffe, 1996; 
Grunstein, 1997; Kuo and Allis, 1998). There are 18 mammalian HDACs, which are 
classified into four classes (I-IV) based on three properties: (1) homology to prototypical 
HDACs in yeast, (2) subcellular localization and (3) enzymatic activity. Inhibition of 
Class I and II HDACs by butyrate caused hyperacetylation of histones (particularly H3 
and H4) which led to nucleosomal unfolding and increased accessibility to specific 
transcription factors (Boffa et al., 1978; Hebbes et al., 1988). This altered gene 
expressions and brought about butyrate’s physiological effects (Della Ragione et al., 
2001). For example, the transcriptional induction of cell cycle inhibitor p21WAF1/Cip1 and 
subsequent growth arrest in the G0/G1 phase by butyrate was proposed to be mediated by 
histone hyperacetylation (Siavoshian et al., 2000; Chai et al., 2000). 
Several findings have also identified non-histone cytosolic protein substrates of 
HDACs, including p53, tubulin, Ku70, Hsp90, and NFκB, which modulates cell survival. 
Acetylation of proteins alters their stability, localization, protein-protein interactions and 
functional activities. For example, acetylation of p53 increases its stability and tumour 
suppressor activity. The identification of a diverse group of non-histone protein targets of 
HDACs stimulated efforts aiming to map the ‘acetylome’ (Kurdistani et al., 2004; 
Minucci and Pelicci, 2006). This would help to elucidate the role of acetylation and 
subsequently, the mechanism behind HDACi’s anti-cancer actions.  
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1.2.5 The Association of HDACs with Cancer 
The identification of butyrate as a prototypical HDACi (Candido et al., 1978; 
Davie, 2003) corroborated with findings that showed over-expression or anomalous 
recruitment of HDACs (Zhu et al., 2004; Wilson et al., 2006), or inactivation of HATs 
and aberrant acetylation in several malignancies (Kouzarides 1999; Marks et al., 2001a). 
Accumulation of genetic and epigenetic alterations drive colorectal carcinogenesis (Jones 
and Baylin, 2002), and the loss of acetylation on histone H4 is a hallmark of cancer cells 
(Fraga et al., 2005). Hypoacetylation and hyperacetylation are closely associated with 
neoplastic processes (Archer and Hodin, 1999; Kim et al., 2003). Over-expression of 
HDAC 1, 2, and 3 was found in human cancers and their expression levels were 
down-regulated by HDACi during epithelial cell maturation (Zhu et al., 2004; Huang et 
al., 2005; Wilson et al., 2006). Furthermore, the anti-cancer effects of butyrate were 
blocked when HDACs were over-expressed (Zhu et al., 2004). Wilson et al. (2006) 
showed that silencing of HDAC 3 resulted in cell cycle arrest and differentiation in colon 
cancer cells. Hence, the inhibition of HDACs by butyrate ‘reversed’ the aberrant 
epigenetic alterations in colon cancer cells thus stimulating the cell maturation pathway. 
 
1.2.6 HDACi as Prospective Anti-Tumoural Drugs 
HDACi include SCFAs, hydroxamic acids, cyclic tetrapeptides and benzamides, 
e.g. sodium butyrate, trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA) and 
valproic acid (VPA). Butyrate is the smallest HDACi known. Escape from differentiation 
and/or apoptosis is an essential step in the course of colorectal carcinogenesis. Several 
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tumour cell types are shown to be highly sensitive to butyrate and other HDACi via 
activation of these pathways (Gibson et al., 1992; Marks et al., 2000; Shao et al., 2004; 
Marks and Jiang, 2005). HDACi attenuated carcinogenesis by disrupting cell cycle 
progression, inducing differentiation and/or apoptosis in several cancer cells including 
breast, prostate, neuroblastoma, colorectal, hepatoma and hematologic malignancies 
(Marks et al., 2000; Herold et al., 2002; Johnstone, 2002). Having little or no toxicity to 
normal cells or tissues, HDACi such as butyrate, VPA and SAHA are portrayed as 
prospective anti-tumoural drugs (Kelly and Marks, 2005; Secrist et al., 2003; Marks et al., 
2001b). Several HDACi e.g. butyrate, depsipeptide, SAHA, MS-275, and VPA were 
found to inhibit tumorigenesis in xenograft and mouse models, and portrayed promising 
anti-neoplasia efficacy in clinical trials, especially in solid and hematological 
malignancies (Kramer et al., 2001; Patnaik et al., 2002; Kelly et al., 2002; Johnstone, 
2002; Somech et al., 2004; Mei et al., 2004; Reid et al., 2004; Monneret, 2005; Bolden et 
al., 2006; Minucci and Pelicci, 2006; Perrine et al., 2007). 
The discovery of HDACi as potential anti-cancer agents provided an avenue for 
the identification of novel therapeutic targets and elucidation of the mechanism of their 
salutary properties. Findings from such work aimed to aid in the design of efficacious 
molecular-targeted anti-neoplastic drugs (Vigushin and Coombes, 2002; Rosato and 
Grant, 2003; Drummond et al., 2005; Dokmanovic and Marks, 2005; Acharya et al., 
2005; Taddei et al., 2005; Lin et al., 2006; Dashwood et al., 2006; Gallinari et al., 2007). 
HDACi are also shown to function synergistically with other biological and 
pharmacological anti-cancer agents. The combination of butyrate with a diverse group of 
compounds including bortezomib, 5-aza-2’-deoxycytidine, flavopiridol, TRAIL or 
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17-AAG was documented to enhance the induction of tumour cell death (Bolden et al., 
2006). Several models have been proposed to explain the synergistic actions of HDACi 
with these transcriptional modulators, death-receptor ligands, kinase inhibitors and 
regulators of proteasomal degradation system to aid in the design of better anti-cancer 
drugs. Currently, there are more than a hundred of ongoing clinical trials on HDACi as 
monotherapies or combination therapies (Dokmanovic et al., 2007). 
 
1.2.7 Butyrate Does Not Solely Inhibit HDACs 
Despite ongoing studies, the exact regulatory mechanism of gene expressions and 
therapeutic activities mediated by butyrate are still poorly understood. Studies have 
revealed that attenuation of HDAC activities by butyrate may be insufficient to explain 
its pleiotropic effects. Microarray studies have shown that only 2-8% of genes (up- and 
down-regulated genes) were regulated by HDACi despite the intricacy of their 
anti-tumoural effects (Van Lint et al., 1996). The expression level of p21 was found to be 
closely associated with growth arrest and apoptosis induced by HDACi, and other 
chemopreventive and therapeutic agents (Mahyar-Roemer and Roemer, 2001; Chopin et 
al., 2004). However, Kobayashi et al. (2004) reported that histone acetylation alone may 
be inadequate to cause transcriptional activation of p21 by butyrate. Siavoshian et al. 
(2000) reported that the effects of TSA, a specific HDACi, on cell cycle events and 
cellular differentiation are not identical to those induced by butyrate. TSA is a fungistatic 
antibiotic from Streptomyces platensis that elicited acetylation of histones by inhibiting 
HDACs. Recently, Stempelj et al. (2007) also showed that the chemopreventive and 
anti-inflammatory properties of butyrate are independent of HDACs activities. Besides 
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inhibiting HDACs, butyrate certainly mediates chemotherapeutic effects via several other 
routes. 
 
1.2.8 Butyrate Initiates Anti-Cancer Effects Through a Complex Cascade of 
Cellular Processes 
1.2.8.1 Butyrate Treatment Leads to Cell Cycle Arrest in Cancer cells 
Butyrate stimulates colonic carcinoma cell maturation; it induces cell cycle arrest, 
differentiation, and/or apoptosis in the cancer cells. Butyrate was found to induce 
transcriptional activation of cyclin-dependent kinase (Cdk) inhibitor p21WAFI/Cip1 in 
cancer cells which leads to cell cycle blockage at the G1 phase and inhibition of cell 
proliferation (Archer et al., 1998b; Siavoshian et al., 2000; Chai et al., 2000). The 
increased expression of p21 inhibited cyclin E-Cdk2 whose activity is required for 
phosphorylation of retinoblastoma protein (Rb) and release of E2F to activate genes 
associated with cell cycle progression at the S phase. Butyrate treatment in cancer cells 
also induced down-regulation of cyclin A and cyclin D, and up-regulation of cyclin D 
kinase inhibitor p16 (Schwartz et al., 1998) which further decreased cdk2 activity and 
promoted cell cycle arrest. Furthermore, butyrate inhibited thymidine kinase activity 
concomitantly with dephosphorylation of Rb and cell cycle arrest at the G0/G1 phase 
(Schwartz et al., 1998).  
Although Archer et al. (1998b) showed that up-regulation of p21 was required for 
growth arrest in response to histone hyperacetylation, Siavoshian et al. (2000) found that 
TSA did not reproduce every effect of butyrate. This demonstrated that butyrate’s 
anti-cancer activities required more than inhibition of HDACs. Indeed, butyrate also 
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down-regulated c-myc which led to reduced expression of its transcriptional target cyclin 
D (Heruth et al., 1993). In addition, butyrate blocked nuclear translocation of NFκB 
transcription factor, and cyclin D1 level was also regulated by this transcription factor 
(Inan et al., 2000). Hence butyrate modulates several regulators of cell cycle progression 
to induce growth arrest in cancer cells. Such butyrate-induced cancer cells may either 
undergo differentiation and/or apoptosis. 
 
1.2.8.2 Butyrate Induces Differentiated Phenotype in Colon Cancer cells 
Butyrate treatment induces an appearance of differentiated phenotype in colon 
cancer cells (Leder and Leder, 1975; Siavoshian et al., 2000). Carcinoembryonic antigen 
(CEA), a well known differentiation marker in colon carcinomas, was shown to be 
induced by butyrate in colon cancer cells (Velcich et al., 1995, Reynolds et al., 1998, 
Mariadason et al., 2000). Other evidence of butyrate’s function as a differentiation 
inducer in cancer cells includes its ability to reduce soft agar colonogenicity, increase 
colonocyte differentiation markers E-cadherin, sucrase and alkaline phosphatase, and 
elicit changes in morphology and ultrastructure (Kruh et al., 1982; Schroy et al., 1994; 
Butt et al., 1997). 
Several signaling pathways were reported to mediate cell differentiation induced 
by butyrate. Vitamin D receptor (VDR) was found to be involved in mediating 
butyrate-induced differentiation in colon cancer cells (Gaschott et al., 2001). p38 MAPK 
and TGFβ/Smad 3 – signaling pathways played key roles in the butyrate-mediated 
expression of VDR and induction of differentiation in colon cancer cells (Daniel et al., 
2004; Daniel et al., 2007). Using various protein kinase inhibitors, Orchel et al. (2005) 
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documented that the protein kinase C (PKC) and c-Jun NH2-terminal kinase (JNK) signal 
transduction pathways were required for butyrate-induced differentiation in colon cancer 
cells. In addition, Wang et al. (2007) showed that both PTEN protein and activation of 
JNK functioned in butyrate-mediated cell death and differentiation. Interestingly, the 
reduction of cell cycle promoter cyclin B and induction of p21 by butyrate in human 
colon cancer cells were shown to be associated with the promotion of differentiation as 
well (Archer et al., 2005). A recent work by Wang et al. (2008) illustrated that glycogen 
synthase kinase-3 (GSK-3) regulated nuclear p27(Kip1) expression and assembly with 
cdk2, which functioned to block cellular proliferation associated with intestinal cell 
differentiation. Besides mediating cellular differentiation, signaling pathways such the 
MAPKs, PI3K and NFκB were also shown to mediate butyrate-induced apoptosis (Ding 
et al., 2001; Wang et al., 2002; Lührs et al., 2002; Lévy et al., 2003). Interestingly, 
caspase activation and expression of anti-apoptotic members of the Bcl-2 family were 
found to be tightly associated with butyrate-induced terminal differentiation in colon 
carcinoma cells (Cai et al., 2004). 
 
1.2.8.3 Butyrate Activates Apoptotic Cascades in Cancer cells 
HDACi including butyrate induce apoptosis in cancer cells through activating 
various important mediators in both the death-receptor (extrinsic) and mitochondrial 
(intrinsic) apoptotic pathways (Bolden et al., 2006). Butyrate was found to sensitize 
colon cancer cells to the extrinsic apoptotic pathway mediated by Fas-ligand without 
regulating the expression of Fas ligand or receptor (Bonnotte et al., 1998; Giardina et al., 
1999). Chapkin et al. (2000) showed that this death-receptor apoptotic pathway is 
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required for the induction of apoptosis by butyrate in colon cancer cells. In addition, 
butyrate also sensitized cancer cells to TNF-α related apoptosis-inducing ligand 
(TRAIL)-mediated apoptosis (Hernandez et al., 2001; Inoue et al., 2002; Rosato et al., 
2003; Kim et al., 2004b). Butyrate-treated colorectal cancer cells up-regulated and 
activated BH3-only pro-apoptotic proteins, Bak and Bax (Mandal et al., 1998; Chirakkal 
et al., 2006), and down-regulated anti-apoptotic proteins, Bcl-2 and Bcl-XL (Mandal et al., 
1997; Hague et al., 1997). Butyrate also induced down-regulation of other anti-apoptotic 
proteins, such as XIAP and c-FLIP that blocked caspases activities, which further 
amplified the promotion of cell death in cancer cells (Natoni et al., 2005). In all, butyrate 
treatment led to the activation of caspase cascades in the apoptotic pathways. Medina et 
al. (1997) and Chai et al. (2000) have showed that butyrate activated caspases in cancer 
cells, which led to cleavage of several cellular proteins, such as poly-(ADP-ribose) 
polymerase (PARP) (Ruemmele et al., 1999), p21 (Chai et al., 2000) and adenomatous 
polyposis coli (APC) (Browne et al., 1994). One of the targets of active caspase is Bid, a 
pro-apoptotic member of the Bcl-2 family. The cleaved Bid (tBid) can insert into the 
mitochondrial membrane to promote the release of cytochrome c and trigger 
butyrate-induced mitochondrial apoptotic cascades. 
Butyrate can also induce apoptosis by modulating mitochondrial permeability 
transition such that pro-apoptotic cytochrome c is released into the cytosol thereby 
activating the caspase cascade through the mitochondrial-dependent pathway (Natoni et 
al., 2005; Emanuele et al., 2004; Ruemmele et al., 2003; Medina et al., 1997). In 
correlation to the reduced mitochondrial gene expressions and dysregulation of 
mitochondrial enzyme activities in colonic cancer cells, butyrate initiated growth arrest 
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and apoptosis by enhancing mitochondrial gene expressions and activities (Heerdt and 
Augenlicht, 1991; Heerdt et al., 1997). The mitochondrial electron transport and 
membrane potential are thus found to play critical roles in butyrate-mediated growth 
arrest and apoptosis (Heerdt et al., 2003; Heerdt et al., 2006). 
 
1.2.8.4 Other Players Involved in Butyrate’s Anti-cancer Effects 
It was demonstrated that butyrate improved the immunosurveillance of the gut by 
increasing the expression of antimicrobial peptides (Scheppach and Weiler, 2004) and 
activating gut-associated immune cells (Gupta et al., 2006). Perrin et al. (1994) showed 
that butyrate stimulated the immunogenicity of cancer cells, and Williams et al. (2003) 
proved that butyrate treatment enhanced the cell’s immunosurveillance and 
anti-inflammatory activities. Similarly, butyrate can inhibit mucosal inflammation via 
pathways including STAT1 (Scheppach and Weiler, 2004), COX 2 (Tong et al., 2005), 
nuclear factor kappa B (NF-κB) (Yin et al., 2001), and transforming growth factor beta 
(TGF-β) (Nguyen et al., 2006). 
Li et al. (2004c) showed that butyrate significantly reduced the metastatic 
potential of rat colon carcinoma cells. Butyrate was illustrated to possess anti-angiogenic 
properties via down-regulating the expression of two angiogenesis-associated proteins, 
vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1 alpha 
(HIF-1 alpha) (Pellizzaro et al., 2002). The lowered nuclear expression and activity of 
HIF-1 alpha in butyrate-treated Caco-2 cells led to decreased VEGF expression and 
anti-angiogenic effects (Zgouras et al., 2003). Butyrate also inhibited invasive human 
colon cancer cells by regulating proteolytic urokinase plasminogen activator (uPA) and 
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anti-proteolytic tissue inhibitors of metalloproteinase 1 (TIMP-1) and TIMP-2 activities 
(Emenaker et al., 2001).  
The ubiquitination-proteasome pathway has also been suggested to be involved in 
butyrate-induced growth inhibition, differentiation and apoptosis of colorectal carcinoma 
cells (Kim et al., 2004a; Tan et al., 2002). In addition, protein synthesis was found to be 
essential for the induction of cytochrome c – mediated apoptosis and activation of the 
ubiquitination-proteasome pathway by butyrate (Medina et al., 1997; Ruemmele et al., 
1999; Della Ragione et al., 2001; Drexler and Euler, 2005). Other effects of butyrate on 
cancer cells include the impairment of growth factor responsiveness (Archer et al 1998a), 
interruption of integrin-mediated signaling (Levy et al., 2003), increased susceptibility to 
oxidative stress (Li et al., 2004c), and modification of telomerase activity (Fajkus et al., 
2003; Choi et al., 2006; Xi et al., 2006). Undeniably, butyrate stimulates a complex 
cascade of cellular pathways which involved numerous protein targets to induce cell 
maturation in colonic cancer cells (Table 1.3). The complete mechanistic understanding 






Table 1.3 A complex cascades of cellular processes is involved in the anti-cancer effects of butyrate treatment which includes 
induction of cell cycle arrest, differentiation and apoptosis. ↑ represents increase and ↓ represents decrease. 
 
Cell Cycle Arrest Differentiation Apoptosis Other Effects 
 ↑ cdk inhibitor p21 
- inhibits cyclin E-cdk2 
 ↑ cyclin D kinase inhibitor 
p16 
 ↓ cyclin A and cyclin D 
 ↓ c-myc → ↓ cyclin D 
 Block NFκB nuclear 
translocation  
- Inhibits cyclin D 
 Inhibit thymidine kinase 
 ↑ Vitamin D receptor 
- p38 MAPK 
- TGFβ/Smad 3 
 Signaling pathways 
- Protein kinase C 
- C-Jun NH2-terminal 
kinase 
- PTEN protein 
- MAPKs, PI3K and 
NFκB 
 ↓ cyclin B and ↑ p21 
 Glycogen synthase 
kinase-3 (GSK-3) 
 Caspases activation 




 ↑ BH3-only pro-apoptotic 
proteins Bak and Bax 
 ↓ anti-apoptotic proteins 
Bcl-2, Bcl-XL, XIAP and 
c-FLIP 




- Cytochrome c release 
- Enhance mitochondrial 
genes expression and 
activities 
 Caspases activation 
 Immunosurveillance 





- STAT1, COX2, NFκB, 
TGF-β 
 ↓ metastatic potential 
 Anti-angiogenic 
- ↓ VEGF and HIF-1 




 Impair growth factor 
responsiveness 
 Increase susceptibility to 
oxidative stress 




1.2.9 ‘Butyrate Paradox’ or Phenotypic Specificity 
Butyrate serves as a metabolic fuel for normal colonic epithelial cells but it leads 
to growth inhibition and apoptosis in colon cancer cells (Hague et al., 1996). This 
paradoxical property of butyrate has supported its role as a lead for anti-cancer drug 
development. This ‘butyrate paradox’ has been reviewed by studies which showed that 
the differential response to butyrate depended upon physiological conditions such as the 
energy status and phenotype of the cells (Sengupta et al., 2006). The resulting 
pro-neoplastic or anti-neoplastic effects exhibited by the cells may depend on how 
butyrate is metabolized. Butyrate is metabolized to stimulate growth in atrophic 
colonocytes, probably due to the utilization of butyrate as a metabolic fuel by the colonic 
epithelial cells (Sengupta et al., 2006). On the other hand, butyrate required the presence 
of alternate energy sources to induce apoptosis in colorectal cancer cells (Singh et al., 
1997). Phenotypic specificity of butyrate’s effects was also demonstrated, as revealed by 
its anti-tumoural effects on non-differentiated hyperproliferative adenocarcinoma cells 
but promotion of regeneration of damaged cells in normal or differentiated epithelial cells 
(Comalada et al., 2006). Thus, the mechanism mediating the salutary effects of butyrate 
on colon cancer cells is strongly influenced by the external environment and cellular 
network responses, and requires further characterization. Since butyrate is a physiological 
mediator of colonic cell maturation, proteins or cellular processes regulated in 





1.2.10 Studies on the Global Targets of Butyrate 
Though the biological effects of butyrate are well documented, the complete 
understanding of butyrate’s anti-cancer mechanism is still far from complete. Numerous 
research have identified targets of butyrate to elucidate the molecular mechanism and 
signaling pathways that mediates its therapeutic effects. However, most of the 
investigations done on butyrate focused on one target at any one time and are thus unable 
to systematically elucidate butyrate’s mode of actions in an integrated manner. With the 
advancement of technology, recent work has sought to identify the global targets of 
butyrate, with the hope of uncovering the complete mechanism of butyrate’s action to aid 
in the discovery of potential therapeutic targets. For example, the first transcriptomic and 
proteome profile of butyrate-treated colonic cancer cells were reported by Mariadason et 
al. (2000) and Tan et al. (2002) respectively. 
 
1.3 FUNCTIONAL GENOMICS 
With the completion of genome sequencing for several organisms including 
humans, functional genomics in the post-genomic era aims to decipher the global gene 
functions in various cellular processes, such as responses to environmental factors, 
disease conditions and therapeutic interventions. This has driven the development and 
application of new technologies for large-scale and high-throughput analysis. Functional 
genomics provides an excellent route to the elucidation of the mechanism underpinning 




1.3.1 Gene Expression Study: Transcriptomics 
“Omics” such as genomics (genome study), transcriptomics (study of mRNA 
expression), proteomics (proteome analysis), interactomics (global protein-protein 
interactions) and metabolomics (study of metabolic status) involves the monitoring of 
thousands of genes/proteins/protein complexes/molecules on a system-wide level. 
Applications of the various ‘omics’ technologies in the biomedical field have helped to 
systematically characterize disease development and identify biomarkers and therapeutic 
targets. DNA microarray (also known as gene chip) is the typical tool used in 
transcriptomics or gene expression profiling to study quantitative gene expression (van 
Hal et al., 2000). The gene chip is widely used to investigate the regulation of genes 
expression in disease progression, staging and response to drug treatment (Mantripragada 
et al., 2004; Hoheisel, 2006). For instance, transcriptional profiling was reported to be 
able to predict clinical outcome and chemosensitivity (Staunton et al., 2001; van′t Veer et 
al., 2002). A genetic signature had also been proposed to predict recurrence of Duke’s B 
tumours (Wang et al., 2004b).  
The analysis of the transcriptomes of butyrate-treated colon cell lines using DNA 
microarray was first described by Mariadason et al. (2000), who showed that butyrate 
mediates a cell maturation pathway via genetic reprogramming to induce anti-cancer 
actions. Following this, several other DNA profiling studies were conducted to identify 
genes responsive to butyrate’s pleiotropic effects on colon carcinoma cells (Iacomino et 
al., 2001; Della Ragione et al., 2001; Germann et al., 2003; Daly et al., 2005; Daly and 
Shirazi-Beechey, 2006; Tabuchi et al., 2006). These gene expression studies have 
identified a number of gene targets of butyrate that functions in cell growth, 
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differentiation, apoptosis, oxidative metabolism, transport, and signaling. For instance, 
Iacomino et al. (2001) detected differential expression of several transcription factors 
related to cell growth, apoptosis and oxidative metabolism after butyrate treatment in a 
colon adenocarcinoma cell line. From an array of 19,400 genes in a human colonic 
epithelial cell line, Daly and Shirazi-Bechey (2006) identified 221 potential 
butyrate-responsive genes associated with proliferation, differentiation, and apoptosis. 
The changes in the expression levels of many of these targets were found to be opposite 
to that in colon cancer tissue. Recently, Tabuchi et al. (2006) identified 2,604 
differentially expressed probe sets from a mouse colonic epithelial MCE301 cells after 
butyrate treatment, which includes genetic networks for cellular development and cell 
cycles, and canonical pathways for fatty acid biosynthesis and pyrimidine metabolism. 
 
1.3.2 Proteomics: Proteome Analysis versus Genome Analysis 
Proteomics is the systematic analysis of the proteome, which is defined as the 
totality of proteins expressed by a genome (Wilkins et al., 1996). In comparison with 
genome analysis, investigation at the global protein level is a better representation of the 
dynamic biological system. Unlike the relatively static genome, protein molecules are the 
functional entities of cells and are in dynamic flux. They respond readily to exogenous 
stimuli such as dietary factors and pharmaceutical agents (Anderson and Anderson, 1998). 
Proteomics monitors and analyzes the molecular networks and fluxes within the living 
cells, as well as identifies molecular species that participate in these networks upon 
perturbation of cellular milieu (Godovac-Zimmermann and Brown, 2001). 
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Although transcriptomics facilitates one to investigate huge numbers of genes 
simultaneously, genomic data lacks information on the regulation of protein expressions, 
structures and functional activities which are not solely dependent on gene expression. 
Furthermore, there is a poor correlation between mRNA abundance and the 
corresponding protein expression level (Gygi et al., 1999b). Gene expression studies are 
also unable to predict post-translational modifications (PTMs) of proteins, e.g. 
proteolysis, acetylation, phosphorylation, and glycosylation. Most proteins undergo 
PTMs which affect protein folding, stability, trafficking, activity and function. Likewise, 
cellular localizations that define the proteins’ functional role are also not detectable from 
gene studies. Moreover, biological fluids such as urine and serum, which are ideal 
sources of biomarkers, do not contain nucleic acids, implying that nucleic acids may not 
be useful as biomarkers. Thus, mRNA expression studies must be supported with protein 
information to provide a complete picture of the cellular processes (Banks et al., 2000).  
 
1.3.3 Applications of Proteomics in Cancer Study 
Proteomics has the advantage of being non-prejudicial through unbiased search 
for novel relationships at the global protein level, and hence can delineate unexpected 
ways in which proteins modulate cellular responses to disease or therapy. Thus, data from 
proteome studies provide a superior insight into disease diagnosis, progression, 
prevention, and therapeutic intervention. Comparative proteomics (also known as 
differential expression proteomics) commonly contrasts the proteome profile of normal 
versus diseased or naïve versus drug-treated samples. As changes in protein expressions 
precede manifestations at the morphological level, these proteins may be used as disease 
 38
biomarkers, or as efficacy or toxicity markers in the screening of lead compound (Steiner 
and Witzmann, 2000). Thus it is not surprising that proteomics has been widely applied 
in the clinical and biomedical fields (Wasing and Corthals, 2002) to define the distinctive 
protein signatures and molecular pathways perturbed in disease or treatment. This is 
particularly applicable in cancer study as a complex cascade of cellular processes is 
involved during carcinogenesis and cancer therapy (Bichsel et al., 2001; Resing, 2002; 
Srinivas et al., 2002; Hanash, 2003). 
  Cancer remains a major public healthcare challenge due to the limited knowledge of 
the players and biochemical pathways involved in carcinogenesis. Moreover, the absence 
of effective biomarkers for early cancer detection necessitates the need to find new 
candidates as potential tumour biomarkers and therapeutic targets. Onco-proteomics, the 
characterization of cancer-associated proteins using proteomics, aims to understand 
carcinogenesis, and to unravel novel diagnostic biomarkers and therapeutic targets to 
improve cancer screening and drug development (Simpson and Dorrow, 2001; Martin 
and Nelson, 2001; Vlahou and Fountoulakis, 2005; Cho, 2007). The application of 
proteomics in drug research and development can also reveal proteins associated with 
drugs’ actions and resistance in cancers as well as develop personalized medicine in the 
future (Verrills and Kavallaris, 2003; Jain, 2004). Hence, proteomics offers a holistic 
approach to pharmacological investigation while greatly improving the understanding of 





1.4 PROTEOMICS IS A TECHNOLOGY – DRIVEN SCIENCE 
Proteomics deals mainly with high-throughput analysis of the total protein content in 
a cell or tissue (expression proteomics), identification of protein functions in a given 
biological context (functional proteomics), and study of protein-protein interactions (cell 
mapping proteomics) (Blackstock and Weir, 1999; Panisko et al., 2002; Tyers and Mann, 
2003). The human proteome is much more complex than its genome. In human, 
alternative splicing and RNA editing result in more than the ~25,000 putative protein 
coding genes. There is an estimate of over 1.5 million proteins due to the various 
processing and modifications occurring in a human cell. Hence, proteomics is a 
technology-driven science that necessitates a high level of separation, identification and 
quantification power using a plethora of state-of-the-art techniques to obtain a global, 
integrated view of the complex cellular processes and networks.  
 
1.4.1 Two-dimensional Gel Electrophoresis (2-DE) 
  High-resolution two-dimensional gel electrophoresis (2-DE) coupled with protein 
identification by mass spectrometry (MS) analysis has been the mainstay platform for 
differential expression proteomics (Klose, 1975; O’Farrell, 1975; Chambers et al., 2000; 
Rabilloud, 2002; Gorg et al., 2004). There is an extensive literature on the use of 2-DE in 
differential expression proteomics to visualize protein-related alterations upon changes in 
physiology due to diseases or treatment with therapeutic drugs (Issaq and Veenstra, 2007). 
A distinct advantage of applying 2-DE in proteomics is the technique’s ability to allow 
concurrent investigation of thousands of proteins in a single experiment, and to display 
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changes in protein expression levels and PTMs, which can be identified from the protein 
spot’s staining intensity and mobility shift respectively. 
  However, the 2-DE approach is technically demanding, labor intensive, and fraught 
with potential artifacts that hamper accurate comparison among gels. Undoubtedly, 2-DE 
requires manual dexterity and precision to obtain reproducible gels, and is not well-suited 
for high-throughput as this technique is not easily amenable to automation (Fey and 
Larsen, 2001). Hence, differential expression analysis in proteomics has been hindered by 
gel-to-gel variations (Gorg et al., 2000; Hanash, 2000).  
The protein universe of a cell is extremely complex and highly diverse with a 
large dynamic range of protein expression, post-translational processing and 
modifications, as well as protein-protein interactions. The dynamic range of a 2-DE gel 
image is ~104 (Rabilloud, 2002) whereas that of protein expressions in a given cell type 
reaches up to 7 to 8 orders of magnitude. Due to the limited loading capacity of a 2-DE 
gel, low-abundance proteins tend to be masked by house-keeping proteins present at 
several orders of magnitude higher (Gygi et al., 2000; Fey and Larsen, 2001; Rabilloud, 
2002). These low-copy proteins cannot be detected in a 2-DE gel without any pre-run 
enrichment (Futcher et al., 1999; Gygi et al., 2000). Considering the key roles such 
proteins play including signaling, cell adhesion, molecular transport and cellular 
regulation, and the fact that they are often the targets of therapeutic drugs, it is imperative 
to improve the resolving power and detection sensitivity of proteomics technologies so as 
to track these low abundance proteins. 
Another limitation of the 2-DE approach is its under-representation of certain 
classes of proteins viz. those of extreme pI ( 4 or > 9), molecular weight (< 15 kDa or > 
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100 kDa) and hydrophobicity (Garrels et al., 1997; Gygi et al., 2000; Santoni et al., 2000; 
Josic et al., 2005). Hydrophobic membrane proteins are present in low copy number, yet 
play important roles in various signaling pathways. Furthermore, this class of proteins 
represents nearly 50% of important drug targets (Pedersen et al., 2003). Other proteomics 
techniques are necessary to ‘fish’ for these proteins that are refractory to separation by 
2-DE. The data obtained from these non-2-DE proteomics techniques will complement 
that from 2-DE analysis and increase the proteome coverage to have a better insight into 
the proteome of interest. 
 
1.4.2 2-Dimensional Difference Gel Electrophoresis (2-D DIGE) 
  Silver staining is the most popular and sensitive non-radioactive method (sensitivity 
<10ng) for visualization of protein spots in 2-D gels. However, silver stain provides poor 
accuracy in quantification due to its low response range of two orders of magnitude 
(Rabilloud, 1990). In addition, silver staining methods are usually complex, with 
multi-step procedures that must be stopped at some arbitrary time-points to avoid 
over-development, and this frequently leads to non-reproducible gel images. In addition, 
saturation and negative staining are often seen in silver-stained spots of high abundance 
protein. These limitations greatly affect quantitation accuracy when used in differential 
expression proteomics. 
Several fluorescent dyes have been introduced to provide high detection 
sensitivity, broad dynamic and linear quantitative range for 2-DE gels (Patton, 2002). 2-D 
DIGE is a revolutionary 2-DE technology that uses three spectrally resolvable amine 
reactive fluorescent dyes in comparative proteomics analysis (Unlu et al., 1997). In this 
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technique, one of the three mass– and charge– matched fluorescent CyDye Fluor dyes are 
used to pre-electrophoretic label different protein populations prior to 2-DE. The 
N-hydroxysuccinimidyl (NHS) esters of cyanine 2 (Cy2), cyanine 3 (Cy3) and cyanine 5 
(Cy5) dyes label the epsilon amino group of lysines via amide linkage. The labeled 
protein samples are then pooled and resolved in a single 2-DE gel. Each of the three 
fluorescent images is individually scanned at their appropriate excitation and emission 
wavelengths. As the three fluorescent 2-DE images originate from the same gel, every 
identical protein spots will superimpose with its differentially labeled counterpart in the 
resultant fluorographs and be compared unequivocally. The ability to multiplex different 
samples in the same 2-D DIGE gel overcomes the pitfall of inter-gel variability inherent 
in conventional 2-DE technique where different samples are resolved in separate gels. 
The DeCyder software (GE Healthcare) is used to analyze the fluorescent 2-D DIGE 
images. This software matches the fluorescent 2-D DIGE images, quantifies the protein 
spots intensity, normalizes the fluorescent signals, and distinguishes clear statistical 
differences between experimental and biological samples. This automated gel imaging 
and analysis procedure of 2-D DIGE contribute to the robustness of statistical assessment 
and high throughput for differential expression proteomics. Furthermore, 2-D DIGE has 
been reported to show higher sensitivity, reproducibility and wide dynamic range 
compared to conventional 2-DE (Tonge et al., 2001). 
  Most often, 2-D DIGE technology is used to examine differences between two or 
more samples, e.g. drug challenged versus naïve cells or diseased versus normal cells. 
Cy3 and Cy5 are usually used to label the control (normal) and experimental (diseased or 
treated) samples respectively. In addition, a Cy2-labeled “internal standard” comprising 
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of a pool of all samples is incorporated in every gel to increase the statistical confidence 
in detecting and quantifying true biological changes. As different Cy3- and Cy5-labeled 
samples can be normalized with a Cy2-labeled internal standard run on each gel, this 
provides a much more accurate cross-gels quantitative analysis of expression differences. 
This reduces the experimental variance and enhances the true biological difference 
between samples. Hence, the use of this triple dye labeling technology to multiplex 
samples for 2-DE analysis increases the sensitivity and reliability in detecting subtle 
differences between biological samples. 
 
1.4.3 Pre-fractionation and Enrichment Strategies in Proteomics 
Various strategies were employed as sub-proteomic approaches for fractionation 
of complex protein mixtures to reduce the proteome complexity and enrich particular 
subset of proteins prior to 2-DE (Stasyk and Huber, 2004; Lescuyer et al., 2004; Righetti 
et al 2005). There are two major enrichment platforms advocated for proteome analyses 
viz., (i) subcellular fractionation and (ii) protein pre-fractionation. The cells or tissues 
lysates can be fractionated into organelles to provide important clues on protein’s cellular 
localization, interacting partners and functions in a subcellular proteome context (Taylor 
et al., 2003). Subproteomes of each organelle are usually achieved by cellular 
fractionation using differential and gradient centrifugation methods.  
Various chromatographic procedures can be used to pre-fractionate complex 
protein mixtures to enrich a particular subset of proteins from the biological samples 
prior to 2-DE separation. This will increase the probability of identifying low abundant 
proteins (Pedersen et al., 2003). Several classical chromatographic pre-fractionation 
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approaches including ion exchange, size-exclusion, hydrophobic interaction, 
chromatofocusing and affinity chromatography have been successfully applied as a 
prelude to 2-DE (Fountoulakis et al., 1999; Butt et al., 2001; Shin et al., 2005). For 
example, Butt et al. (2001) showed that fractionation of protein extract from E. coli by 
anion exchange chromatography enriches up to 13-fold for individual protein spots. Shin 
et al. (2006) reported the largest brain protein reference database by subjecting the 
cytosolic proteins of mouse brain to ion-exchange and hydrophobic interaction 
chromatography prior to 2-DE. 
 
1.4.4 Heparin Affinity Chromatography 
Affinity chromatography separates proteins based on specific interactions 
between immobilized ligands and target proteins. It was reported that the use of affinity 
chromatography as pre-fractionation step prior to 2-DE helped to reduce sample 
complexity and identify novel proteins from biological samples (Righetti et al., 2005; Lee 
and Lee, 2004). Targeting a particular subset of the proteome selectively concentrates 
proteins of interest for 2-DE. This in turn facilitates the detection and identification of 
proteins that exist in whole cells or tissues lysates below the sensitivity level of the 
staining and/or identification technique. These low abundance proteins may be key 
mediators in disease progression or drug responses. 
Heparin affinity chromatography is one of the chromatographic pre-fractionation 
approaches applied in proteome analysis. Heparin is a carbohydrate copolymer of 
hexosamine and aldouronic acid, and belongs to the class of glycosaminoglycan. Heparin 
has an affinity for a broad range of proteins via electrostatic interactions between sulfate 
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and carboxylate groups of the glycosaminoglycan and the basic residues of interacting 
proteins. For example, it displayed a high binding affinity to different classes of proteins 
such as growth factor receptors, protein synthesis factors, metabolic enzymes, 
coagulation factors and nucleic acid binding proteins (Conrad, 1998; Fountoulakis et al., 
1998; Imai et al., 2002). The ability of heparin to bind particular groups of proteins 
facilitates the use of heparin affinity chromatography as an appropriate pre-fractionation 
step prior to 2-DE. Specific dissociation of proteins of interest from heparin affinity 
column can be induced by altering the protein’s affinity to heparin. There have been 
several successful applications of heparin’s unique combination of affinity binding and 
ions pairing capabilities to fractionate complex protein mixtures as an enrichment 
strategy (Fountoulakis and Takacs, 1998; Karlsson et al., 1999; Ueberle et al., 2002). 
After fractionating the proteins with heparin affinity chromatography, Fountoulakis et al. 
(1998) identified numerous new proteins from Haemophilus influenzae. As illustrated 
from their work, a large number of the basic proteins found from H. influenzae were 
nucleic acid binding and ribosomal proteins. Karlsson et al. (1999) identified eighteen 
new brain proteins from heparin enriched fractions of human fetal brain extract. Utt et al. 
(2002) identified novel immunogenic proteins from Helicobacter pylori cell surface 
proteins by applying heparin affinity chromatography before 2-DE. These results clearly 
showed that pre-fractionation of complex biological samples using heparin affinity 





1.4.5 Non-Gel Based Proteomics Approach: Liquid Chromatography (LC) – Based 
Separation 
With the current existing technologies, no single proteomics platform is able to 
achieve a comprehensive expression profiling of complex biological samples (Garbis et 
al., 2005). Other sample preparation, separation and detection methods, in particular 
gel-free approaches, are required as complementary approaches to overcome the 
shortcomings of 2-DE. This has prompted much interest in non – 2-DE approaches to 
study proteome profiles, with the aim of increasing the proteome coverage 
(Humphrey-Smith et al., 1997; Haynes and Yates, 2000; Issaq et al., 2002). In order to 
bypass the limitations of gel-based separation techniques in proteomics, a number of 
laboratories are using liquid chromatography (LC) systems as alternatives (Haynes and 
Yates, 2000). Furthermore, LC-MS based platforms are able to identify hundreds to 
thousands of proteins from biological samples with a higher sensitivity and throughput 
than 2-DE. 
Certain technological procedures in 2-DE are inherently skill-based and remain 
difficult to deliver quantitative analysis in an automated fashion (Ong and Pandey, 2001). 
Conversely, separation and detection techniques via LC systems are more amenable to 
automation. Following proteins separation, resolved protein fractions can be collected 
automatically for further analysis. Compared to 2-DE, LC-based approaches certainly 
have a higher throughput for proteomics. The direct coupling of LC to MS avoids several 
drawbacks intrinsic in 2-D gel approach. Gel electrophoresis and in-gel digestion prior to 
MS analysis are steps preferred to be avoided due to the low recovery yield from gels and 
the potential for contamination during the series of in-gel digestion steps. As protein 
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samples exist in liquid phase at all times during LC separation, this allows a more direct 
interface between sample separation and proteins analyses. Many of the liquid 
chromatographic separation techniques are employed in the proteome study of cancer 
cells to identify proteins involved in carcinogenesis (Lubman et al., 2002 and references 
therein). Generally, high throughput 2-D LC or multidimensional liquid chromatography 
(MDLC) has a greater capacity to identify a larger number of proteins than gel-based 
separation techniques in proteomics (Wang and Hanash, 2003).  
 
1.4.6 ‘Bottom-up’ or ‘Shotgun’ Proteomics 
In contrast to separation of undigested proteins in 2-DE, solution-based 
‘bottom-up’ or ‘shotgun’ proteomics couples MDLC separation of peptide digests from 
crude sample extracts to MS analysis. This gel-free technology is advocated to 
complement 2-DE analysis in proteomics (Swanson and Washburn, 2005).The 
fractionated peptide digest is subjected to tandem MS (MS/MS) and the precursor 
proteins are identified from the MS/MS spectra using computer algorithms. The profiling 
of peptides circumvents problems associated with hydrophobicity, pI, size and low 
abundance that are commonly encountered during separation of intact proteins by 2-DE 
(Wolters et al., 2001; Wu and MacCoss, 2004). 
Most frequently, ‘shotgun’ proteomics couples strong cation exchange (SCX) and 
reverse phase liquid chromatography (RPLC), either offline or online, to MS/MS analysis. 
Multidimensional Protein Identification Technology (MudPIT), developed by Yates’ 
group (Link et al., 1999), utilizes online ion-exchange (IEX)-RPLC-MS/MS to 
fractionate tryptic digests of proteome and was shown to be a robust and successful 
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method for proteome profiling (Washburn et al., 2001; Peng and Gygi 2001; Koller et al., 
2002 ; Schirmer et al., 2003; Washburn et al., 2003; Kislinger and Emili, 2003; Peng et 
al., 2003; Le Roch et al., 2004). Wolters et al. (2001) demonstrated that MudPIT has a 
high reproducibility and dynamic range of 0.5% (variation in retention time) and 
10,000:1 respectively. The dataset generated from ‘shotgun’ proteomics usually contains 
at least a few hundred proteins, including membrane proteins (Wu et al., 2002), low 
abundance proteins like transcription factors and signaling proteins (Washburn et al., 
2001). Recently, Fischer et al. (2006) performed a comprehensive functional 
characterization of the Corynebacterium glutamicum membrane proteome using the 
MudPIT technology and identified 326 integral membrane proteins (~50% of all 
predicted membrane proteins), including some acidic and basic proteins. Hence, 
proteome analysis using ‘bottom-up’ proteomics approach can generate valuable data 
lacking from 2-DE analysis. 
 
1.4.7 Quantitative Differential Proteomics Using Stable Isotope Labeling Strategies 
In addition to protein identification, quantitative data in proteome analysis 
provides a deeper understanding of the association of differential protein expressions 
with the biological state of the sample. Global quantitative measurement of protein 
expression levels identifies proteins that are regulated in response to specific 
physiological events and relates the quantitative readout to the biochemical processes 
involved. Hence, quantitative differential proteomics facilitates the assignment of key 
proteins to a particular biological context, such as pathological conditions or therapeutic 
interventions. For example, quantitative proteomics in the temporal analysis of drug 
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treatment responses identifies potential drug targets and cellular processes that can be 
used for therapeutic intervention and monitoring. 
MDLC – MS/MS is a powerful tool for protein separation, identification and 
quantitation in proteomics. Although the MS peak ion area and intensity correlate with 
peptide abundance, it is of poor accuracy for quantitative comparison due to suppression 
effects and differences in ionization efficiency during mass spectrometric acquisition. 
The introduction of stable isotope labeling techniques in proteomics has facilitated the 
generation of quantitative data for statistical assessment of the biological significance of 
protein expression changes. This is commonly achieved by incorporating non-radioactive 
stable isotopic tags into specific amino acids or functional moieties of peptides either 
metabolically by in vivo labeling using isotopic 2H, 13C, or 15N containing amino acids in 
medium, e.g. stable isotope labeling with amino acids in cell culture (SILACTM) (Conrads 
et al., 2001; Ong et al., 2002; Berger et al., 2002; Lill, 2003), enzymatically, e.g. 16O/18O 
exchange (Yao et al., 2001; Yao et al., 2003; Brown and Fenselan, 2004) or 
post-isolation chemical tagging with isotopically labeled reagents such as the 
isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute 
quantification (iTRAQ) reagents (Gygi et al., 1999a; Cagney and Emili, 2002; Goshe and 
Smith, 2003; Tao and Aebersold, 2003; Ross et al., 2004). 
Stable isotope labeling strategies have become the gold standard for 
LC-MS/MS-based quantitative proteomics. The relative quantitative ratios can be directly 
obtained from the comparison of ions signal intensities in the MS or MS/MS mode (Ong 
and Mann, 2005). In particular, post-harvest labeling with stable isotopes using ICAT® 
(Gygi et al., 1999a) or iTRAQTM reagents (Ross et al., 2004) was demonstrated to be a 
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complementary strategy to 2-DE in quantitative proteomics (Han et al., 2001; Goshe and 
Smith, 2003; Tao and Aebersold, 2003; Kubota et al., 2003; Choe et al., 2005). 
 
1.4.8 Cleavable Isotope Coded Affinity Tags (cICAT)  
The isotope coded affinity tags (ICAT) methodology is a binary sample labeling 
approach used for pairwise comparison of samples to determine the relative abundance of 
proteins present in two samples (Gygi et al., 1999a). In the original ICAT reagents, the 
pair of protein samples is labeled with ICAT tags which comprise of a heavy 
(deuterium-labeled) or light isotope-coded linker that differ by 8 Da, a biotin affinity tag 
and a thiol specific iodoacetamide group. These tags covalently attach to cysteinyl 
residue of proteins, and the two differentially labeled samples are pooled for enzymatic 
digestion, avidin affinity purification and 2-D LC – MS/MS analysis. Each pair of 
identical peptides with the unique 8Da mass-shift signature (detected in MS spectrum) is 
selected for relative quantitation and peptide sequencing by MS and MS/MS analysis 
respectively (Shiio and Aebersold, 2006). 
Cleavable ICAT (cICAT) is the new generation of ICAT technology that uses 
acid-cleavable ICAT reagents to overcome several drawbacks of the original ICAT 
reagents. The replacement of the deuterated and undeuterated forms by nine 13C (Heavy) 
and 12C (Light) atoms in the linker respectively, eliminates the chromatographic shift in 
RPLC observed in the original ICAT version (Yu et al., 2004). The addition of the 
acid-cleavable bond to remove the biotin tag imparts a higher recovery yield and better 
MS/MS fragmentation pattern than the original ICAT reagent. After the coelution of the 
heavy- and light-labeled peptides from 2-D LC, they are identified as peak pairs with a 
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9Da difference in the MS spectra. These characteristics of cICAT technology was shown 
to result in unambiguous protein identification and superior quantitation (Zhou et al., 
2002; Li et al., 2003a; Li et al., 2004a; Chiang et al., 2007). 
As the cysteinyl residues are rare in proteins, selective enrichment of the 
ICAT-labeled peptides by avidin affinity purification will simplify the complex peptide 
mixtures and increase the probability of identifying low abundance proteins (Gygi et al., 
2002; Qu et al., 2006). ICAT technology has also been used to analyze hydrophobic 
membrane proteins (Han et al., 2001), protein complexes (Hara et al., 2007), PTMs 
(Sethuraman et al., 2007), and protein localizations (MacLellan et al., 2005). The 
comparison of proteins identified by 2-DE and ICAT revealed that these two techniques 
are complementary. However, ICAT is more suited than 2-DE for detecting small, large, 
basic, hydrophobic and secreted proteins (Haqqani et al., 2007). Nonetheless, this 
labeling method is unable to detect non-cysteine containing protein. Moreover, only 
ICAT-labeled peptides of an appropriate length and sequence can be identified by 
MS/MS analysis. Most often, PTMs containing peptides are missed from the protein list 
generated by ICAT technology. 
 
1.4.9 Isobaric Tags for Relative and Absolute Quantification (iTRAQ) 
The isobaric tags for relative and absolute quantification (iTRAQ) strategy uses 
four isobaric species to multiplex up to four different samples in a single LC-MS/MS 
experiment. Each of the iTRAQ tags consists of a reporter group, a balance group and an 
amino-reactive group. First, each of the samples is digested by a proteolytic enzyme and 
the sample peptides mixtures are then labeled with one of the isobaric iTRAQ reagents 
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(Tag 114, 115, 116 and 117). Subsequently, the amine-derivatized samples are pooled 
and fractionated by 2-D LC – MS/MS. Due to the isobaric nature (identical charge and 
overall mass) of the four iTRAQ tags, identical peptides (labeled with different iTRAQ 
tags) derived from different samples have the same precursor ion m/z (DeSouza et al., 
2005). This absence of precursor mass splitting results in higher signal intensity and 
reduces the complexity of the MS spectrum despite pooling of 4 samples. This is in 
contrast to the ICAT method which introduces additional MS peaks due to mass-shift 
caused by difference in the ICAT linker. Furthermore, ICAT relies on mass difference in 
the MS mode for quantitation. Unavoidably, pooling of proteins from the two 
ICAT-labeled samples increases the complexity in the MS spectrum. 
Although indistinguishable in the MS mode, strong diagnostic ions from each 
unique iTRAQ reporter group and sequence specific fragment ions are generated in the 
MS/MS spectra upon collision induced dissociation (CID) of precursor ions. The four 
low-mass reporter ions (m/z 114, 115, 116 and 117) peak areas correspond to the relative 
abundance of the labeled peptides derived from different samples (Ross et al., 2004; 
Aggarwal et al., 2005). The MS/MS peak intensity signals of the reporter ions from 
multiple peptides of each precursor proteins are statistically analyzed to compute the 
relative abundance of each protein. In the MS/MS mode, iTRAQ-labeled peptides are 
shown to have enhanced fragmentation pattern with high signal intensities and 
signal-to-noise ratios (Hardt et al., 2005). The high ionization efficiency of 
iTRAQ-labeled peptides results in higher sequence coverage due to the more complete b- 
and y- ions series. Hence, labeling of samples with iTRAQ reagents provides high 
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confidence in identifying proteins that are regulated in the proteome (Aggarwal et al., 
2005). 
Unlike ICAT reagents that label only cysteinyl residues, iTRAQ targets all 
peptides including non-cysteine containing peptides to provide higher proteome coverage. 
As iTRAQ reagents label primary amines of all peptides via the N-termini and ε-amino 
group of lysine side chain, extensive peptide fractionation, such as by MDLC, is 
necessary for the analysis of peptide digests derived from complex biological samples. 
Nonetheless, this iTRAQ labeling technology has been shown to be able to identify low 
abundance proteins, such as transcription factors (Aggarwal et al., 2005). 
iTRAQ technology is a robust, reproducible and reliable tool for quantitative 
proteomics (Chong et al., 2006). This labeling method has been used in various 
applications such as for biomarker discovery (DeSouza et al., 2005; Gluckmann et al., 
2007; Ralhan et al., 2008), PTMs identifications (Meany et al., 2007; Chen et al., 2007), 
protein complexes (Bai et al., 2008; Pflieger et al., 2008) and membrane proteins analysis 
(Chen et al., 2006; Lund et al., 2007). iTRAQ was shown to be more sensitive than ICAT 
and 2-D DIGE for protein quantitation (Wu et al., 2006). Moreover, the proteins 
identified by iTRAQ were also shown to match to more peptides than those identified by 
ICAT (Dean and Overall, 2007). This peptide-based labeling strategy was also shown to 
have a better average coefficient of variation (CV) than that of 2-DE (Choe et al., 2005). 
Thus iTRAQ-coupled 2-D LC-MS/MS is a powerful tool in quantitative differential 




1.5 OBJECTIVES OF THIS STUDY 
Butyrate is a physiological regulator of colonic carcinoma cell maturation. It 
induces cell cycle arrest, differentiation and/or apoptosis in these cancer cells. Despite the 
well known anti-cancer effects of butyrate, the complete cellular mechanism underlying 
its chemopreventive properties is still unclear. Most of the studies done on butyrate have 
focused on one target at any one time. A comprehensive proteome study of butyrate 
treatment that can systematically elucidate butyrate’s mode of actions in an integrated 
manner is thus required. In this study, we aim to perform the first proteome analysis of 
butyrate-treated HCT-116 cells so as to better understand the underlying mechanism of 
butyrate’s anti-cancer effects in colorectal cancer. HCT-116 cells were chosen for this 
study because they are tumourigenic colorectal cancer cells that were previously shown 
to be sensitive to butyrate-induced growth inhibition and apoptosis (Tan et al., 2002). In 
order to identify the proteins and cellular processes that are regulated by butyrate 
treatment which may be putative targets for cancer therapies, we plan to carry out the 
following: 
 
1. Proteome analysis of 24h butyrate – treated HCT-116 colorectal cancer cells. 
2-D DIGE technology will be used to analyze 24h butyrate-treated HCT-116 cells to 
identify proteins associated with the initiation of growth arrest and apoptosis. Heparin 
affinity chromatography will be adopted as a pre-fractionation step to provide a more 
in-depth ‘window’ of the butyrate-treated proteome. 
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2. Temporal analysis of butyrate treatment (24h, 36h and 48h) using multiplexed 
proteomics approaches. 
The study of a single time-point butyrate treatment may not be adequate to fully 
elucidate the mechanism of butyrate’s anti-cancer effects. Subsequently, iTRAQ and 
cICAT labeling methodologies will be employed for a temporal study of butyrate 
treatment to identify cellular processes and pathways involved during the progression of 


































Chapter 2   MATERIALS AND METHODS 
 
2.1 CELL CULTURE 
 HCT-116 human colorectal carcinoma cell line (American Type Culture 
Collection, Rockville, MD) was cultured in modified McCoy’s 5A media (Sigma, St. 
Louis, MO) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Gibco, 
Green Island, NY) and antimycotic antibiotics (Sigma) in a humidified incubator (37°C, 
5% CO2). Upon reaching 60% confluency, the media were changed to fresh media or 
media containing 5mM sodium butyrate (Sigma). After the cells were mock-treated or 
butyrate-treated for a specific time-point (12, 24, 36 and 48h), they were harvested via 
trypsinization using 0.05% (v/v) trypsin – 0.53mM EDTA solution (Gibco). The cell 
suspension was pelleted by centrifugation at 1,000g for 5min at 4oC. This step was 
repeated with washing in phosphate-buffered saline (PBS) thrice, followed by a final 
centrifugation step at 500g for 3min at 4oC. The resultant cell pellets were used for cell 
lysate preparations. 
 
2.2 SAMPLE PREPARATION 
2.2.1 Cell Lysates Preparation for 2-D DIGE 
Control and 24h butyrate-treated HCT-116 cells were disrupted with a cocktail 
solution containing 7M urea (USB, Cleveland, USA), 2M thiourea (Fluka, Buchs, 
Switzerland), 4% (w/v) [(3-cholamidopropyl)dimethylaminonio]-1-propanesulphonate 
(CHAPS) (USB), 40mM tris[hydroxymethyl] aminomethane (Tris) (USB), 1mM PMSF 
(Sigma), 50μg/ml DNase I and 50μg/ml RNase A (Roche Diagnostic, Mannheim, 
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Germany). After incubation at room temperature for 30min, the cell lysates were 
centrifuged at 18,800g for 1h at 15oC. 
 
2.2.2 Cell Lysates Preparation for Heparin Affinity Chromatography 
For heparin affinity chromatography, harvested control and 24h butyrate-treated 
HCT-116 cells were resuspended in 10mM sodium phosphate buffer (pH 7.0) (Merck, 
Darmstadt, Germany), 1x HaltTM protease inhibitor cocktail (Pierce, Rockford, IL), 
50μg/ml DNase I and 50μg/ml RNase A. The cells were then lysed by sonication using a 
mini probe sonicator connected to a Sonicator Ultrasonic Liquid Processor, XL2020 
model (Farmingdale, New York, USA). Subsequently, the cell lysates were centrifuged at 
100,000g for 2h at 15oC using the TLA 100.3 rotor in a Beckman TL-100 Ultracentrifuge 
(Beckman Instrument, USA) to obtain the supernatants for liquid chromatographic 
separation. 
 
2.3 HEPARIN AFFINITY CHROMATOGRAPHY 
2mg of proteins from control and 24h butyrate-treated HCT-116 cell lysates were 
fractionated by a HiTrap Heparin HP column connected to the ÄKTApurifier liquid 
chromatography (LC) system (GE Healthcare, formally known as Amersham Biosciences, 
Uppsala, Sweden). UNICORNTM (GE Healthcare) software was used to allow real-time 
control of the LC system. The heparin affinity column was equilibrated with 5 column 
volumes (5 x 1ml) of 10mM sodium phosphate, pH 7.0 at a flow-rate of 1.0ml/min prior 
to sample loading. All buffers were filtered through a 0.22μm membrane filter (Millipore 
Corporation, Billerica, USA) before use for liquid chromatography. Flow-through 
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fractions which contained the unbound proteins were collected till the optical density at 
214nm returned to the baseline level. Heparin-bound proteins were then fractionated via 
step-wise elution using 10mM sodium phosphate, pH 7.0 containing 0.4M, 0.8M, 1.2M, 
1.6M and 2.0M sodium chloride (NaCl). The eluates from each salt concentration were 
pooled, desalted and concentrated using the Amicon Ultra 4 centrifugal filter devices 
(nominal molecular weight cut-off of 10kDa) (Millipore). Fraction II which contained 
heparin-bound proteins eluted with 0.4M NaCl was used for 2-D DIGE analysis. 
 
2.4 PROTEIN ASSAY 
Protein concentration of each sample was determined using the Coomassie Plus 
Protein Assay Reagent kit (Pierce) using bovine serum albumin (BSA) as the calibrating 
standard. The colorimetric assay was performed by measuring the absorbance of the 
coomassie dye-protein complex at 595nm in a microplate format. 
 
2.5 2-DIMENSIONAL GEL ELECTROPHORESIS (2-DE) 
2.5.1 Labeling of Samples with CyDye Fluors for 2-D DIGE 
Labeling of the proteins for 2-D DIGE was performed according to the protocol 
stated in the Ettan DIGE User Manual (GE Healthcare). The pH of each sample was 
determined using a pH indicator strip (Sigma) to ensure that the pH was around 8.5 
before labeling with the CyDye Fluors. Cy3 and Cy5 dyes were used to label the control 
and butyrate-treated samples respectively. 320pmol of each dye was added to 40μg of 
protein from each sample. An equal amount of Cy2 was added to a mixture of the control 
and treated sample (each contributing 20μg of protein), to act as the internal standard for 
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image matching and cross-gel statistical analysis. The samples were incubated on ice in 
the dark for 30min, followed by addition of 10mM lysine to quench the reaction. The 
three labeled samples were then pooled for isoelectric focusing (IEF). 
 
2.5.2 Isoelectric Focusing (IEF) 
7cm and 18cm immobilized pH gradient (IPG) strips (GE Healthcare) were 
rehydrated passively overnight at room temperature with rehydration buffer consisting of 
7M urea, 2M thiourea, 4% (w/v) CHAPS, 20mM dithiothreitol (DTT) (Bio-Rad, 
Hercules, CA, USA), 0.2% (v/v) IPG buffer (GE Healthcare), and trace bromophenol 
blue (Merck). Samples containing 20mM DTT and 0.5% (v/v) IPG buffer were then 
loaded using a sample loading cup on a universal strip holder, and focused on the Ettan 
IPGphor IEF unit (GE Healthcare). Whole cell lysates were fractionated with pH 3-10 
nonlinear (NL) IPG strips, while pH 4-7 linear (L) and pH 6-11 L IPG strips were used to 
fractionate heparin bound proteins obtained from heparin affinity chromatography. 
Isoelectric focusing (IEF) was performed at 20oC, with a maximum current setting 
of 50μA. Focusing parameters for the 7cm (pH 3-10 NL) IPG strips were: (i) 100V, 
50Vhr; (ii) 200V, 100Vhr: (iii) 500V, 250Vhr; (iv) 1000V, 500Vhr; (v) 1000-8000V, 
2250Vhr, and (vi) 8000V, 12000Vhr. Focusing parameters for the 18cm wide range (pH 
3-10 NL) and narrow range (pH 4-7 L and pH 6-11 L) IPG strips were as follows 
respectively: (i) 200V, 200Vhr; (ii) 500V, 500Vhr: (iii) 1000V, 500Vhr; (iv) 1000-8000V, 
2250Vhr; (v) 8000V, 32000Vhr and (i) 100V, 50Vhr; (ii) 200V, 1200Vhr; (iii) 500V, 
250Vhr; (iv) 1000V, 500Vhr; (v) 1000-8000V, 2250Vhr; (vi) 8000V, 32000Vhr. After 
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IEF step was completed, the IPG strips were kept at -80oC before conducting 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in the second dimension. 
 
2.5.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
A two-step equilibration procedure (15mins per step) prior to SDS-PAGE was 
used to reduce and alkylate the separated proteins in the IPG strips using 1% (w/v) DTT 
and 2.5% (w/v) iodoacetamide (IAA) (Fluka) in equilibration buffer respectively. The 
equilibration buffer consisted of 50mM Tris-HCl, 6M urea, 30% (v/v) glycerol (Merck), 
2% (w/v) SDS and trace amount of bromophenol blue. The solutions were buffered at pH 
6.8 and pH 8.8 for the reduction and alkylation steps respectively. 
Subsequently, the IPG strips were sealed with 0.75% (w/v) low-melting agarose 
on top of 12.5% (v/v) polyacrylamide gels (1.0mm thick) which consisted of 0.375M 
Tris-HCl pH 8.8, 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulfate (APS) and 0.05% 
(v/v) N,N,N,N-Tetramethylenediamine (TEMED). SDS-PAGE was performed using 
PROTEAN II xi cell electrophoresis unit (Bio-Rad) at a constant current of 15mA/gel for 
20mins, followed by 30mA/gel for the rest of the run. The running buffer used for the 
separation contained 0.025M Tris, 0.192M glycine (Merck) and 0.1% (w/v) SDS. Broad 
range molecular weight standards (Bio-Rad) were electrophoresed concurrently. For 






2.5.4 2-D DIGE Image Analysis 
Fluorescent images of the 2-D DIGE gels were obtained using the Typhoon 
Variable Mode Imager 9400 (GE Healthcare) and viewed using the ImageQuant software 
Version 5.0 (Molecular Dynamics, Sunnyvale, CA). Computerized evaluations of the 2-D 
DIGE gel patterns were performed using DeCyder Version 5.02 (GE Healthcare) as 
described in the Ettan DIGE User Manual; Differential In-gel Analysis (DIA) and 
Biological Variation Analysis (BVA) modules were used. The protein spots were also 
manually screened to ensure correct matching across gels. A threshold limit of 2.0-fold 
difference was set as the statistically significant quantitative change and only spots that 
were present in at least 3 out of the 4 gels for each experiment were selected for MS 
analysis. Student’s t-test at 95% statistical confidence (significance level, p  0.05) was 
set. Each spot that was identified as up- or down-regulated was confirmed by viewing the 
3-D stimulation of protein spots generated by the DeCyder software. After obtaining the 
fluorescent images, the 2-DE gels were silver-stained. The silver-stained gel images were 
then aligned with the 2-D DIGE fluorescent images, and protein spots of interest were 
excised for in-gel tryptic digestion. 
 
2.5.5 Silver Staining 
  The 2-D gels were silver stained based on a modified Vorum protocol (Mortz et 
al., 2001). First, the gels were fixed in 50% (v/v) methanol (Merck), 12% (v/v) acetic 
acid (Merck) and 0.05% (v/v) formalin (Merck) for at least 2h. This was followed by 
washing in 35% (v/v) ethanol (Merck) for 20min thrice. The gels were then sensitized in 
0.02% (w/v) sodium thiosulphate (Merck) for 2min. After the gels were rinsed thrice with 
 62
water for 5min each, the gels were incubated in 0.2% (w/v) silver nitrate (Merck) and 
0.076% (v/v) formalin for 20min. The silver nitrate solution was discarded and the gels 
were washed twice with water, each for 1min. The gels were then developed in 6% (w/v) 
sodium carbonate (Merck), 0.004% (w/v) sodium thiosulphate (Merck) and 0.05% (v/v) 
formalin. The developing solution was removed upon attaining the desired intensity and 
1.46% (w/v) sodium ethylenediaminetetraacetic acid (EDTA) (Bio-Rad) was added for 
20min to stop the development. Lastly, the gels were washed thrice with water for 5min 
each. Every step was conducted with constant shaking. Silver stained gels were 
visualized with ImageScanner using Image Master Lab Scan Version 3.01 software (GE 
Healthcare). 
 
2.5.6 In-gel Tryptic Digestion 
  Silver stained protein spots that showed differential expression upon butyrate 
treatment, as shown by DeCyder Image Analysis, were excised for MALDI-TOF MS 
analysis. The silver stained gels were washed with fresh Milli-Q water before manual 
excision of protein spots of interest. Each spot was soaked in 150μl of 50% acetonitrile 
(ACN) (Applied Biosystems, Foster City, USA), 2.5mM ammonium bicarbonate 
(NH4HCO3) (Sigma) washing buffer for at least 24h at 4oC. Subsequently, the washing 
buffer was replaced with a fresh aliquot of 150μl of 50% ACN, 2.5mM NH4HCO3 and 
further incubated at 37oC for 10min. The solution was then removed and gel spots 
vacuum dried for 10min. 20μl of 10mM DTT in 100mM NH4HCO3 was then added to 
each gel piece before being incubated at 56oC for 1h. The DTT solution was then 
discarded and each gel spot was incubated with 20μl of 55mM IAA in 100mM NH4HCO3 
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for 45min at room temperature in the dark. Following that, IAA was replaced with 100μl 
of 100mM NH4HCO3 and incubated at 37oC for 10min. The NH4HCO3 solution was then 
replaced with 100μl of ACN and left for 10min at room temperature. These two 
incubation steps of NH4HCO3 followed by ACN were repeated. After the ACN was 
removed and gel spots vacuum dried, 0.3μg of sequence grade modified trypsin 
(Promega, Madison, WI, USA) was added to each gel spot. Trypsinization was performed 
at 37oC for 16h with constant shaking. After digestion, peptide extraction was enhanced 
by the addition of 10μl of 0.1% trifluroacetic acid (TFA) (Sigma) in 50% ACN to each 
gel plug and sonicated for 20min in an ultrasonic water bath. 
 
2.5.7 Mass Spectrometry Analysis and Database Search 
Peptides from each gel spot were spotted onto a 100-well MALDI sample plate 
(Applied Biosystems) and mixed with equal volume of CHCA matrix solution (10mg/ml 
α-cyano-4-hydroxy-cinnamic acid in 0.1% TFA, 50% ACN). Peptide mass spectra were 
obtained using a MALDI-TOF Voyager-DE STR mass spectrometer (Applied 
Biosystems). Laser intensity was set at 2,400 with 100 shots per spectrum over the 
window of m/z 700 to m/z 3,000. The mass spectrometric automatic data acquisition was 
performed in delayed extraction and reflector mode. Instrumental calibration was 
performed internally using two trypsin autodigest ions (m/z 842.51, m/z 2211.104). 
Proteins of interest were identified by peptide mass fingerprinting using the 
ProteinProspector MS-Fit software (http://prospector.ucsf.edu/ucsfhtml4.0/msfit.htm, 
Protein Prospector; UCSF, San Francisco, CA, USA). Human and rodent subsets of 
SWISS-PROT databases were used in the MS-Fit search. The search parameters allowed 
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oxidation of methioine, N-terminal acetylation, carboxyamidomethylation of cysteine, 
and phosphorylation of serine, threonine and tyrosine, and mass tolerance was set at 
50ppm. The experimental Mr and pI of protein spots in the 2-DE gels were estimated 
using an in-house program known as ClickMe Version 3.11. 
 
2.6 SUBCELLULAR FRACTIONATION 
The cytosolic fraction of HCT-116 cells was prepared according to Thiede et al. 
(2002) except that a series of three freeze-thawing processes was incorporated prior to the 
homogenization step. The harvested cell pellet was washed twice with PBS, once with 
MB buffer (400mM sucrose, 50mM Tris, 1mM EGTA, 5mM DTT, 10mM potassium 
hydrogen phosphate pH 7.6 and 0.2% BSA), and centrifuged at 300g for 10min at room 
temperature. The pellet was then resuspended in 4ml of MB buffer with 1x protease 
inhibitor cocktail (Pierce) and incubated on ice for 20min. Following this, a series of 
three freeze-thawing processes where the samples were incubated at -80oC for 15min and 
then at room temperature for 20min was adopted. The cell pellet was then homogenised 
using a Dounce homogeniser (30 strokes) and centrifuged at 1,500g for 1min at 4˚C. The 
resulting supernatant was further centrifuged at 8,800g for 10min at 4˚C to obtain the 
mitochondrial pellet and the cytosol/membrane supernatant. This supernatant was finally 






2.7. STABLE ISOTOPE LABELING 
2.7.1 iTRAQ Labeling 
Four batches each of control cells (24h mock-treated), and cells treated with 5mM 
sodium butyrate for 24h, 36h, and 48h respectively were harvested as described above. 
500 mM triethylammonium bicarbonate/1.0% (w/v) SDS was used for the extraction and 
denaturation of cellular proteins by boiling at 100oC for 10min. Cellular debris was 
removed after centrifugation at 18,800g for 1h at 23oC. Protein conent of the cell lysates 
was quantitated prior to iTRAQ labeling. 
iTRAQ labeling of each sample was performed according to the manufacturer’s 
protocol (Applied Biosystems). 100μg of protein was reduced with 5mM 
tris-(2-carboxyethyl)phosphine (TCEP) at 60oC for 1h, and subsequently alkylated with 
10mM methyl methane-thiosulfonate (MMTS) for 10min. After cysteine blocking, each 
sample was diluted to 0.05% (w/v) SDS prior to trypsinization at 37oC for 16h. Following 
this, each tryptic digest was labeled for 1h with one of the four isobaric amine-reactive 
tags as follows: Tag114 – 24h control; Tag115 – 24h treated; Tag116 – 36h treated; and 
Tag117 – 48h treated samples. These four iTRAQ-derivatized samples were then pooled 
and passed through a strong cation exchange cartridge as recommended by the 
manufacturer (Applied Biosystems). The eluate from the ion exchange step was desalted 
using a Sep-Pak cartridge (Millipore), vacuum dried and reconstituted for 2-D LC. 
 
2.7.2 cICAT Labeling 
The control and butyrate-treated HCT-116 cells harvested from the 3 time-points 
(24h, 36h, and 48h) were lysed in 50mM Tris, 1.0% (w/v) SDS, pH 8.5, and boiled at 
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100oC for 10min. They were then subjected to centrifugation at 18,800g for 1h at 23oC to 
remove cell debris. cICAT labeling and processing of the samples followed standard 
protocols (Applied Biosystems). After protein quantitation, 100μg of protein from the 
control and butyrate-treated cell lysate of each time-point were each reduced with 
1.25mM TCEP, and subsequently labeled with the respective isotopic light and heavy 
forms of the cICAT reagents, for 2h at 37oC. Each pair of heavy and light cICAT 
derivatized proteins from each time-point was then pooled and trypsinized at 37oC for 
16h. Upon completion of in-situ digestion, the digested peptide mixture was passed 
through a strong-cation exchange cartridge, and then finally purified with an avidin 
affinity cartridge. The cICAT-labeled peptides were then dried by speed vacuuming, 
dissolved in cleaving reagents and incubated at 37oC for 2h. After the removal of biotin, 
peptides were brought to dryness again before being reconstituted for 2-D LC. 
 
2.8 TWO-DIMENSIONAL LIQUID CHROMATOGRAPHY (2-D LC) 
MALDI-TOF/TOF MS 
2.8.1 2-D LC Separation of Labeled Peptides. 
Each of the iTRAQ and cICAT-labeled peptide mixtures was separated using an 
UltimateTM dual-gradient LC system (Dionex-LC Packings) equipped with a ProbotTM 
MALDI spotting device. A 2-D LC separation was performed as follows: the labeled 
peptide mixture was dissolved in 2% acetonitrile (ACN) with 0.05% trifluoroacetic acid 
(TFA) and injected into a 0.3 × 150-mm strong cation-exchange (SCX) column 
(FUS-15-CP, Poros 10S) (Dionex-LC Packings) for the first dimensional separation. The 
mobile phase A and B were 5mM KH2PO4 buffer, pH 3, + 5% ACN and 5mM KH2PO4 
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buffer, pH 3, + 5% ACN + 500mM KCl respectively. The flow rate was 6µl/min. 9 
fractions were obtained using step gradients of mobile phase B: unbound, 0-5, 5-10, 
10-15, 15-20, 20-30, 30-40, 40-50, 50-100% B. The eluting fractions were captured 
alternatively onto two 0.3 × 1-mm trap column (3-µm C18 PepMapTM, 100 Å) 
(Dionex-LC Packings) and washed with 0.05% TFA followed by gradient elution in a 0.2 
× 50-mm reverse-phase column (Monolithic polystyrene-divinylbenzene) (Dionex-LC 
Packings). The mobile phases used for this second-dimensional separation were 2% ACN 
with 0.05% TFA (A) and 80% ACN with 0.04% TFA (B). The gradient elution step was 
0-60% B in 15min at a flow rate of 2.7µl/min. The LC fractions were mixed directly with 
MALDI matrix solution (7mg/ml α-cyano-4-hydroxycinnamic acid and 130µg/ml 
ammonium citrate in 75% ACN) at a flow rate of 5.4µl/min via a 25-nl mixing tee 
(Upchurch Scientific) before they were spotted onto a 192-well stainless steel MALDI 
target plate (Applied Biosystems) using a Probot Micro Precision Fraction collector 
(Dionex-LC Packings), at a speed of 5sec per well. 50 fmol of adrenocorticotropic 
hormone (ACTH) (18-39) peptide (m/z = 2465.199) was spiked into each well as internal 
standard. 
 
2.8.2 MALDI-TOF/TOF MS Analysis 
The samples on the MALDI target plates were analyzed using a 4700 Proteomics 
Analyzer mass spectrometer (Applied Biosystems). MS/MS analyses were performed 
using nitrogen at collision energy of 1 kV and a collision gas pressure of 1 X 10-6 
Torr. The GPS ExplorerTM software Version 3.6 (Applied Biosystems) was used to create 
and search files with the MASCOT search engine (Version 2.1; Matrix Science) for 
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peptide and protein identifications with both the cICAT and iTRAQ-labeled samples. The 
International Protein Index (IPI) human database (Version 3.30, 67922 sequences) 
(Kersey et al., 2004) was used for the search, and this was restricted to tryptic peptides. 
 
2.8.2.1 iTRAQ-Labeled Samples  
One thousand shots were accumulated for each MS spectrum. For MS/MS, 6,000 
shots were combined for each precursor ion with a signal to noise (S/N) ratio greater or 
equal to 100. For precursors with S/N ratio between 50 and 100, 10,000 shots were 
acquired. No smoothing was applied before peak detection for both MS and MS/MS, and 
the peaks were deisotoped. For MS/MS, only the peaks from 60 Da to 20 Da below each 
precursor mass, and with S/N ≥ 10 were selected. Peak density was limited to 30 peaks 
per 200 Da, and the maximum number of peaks was set to 125. Cysteine 
methanethiolation, N-terminal iTRAQ labeling, and iTRAQ labeled-lysine were selected 
as fixed modifications while methionine oxidation was considered as a variable 
modification. One missed cleavage was allowed. Precursor error tolerance was set to 100 
ppm while MS/MS fragment error tolerance was set to 0.4 Da. Maximum peptide rank 
was set to 2. iTRAQ quantification was performed using the GPS Explorer software and 
normalized among samples. iTRAQ ratios were calculated based on the cluster areas of 
the iTRAQ reporter fragment peaks (114, 115, 116 and 117), and the ratios calculation 
included only peptides identified with C.I. % above cutoff thresholds as described below.  
The average iTRAQ ratio and standard deviation (S.D.) were determined using the 






















where R = Average iTRAQ Ratio 
 Xi = natural log of iTRAQ Ratio of each iTRAQ pair 
 N = the number of peptides with non-zero iTRAQ Ratio 
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where sd = iTRAQ Standard Deviation 
Xi = natural log of iTRAQ Ratio of each peptide 
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In this work, 4 biological replicates of iTRAQ-labeled samples were analyzed. 
Student’s t-test was performed, and the p values based on the iTRAQ ratios of peptides 
matched to each protein (48h time-point versus control) were used to assess the 
significance of temporal differential expression. Proteins that have p value <0.05 in at 
least one dataset and shown consistent changes in all datasets were considered as 
significantly altered in the expression level. 
To determine the cutoff threshold of fold changes for proteins with single peptide 
match, 2 equal amounts of tryptic digested six protein mixtures (Applied Biosystems) 
were labeled with iTRAQ reagent 114 and 117 respectively, and analyzed with 1-D LC 
MALDI-TOF/TOF MS (reverse phase liquid chromatography; similar to 
abovementioned). The standard deviation (S.D.) based on the ratios of all the identified 
peptides was 0.15, thus 1.3 (1 + 2 S.D.) was determined to be the significant cutoff 
threshold (p < 0.05) for the up-regulated proteins, and reciprocally 0.77 was the cutoff 
threshold for the down-regulated proteins (Data was shown in the Appendix Data I and 
II). Similar cutoff threshold has been used in other iTRAQ studies (Guo et al., 2007; 
Pierce et al., 2007). 
 
2.8.2.2 cICAT-Labeled Samples 
For MS analysis, typically 1,000 shots were accumulated for each sample well. 
MS/MS acquisition was performed in a result dependent manner. Only cICAT pairs with 
normalized ratio (normalized against median ratio of all the cICAT pairs detected) greater 
than 40% were selected for fragmentation. Singletons were also selected as precursor 
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ions. Stop conditions were implemented so that 3,000 to 6,000 shots were accumulated 
depending on the quality of the spectra. Peak processing and detection procedures were 
the same as abovementioned. Heavy and light cICAT-labeled cysteine, N-terminal 
acetylation and pyroglutamation (Glu & Gln), and methionine oxidation were selected as 
variable modifications. One missed cleavage was allowed. Precursor error tolerance was 
set to 100 ppm and MS/MS fragment error tolerance to 0.3 Da. Maximum peptide rank 
was set to 5. cICAT quantification was performed using GPS ExplorerTM software and 
normalized against median ratio obtained from all the cICAT peptide pairs detected in 
one sample. The ratios were calculated by comparison of the cluster area of the 
heavy-ICAT labeled peptide with that of the light-ICAT labeled peptide.  
Two equal amounts of tryptic digested BSA were labeled with heavy and light 
cICAT tags, and subjected to 1-D LC MALDI-TOF/TOF MS. The standard deviation 
(S.D.) based on the ratios of all the identified cICAT-labeled peptides was 0.12, thus 1.36 
(1 + 3 S.D.) was determined as the significant cutoff threshold (p < 0.01) for the 
significantly up-regulated proteins, and reciprocally 0.74 was the cutoff threshold for the 
down-regulated proteins. 
 
2.8.2.3 Estimation of False Positive Identification Rate to Determine Cut-Off Score 
In addition to the IPI human database, a randomized database (67922 sequences) 
generated using IPI human database Version 3.30 (generated using a Pearl script 
downloaded from Matrix Science, http://www.matrixscience.com/help/decoy_help.html) 
was also used to search both the iTRAQ- and cICAT-labeled samples. The false positive 
rate was calculated by comparing the peptide hits obtained from these 2 databases at 
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different ion score C.I. % (peptide). The minimum ion score C.I. % was set such that no 
more than 5% false positive rate was achieved. Based on this cut-off threshold, all the 
proteins identified from the random database search were single-peptide matched. Hence, 
proteins identified from the human database that were matched to at least 2 peptides are 
statistically confident. For single-peptide matched proteins, only those with ion score C.I. 
% greater than the highest C.I. % attained from the random database search were selected. 
With these cut-off thresholds, we essentially achieved 0% false-positive identification 
rate at protein level. The minimum ion score thresholds that were used for each 
iTRAQ-labeled sample were shown in the Appendix Data I. 
 
2.9 REAL-TIME POLYMERASE CHAIN REACTION (PCR) 
2.9.1 RNA Isolation 
RNA was isolated from 2 batches of HCT-116 cells using the RNeasy Plus Mini 
Kit (Qiagen, Chatsworth, CA) according to the manufacturer’s instructions. First, the 
cells were disrupted in Buffer RLT and homogenized using syringe and 20-gauge needle. 
70% ethanol was then added to the homogenized lysate, and mixed well by pipetting. The 
samples were then added onto the RNeasy Mini spin column placed in the collection tube. 
The spin column membranes were washed once using Buffer RW1 and twice with RPE 
to remove any contaminants from the samples. The total RNA was then eluted in 
RNase-free water. RNA purity was assessed by ratio of A260/A280 and denaturing agarose 





2.9.2 Real-Time PCR (RT-PCR) 
MultiScribe™ Reverse Transcriptase (Applied Biosystems) was used to reverse 
transcribe RNA from each sample to cDNA, following the manufacturer’s protocol. The 
RT reaction mix consisted of RNase-free water, TaqMan RT buffer, 5.5mM MgCl2, 
0.8mM deoxyNTPs mixture, 2.5μM random hexamers, 0.4U/μl RNase inhibitors and 
1.25U/μl MultiScribeTM reverse transcriptase. The thermal cycling parameters for reverse 
transcription were as recommended by the manufacturer’s protocol (Table 2.1) 
 
Table 2.1 Thermal cycling parameters for reverse transcription reactions. 




HOLD HOLD HOLD 
Time 10 min 30 min 5 min 
Temperature 25oC 48oC 95oC 
 
Sequences for the primers specific for each gene target were designed using the 
Primer ExpressTM software (Applied Biosystems) and synthesized by 1st Base Pte Ltd 
(Singapore). BLAST (NCBI) searches for all primer sequences were performed to 
confirm gene specificity. For quantification of each gene in the samples, amplification 
was performed in triplicates with SYBR Green PCR Master Mix (Applied Biosystems) 
on the ABI PRISM 7000 Sequence Detection System instrument (Applied Biosystems), 
according to the manufacturer’s instructions. Real-time PCR (RT-PCR) was performed 
with the set of primers listed in Table 2.2. Non-template controls were included for each 
run. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the endogenous 
control reference for normalization. Thermal cycling parameters were as follows: 
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denaturation at 95oC for 10 min followed by 40 cycles at 95oC for 15 sec and 60oC for 1 
min (Table 2.3). 
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Table 2.2 Sequences of the primers used for RT-PCR. 
GENE TARGET FORWARD PRIMER REVERSE PRIMER 
   
Metallothionein-1X 5’-TGTCCCGCTGCGTGTTTT-3’ 5’-TTCGAGGCAAGGAGAAGCA-3’ 
   
Nucleosome assembly protein 1-like 1 5’-CTATGACCCAAAGAAGGATCAAAAC-3’ 5’-GGCCACATACATCCTGCTTCA-3’ 
   
Caprin 1 5’-CCCATCAAGTGACTGGTAACCA-3’ 5’-CGAGACACACCACGACTATTGTAAT-3’ 
   
A-kinase anchor protein 12 5’-AGAGCATAGAGTCCAGTGAGCTTGT-3’ 5’-TGTGATTTTACCCCAGCTAAGGTT-3’ 
   
Cytochrome c oxidase subunit VIb 5’-GCTGGCAGAACTACCTGGACTT-3’ 5’-GCCTCCTTTAGCGGTCATTG-3’ 
   
Cytochrome c oxidase polypeptide Va 5’-GCCGTGGCTATCCAGTCAGT-3’ 5’-AAACTCCTCATCTGTCTCCTGTGA-3’ 
   
Ornithine aminotransferase 5’-GAACCAATTCAGGGTGAAGCA-3’ 5’-TCGCACTCCCATTAGGTAACCT-3’ 
   
Cytoskeletal 19 5’-GAACCAAGTTTGAGACGGAACAG-3’ 5’-CGCAGGCCGTTGATGTC-3’ 
   
HSP-90 Beta 5’-TTTGGGAACCATTGCCAAGT-3’ 5’-TGTCTGCACCAGCCTGAAGA-3’ 
   
Vesicle trafficking protein SEC22b 5’-CCCCTACCAGATGTACCTTGGA-3’ 5’-CACACCCCCTGCTCAATAATG-3’ 
   
GAPDH 5’-CCTCCCGCTTCGCTCTCT-3’ 5’-GGCGACGCAAAAGAAGATG-3’ 




Table 2.3 Thermal cycling parameters for RT-PCR. 
PCR 











2.10 WESTERN BLOTTING 
2.10.1 hnRNP A1 Immuno-detection 
Proteins from the cytosolic samples were precipitated using the 2-D Clean-up kit 
(GE Healthcare) according to the manufacturer’s protocol, and resolubilised in a cocktail 
solution containing 7M urea, 2M thiourea, 4% CHAPS, 40mM Tris, 1x HaltTM protease 
inhibitor cocktail, 50μg/ml DNase I and 50μg/ml RNase A. 120µg of whole cell lysate 
and cytosolic fractions were resolved in 2-DE gels of pH 6-11 range. Upon completion of 
electrophoresis, the gels were rinsed in Towbin transfer buffer which comprised of 
25mM Tris, 192mM glycine (USB), 0.1% SDS, 20% methanol (Merck). Proteins were 
then blotted onto nitrocellulose membranes (Bio-Rad) using a Hoefer®TE 70 Series 
Semi-PhorTM Semi-dry Transfer Unit (GE Healthcare). After 1h transfer, the blots were 
blocked using 5% (w/v) BSA in TBS-T (20mM Tris-HCl, 137mM NaCl, 0.1% Tween 20, 
pH 7.5) overnight. Goat anti-hnRNP A1 and rabbit HRP-conjugated anti-goat IgG 
antibodies (Santa Cruz, CA, USA) were used at a dilution of 1:500 and 1:100,000 in 
TBS-T with 1% (w/v) BSA (Sigma) respectively. 3 washes in TBS-T were performed in 
between primary and secondary antibody incubation which consisted of 1h each. After 
incubating with the secondary antibodies, the membranes were washed with TBS-T prior 
to ECL detection. 
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2.10.2 Phosphoserine and Phosphotyrosine Immuno-detection 
Immuno-detection of phosphoproteins in the 2-DE blots was conducted using 
mouse anti-phosphotyrosine IgG2b PY20 (BD Biosciences, Franklin Lakes, NJ) and 
mouse anti-phosphoserine IgM (Calbiochem, San Diego, CA) at 1:1,000 and 1:200 
dilutions respectively. The membranes were incubated with the primary antibodies for 1h 
each. The secondary antibodies used for phosphotyrosine and phosphoserine 
immuno-detection were HRP-conjugated anti-mouse IgG (Sigma) and HRP-conjugated 
goat anti-mouse IgM (Pierce), used at 1:2,000 and 1:2,500 dilutions respectively. 3 
washes (of 15min each) in TBS-T were carried out in between primary and secondary 
antibody incubation. All dilutions were conducted in TBS-T with 1% (w/v) BSA. After 
1h of incubation with the secondary antibodies, the membranes were washed with TBS-T 
prior to ECL detection. 
 
2.10.3 Immuno-detection for iTRAQ – and cICAT – Identified Proteins 
Equal aliquot of proteins extracted from both control and treated cells of each 
time-point was resolved in 1-D SDS-PAGE. Upon completion of electrophoresis, the 
proteins were electroblotted onto nitrocellulose membranes (Bio-Rad). The blots were 
then blocked using 5% (w/v) non-fat dry milk in TBS-T overnight prior to 
immunoprobing with antibodies diluted in TBS-T with 1% (w/v) milk for 1h each. The 
membranes were incubated with rabbit anti-GAPDH (1:200) from Santa Cruz, mouse 
anti-HSP-90 beta (1:1,000) from Stressgen (Stressgen, CA, USA), mouse anti-Galectin-1 
(1:500), mouse anti-AKAP12 (1:500), mouse anti-SEC22b (1:750), or mouse 
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anti-cytochrome c oxidase VIb (1:750) from Abnova (Abnova Corporation, Taiwan). 
HRP-conjugated anti-rabbit IgG (1:2,500) from Santa Cruz, HRP-conjugated anti-mouse 
IgG (1:5,000) from GE Healthcare or HRP-conjugated anti-mouse IgM (1:5,000) from 
Pierce were used as secondary antibodies. 3 washes in TBS-T were carried out in 
between primary and secondary antibody incubation. The membranes were incubated 
with the respective secondary antibodies for 1h prior to 3 washes in TBS-T and followed 
by ECL detection. 
 
2.10.4 Enhanced Chemiluminescence (ECL) Detection 
Immuno-reactive protein spots or bands were visualized using the Enhanced 
Chemiluminescence (ECLTM) detection system (GE Healthcare) and Biomax film 
(Eastman Kodak). 
 
2.10.5 Membrane Reprobing 
For reprobing of the membrane with another antibody, the membrane was 
incubated with a stripping solution consisting of 100mM 2-mercaptoethanol (Merck), 
62.5mM Tris-HCl (pH 6.8), and 2% (w/v) SDS for 45min at 50-60oC, with periodical 
shaking. After this, the membrane was washed with TBS-T for 15min thrice. 
Subsequently, the membrane was blocked with 1% (w/v) BSA or 5% (w/v) milk prior to 





2.10.6 Colloidal Silver Staining of Membranes 
After immuno-detection, the membranes were stained with colloidal silver 
solution containing 40% (w/v) sodium citrate dehydrate (Merck), 20% (w/v) ferrous 
sulfate heptahydrate (Merck), and 20% (w/v) silver nitrate for visualization of protein 
bands or spots (Vettermann et al., 2002). Briefly, the membrane was rinsed with Milli Q 
water and then immersed in the colloidal silver solution with constant shaking. The 
staining procedure was stopped after the desired intensity was obtained by replacing the 















Chapter 3      RESULTS 
 
3.1 2-D DIGE Analysis of 24h Butyrate-Treated HCT-116 Cells 
Our previous study had shown that upon 24h post-treatment with physiological 
concentration (5mM) of sodium butyrate, HCT-116 colorectal cancer cells demonstrated 
initiation of growth inhibition and apoptosis (Figure 3.1; Tan et al., 2002). In this current 
work, 2-D DIGE was used to generate protein expression maps as an unbiased method to 
uncover participating players in butyrate’s anti-cancer actions on HCT-116 cells. This 
would help to identify proteins involved in the initiation of cell maturation by butyrate in 
cancer cells. 2-D DIGE approach has circumvented the technical bottleneck of intergel 
variations in conventional 2-DE, ensuring more accurate and reproducible results during 
comparative expression profiling.  
 
Figure 3.1 Butyrate initiated cell growth arrest and apoptosis in HCT-116 colorectal 
cancer cells after 24h treatment (Reproduced from Tan et al., 2002; reprinted with 
permission of John Wiley & Sons, Inc. and Wiley-Liss, Inc.). Using cell viability and 
apoptotic assays, we had shown that 5mM butyrate initiated cell maturation in HCT-116 
cells at 24h treatment. 
 
The 24h control and butyrate-treated HCT-116 cell lysates were labeled with Cy3 
and Cy5 respectively. These two populations of labeled samples were mixed with a 
Cy2-labeled “internal standard” which consisted of an equal amount of the control and 
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butyrate-treated cell lysates, and ran on a 2-DE gel with a pH 3-10 IPG strip (Figure 3.2). 
Quadruplicates of 2-D DIGE gels were run, and a 2-D DIGE fluorescent image of 24h 
butyrate-treated HCT-116 cells was shown in Figure 3.3. Differential expression 
proteomics of HCT-116 whole cell extract with 2-D DIGE gels revealed expression 
modulation of 20 protein spots upon butyrate treatment (at a threshold limit of 2.0-fold 
difference and 95% statistical confidence). Among the 16 up-regulated and 4 
down-regulated protein spots, peptide mass fingerprinting identified 6 of them (Figure 
3.4, Table 3.1 and Table 3.2). They included isoforms of keratin 8, ornithine 















































Figure 3.2 The workflow outlining differential proteome analysis of 24h 
butyrate-treated HCT-116 cell lysate using 2-D DIGE. Cy2-, Cy3- and Cy5-labeled 
samples were pooled and ran on a single 2-DE gel. The overlaid image of Cy3 (control) 
and Cy5 (butyrate-treated) fluorescent images created the differential display image that 
enabled visual detection of differentially expressed protein spots. 
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(Control + Butyrate Treatment) 
Control Butyrate Treatment






































Figure 3.3 A 2-D DIGE image of 24h butyrate-treated HCT-116 cell lysate. Protein 
spots that were up-regulated upon treatment showed progressively higher red hues while 
those down-regulated were greenish in color. Unaffected proteins were represented by 
yellow spots. 2-D DIGE revealed expression modulation of 20 protein spots upon 








pH 3.0 pH 10.0 
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Figure 3.4 Silver stained 2-D DIGE gel map for 24h butyrate-treated HCT-116 
colorectal cancer cells. 120g of CyDye-labeled control and butyrate-treated HCT-116 
cell lysate was first resolved in a pH 3-10 IPG strip and followed by 12.5% SDS-PAGE. 
The spot number of identified proteins was assigned by the DeCyder software. The 















Table 3.1 The 2-D DIGE fluorescence images and 3-D simulations of the 6 identified 
protein spots. The fold ratio of protein expression changes and t-test p values as 
determined by DeCyder analysis were indicated. 
 
3-D Simulation Spot 
No. 
Fluorescence 




































Table 3.2 List of proteins identified to be differentially expressed by butyrate 
treatment as analyzed by 2-D DIGE of HCT-116 whole cell lysate. Average volume 
ratio (fold-ratio) and student’s t-test p value were derived from the DeCyder analysis (Mr 
is in kDa). (a) Represents accession numbers from Swiss-Prot database. (b) A positive value 
signified up-regulation and a negative value signified down-regulation in terms of 




No. Protein Identity Acc. No.
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30 2.15 3.9e-007 53.7/5.5 54.8/5.1 
         
418 









30 2.16 2.4e-006 53.7/5.5 55.5/5.2 
         
427 











37 2.26 1.0e-007 53.7/5.5 56.5/5.4 
         
419 










32 2.77 3.0e-009 53.7/5.5 55.5/5.3 
         
534 Ornithine aminotransferase P04181 
17-31 (2 PO4), 
33-46, 50-64, 67-76, 
170-180, 275-292 
19 2.84 9.8e-010 48.5/6.6 45.3/5.9 

















3.2 The Use of Heparin Affinity Chromatography as a Prefractionation Step prior 
to 2-D DIGE 
To enable us to delve deeper into the proteome, we subsequently performed 
heparin affinity chromatography as a sample pre-fractionation step prior to 2-D DIGE 
and MS analyses. As sample pre-fractionation would enrich for a particular subset of 
proteins, this approach would substantially reduce the diversity and complexity of protein 
mixtures, and thus improve the detection of low abundance proteins in 2-DE. As shown 
in the chromatogram (Figure 3.5), almost all the proteins were eluted in the first three 
fractions, i.e., (I) unbound proteins (flow-through), (II) 0.4M NaCl fraction, and (III) 
0.8M NaCl fraction. There was no significant difference between the chromatograms of 
the control and butyrate-treated HCT-116 cell lysates (Figure 3.5). 
From the three eluted fractions which we obtained, only proteins from fraction II 
was used for 2-D DIGE analysis. The protein content in fraction III was too low to permit 
further investigation. Clearly, a complete proteome of any complex biological sample can 
not be achieved with a single 2-DE gel. Two overlapping narrow-range IPG strips (pH 
4-7 and pH 6-11) were used for 2-D DIGE instead of the wide range pH 3-10 IPG strip 
used in the study of total cell lysate. This provided a better spatial resolution in the pI 
range, thus minimizing the possibility of comigration of spots (Westbrook et al., 2001). 
22 spots from the acidic range gels (pH 4-7) and 24 spots in the basic range gels (pH 6-11) 
were detected as differentially regulated with 10 and 14 spots identified from each range, 
respectively (Figure 3.6 and Table 3.3). Hence, the application of this pre-fractionation 






Figure 3.5 Heparin affinity chromatography profile of control and 24h butyrate-treated HCT-116 cell lysates. Step-wise elution 
gradient was applied using NaCl, and three pooled fractions (I, II and III) were collected. As shown, there was no significant 

















Figure 3.6 Silver-stained 2-D DIGE gels of fraction II obtained from heparin affinity 
chromatography of HCT-116 cell lysate resolved on a (A) pH 4-7 and (B) pH 6-11 IPG 
strip. 10 and 14 protein spots identified from the pH 4-7 and pH 6-11 range gels were 
indicated with their spot numbers (derived from DeCyder) respectively. ↓ represents 
down-regulated and ↑ represents up-regulated protein spots. 
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Table 3.3 List of proteins identified from 2-D DIGE analysis (pH 4-7 and pH 6-11) of fraction II (heparin affinity 
chromatography of HCT-116 cell lysate)a. (a) Mr in kDa. Spot no., t-test, and avg. vol. ratio were obtained from DeCyder differential 
analysis software. (b)Represents accession numbers from Swiss-Prot database. (c)A positive value signifies up-regulation and a negative 
value signifies down-regulation in terms of fold-differences. 
 
Acidic Range (pH 4-7) 
 Spot 
No. 














104-115 (1Met-ox), 156-169, 
195-206, 217-224, 225-241 25 -4.22 7.80 e-009 26.7/9.6 24.1/5.8 
         
1204 Ser/Thr protein phosphatase PP1 P36873 27-36, 61-74, 114-122, 247-260 19 -2.40 1.10 e-006 37.0/6.1 41.1/5.9 
         
1121  Crk-like protein  P46109 12-21, 40-57, 58-69, 90-104, 269-282 22 -2.30 0.00034 33.8/6.3 42.2/6.6 

















1462 Eukaryotic translation initiation factor 4E P06730 22-36, 163-173, 174-181, 193-206 22 -2.08 0.00083 25.1/5.8 31.2/5.9 
         
2454 Cytochrome c oxidase polypeptide VIb P14854 21-28, 29-39, 48-59 36 3.36 0.00076 10.2/6.5 11.8/5.9 
         
930 Heterogeneous nuclear ribonucleoprotein K Q07244 70-86, 140-148, 149-163, 180-191, 208-219, 306-316, 317-325 18 2.81 9.40 e-005 51.0/5.4 51.2/6.4 
         
925 Ornithine aminotransferase P04181 33-46, 50-64, 67-76, 170-180 11 2.60 0.0035 48.5/6.6 51.4/6.4 
         
1092 RGS19-interacting protein 1 O14908 11-24, 58-72, 217-224, 225-240, 249-263, 268-279, 296-307 32 2.43 9.60 e-005 36.1/5.9 42.4/6.4 
         
1049 Acyl-CoA dehydrogenase P45954 160-170, 270-284, 285-294, 326-347, 385-396 16 2.22 1.30 e-005 47.5/6.5 44.4/6.1 
















1265 Elongation factor Tu  P49411 210-227, 239-252, 253-271 11 2.01 0.00034 49.5/7.3 36.8/6.3 
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Basic Range (pH 6-11) 
 Spot 
No. 











824 40kDa peptidyl-prolyl cis trans isomerase Q08752 
18-28, 57-69, 103-111, 115-125, 
146-154, 175-185, 186- 195, 196-214, 
228-235, 236-244, 314-321, 322-331 
34 -2.91 1.50 e-005 40.8/6.8 42.9/6.9 
1462 Dihydrofolate reductase P00374 20-29, 57-64, 72-78, 82-92, 110-123, 124-133, 159-174 46 -2.85 2.80 e-005 21.5/6.9 26.6/7.0 
1972 Profilin-1 P07737 57-70, 76-89 (1Met-ox), 117-126, 128-136,  34 -2.53 1.80 e-006 15.1/ 8.4 15.4/8.4 
1081 Heterogeneous nuclear ribonucleoprotein A1 P09651 
16-31, 32-47, 93-105, 114-122, 
123-130, 131-140 (1Met-ox), 
147-161, 167-178,353-370 
38 -2.52 0.0058 38.8/9.3 38.7/9.7 
1128 Heterogeneous nuclear ribonucleoprotein A1 P09651 16-31, 32-47, 93-105, 114-122, 123-130, 131-140, 147-161, 167-178 29 -2.33 0.017 38.8/9.3 37.7/8.0 
1127 Heterogeneous nuclear ribonucleoprotein A1 P09651 
16-31, 32-47 (1Met-ox), 93-105, 
114-122, 123-130, 131-140 
(1Met-ox), 147-161, 167-178, 
29 -2.29 0.0071 38.8/9.3 37.7/7.9 
1476 Phosphotidylethalonamine-binding protein  P30086 40-47, 48-62, 63-76, 83-93, 94-113, 120-132, 133-141, 162-179, 180-187 62 -2.06 0.00017 21.1/7.0 26.4/8.3 


















1767 Nucleoside Diphosphate kinase B P22392 7-18, 57-66, 89-105, 106-114 31 -2.01 6.10 e-005 17.3/8.5 20.6/8.4 
591 Pre-B cell enhancing factor precursor  P43490 
33-40, 89-99, 100-107, 108-117, 
118-127, 175-189, 190-196, 197-216, 
235-255, 290-296, 303-323, 343-349, 
393-400, 401-415, 435-447, 448-463, 
470-477, 479-491 
46 2.96 7.50 e-007 55.5/6.7 59.9/7.0 
596 Pre-B cell enhancing factor precursor P43490 
33-40, 89-99, 100-107, 108-117, 
118-127, 175-189, 190-196, 197-216, 
235-255, 290-296, 303-323, 343-349, 
470-477, 479-491 
34 2.38 0.00014 55.5/6.7 58.1/6.9 
1406 Heterogeneous nuclear ribonucleoprotein A1 P09651 16-31, 32-47, 93-105, 114-122, 123-130, 131-140, 141-161, 167-178 26 2.21 0.0052 38.8/9.3 26.8/7.0 
















1416 Heterogeneous nuclear ribonucleoprotein A1 P09651 
16-31, 32-47 (1Met-ox), 93-105, 
114-122, 123-130, 131-140 
(1Met-ox), 147-161, 167-178 
29 2.03 7.40 e-005 38.8/9.3 26.8/8.1 
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3.3 hnRNP A1 Undergoes Post-translational Modifications 
Intriguingly, 5 differentially regulated spots with different pIs (Figure 3.6B, 
Table 3.3, spot number 1081, 1127, 1128, 1406, and 1416) on the 2-D DIGE gel (pH 
6-11) were identified as hnRNP A1 by mass spectrometry. Three of the spots with 
apparent Mr of ~38 kDa were down-regulated while the other two spots with Mr of 
~26 kDa were found to be up-regulated (Figure 3.7). The detailed DeCyder software 
analysis of the 5 hnRNP A1 protein spots regulated by butyrate treatment was shown 
in Table 3.4. 
2-DE and western blot analysis were carried out to validate the change in 
expression of hnRNP A1 following butyrate treatment. Our results showed a train of 
hnRNP A1 immuno-reactive spots with reduced intensities in HCT-116 cells treated 
with butyrate (Figure 3.8A). This indicated that hnRNP A1 existed in several isoforms 
probably due to post-translational modifications. Indeed, hnRNP A1 was known to 
undergo post-translational modifications such as phosphorylation (Allemand et al., 
2005), sumoylation (Li et al., 2004b), and ubiquitinylation (Perrotti et al., 2000). An 
anti-phosphoprotein immuno-blot confirmed that the hnRNP A1 isoforms seen in our 
blots were due to phosphorylation at tyrosine and serine residues. However, there 











Figure 3.7 Selected area of the ImageQuant view of CyDye fluorescent image and its corresponding silver-stained pH 6-11 2-DE gel 
showing the 5 protein spots identified as hnRNP A1. Red circles represent proteins that are up-regulated following butyrate treatment. Green 
circles represent proteins down-regulated with butyrate treatment. The expression of these 5 protein spots were in the range of average volume 
ratio of -2.51 to 2.21.
1081 ↓1128 ↓1127 ↓ 
1406 ↑ 1416 ↑ 
1406 ↑ 1416 ↑ 
1127 ↓ 1128 ↓ 
1081 ↓ 
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Table 3.4 Detailed DeCyder software analysis of the 5 hnRNP A1 protein spots 
regulated by 24h butyrate treatment.  
 
3-D Spot Image 2-D Spot Image Fold difference with respect to Control  Spot 
No. 






   
-2.52 
1127 
   
-2.33 
1128 
   
-2.29 
1406 
   
2.03 
1416 











3.4 Butyrate Induced Subcellular Redistribution of hnRNP A1 
In our 2-D DIGE results, the expression level of full-length hnRNP A1 protein 
was shown to be decreased and a smaller form was detected only in butyrate-treated 
HCT-116 cells. It was possible that the native hnRNP A1 underwent cleavage upon 
butyrate treatment. Indeed, an immuno-reactive spot was shown to be induced in the 
treated sample, as detected at the lower molecular weight (Mr ~26kDa) region (Figure 
3.8A). It had been suggested earlier that during apoptosis hnRNP A1 could be cleaved 
and localized to the cytoplasm (Thiede et al., 2002). To explore this, we decided to 
study the expression level of hnRNP A1 in the cytosolic fraction of HCT-116 cells. 
After subcellular fractionation of HCT-116 cells, western blot analysis showed an 
immuno-reactive spot at a low molecular weight region of the gel in the cytosol of 
butyrate-treated cells but which was absent in the control counterpart (Figure 3.8B). 
This supports the hypothesis that butyrate induced the formation of a cleaved hnRNP 

























Figure 3.8 Western blot analysis of hnRNP A1 changes in HCT-116 24 hours after butyrate treatment. 120μg of proteins were loaded on a 
pH6-11 18 cm long strip. (A) Western blot with anti-hnRNP A1 antibodies illustrated a decrease in expression of all isoforms of hnRNP A1 in 
butyrate-treated HCT-116 cells. Analyses using anti-phosphotyrosine and anti-phosphoserine antibodies confirmed that these isoforms were due 
to phosphorylation of tyrosine and serine residues in hnRNP A1. However, there was no significant change in phosphorylation status of hnRNP 
A1 between the control and butyrate-treated cells. (B) Immuno-blotting of the cytosolic fraction of HCT-116 cells showed the presence of a low 









3.5 Temporal Analysis of Butyrate Treatment of HCT-116 Cells via iTRAQ and 
cICAT Labeling and Mass Spectrometry 
After we performed proteome analysis of 24h butyrate treatment using 2-D 
DIGE to study the initiation of growth arrest and apoptosis, we decided to 
characterize the temporal regulation of the proteome by analyzing the dynamic 
cellular response to butyrate treatment over different time-points. This study could 
help us to understand the progression of cell cycle blockage and apoptosis activation 
during cell maturation induced by butyrate in colonic cancer cells. Herein, iTRAQ 
(4-plex) labeling technology which enabled multiplex proteome analysis was used for 
the quantitative comparison of three populations of HCT-116 cells treated with 
butyrate for three different time-points (24h, 36h, 48h) with the control cells at 24h 
time-point (Figure 3.9A). In addition, we also utilized the cICAT labeling technology 


















Figure 3.9 Workflow outlining the quantitative and temporal proteome analysis of butyrate treatment using (A) iTRAQ and (B) cICAT 
labeling methods. iTRAQ labels primary amines of all peptides via the N-termini and ε-amino group of lysine side chain whereas cICAT 
reagents tags cysteine-containing proteins. The use of these two complementary technology platforms aims to provide valuable data on the 
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Figure 3.10 Quantitation and identification of (A) iTRAQ- and (B) cICAT-labeled peptides by 2-D LC MALDI-TOF/TOF MS. 
Quantitation of iTRAQ-labeled samples is determined by the reporter ions (m/z 114, 115, 116, 117) generated by MS/MS fragmentation whilst 
quantitation of cICAT-labeled samples relies on the relative abundance (heavy vs. light) of the pair of cICAT-labeled peptides with the unique 9 
Da mass shift detected in the MS spectrum.
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3.6 Protein Identification from iTRAQ- and cICAT-Labeled Peptides 
783 unique proteins were identified from a total of 3,116 tryptic peptides for 
the iTRAQ-labeled samples. On the other hand, 137 unique proteins were identified 
from a total of 241 peptides obtained from the cICAT labeling approach. Due to the 
difference in labeling chemistry, the result obtained from the cICAT approach 
complemented the iTRAQ data. Recently, quantitative proteomics incorporating 
stable isotope tagging such as post-isolation labeling technologies using ICAT or 
iTRAQ was demonstrated to be a complementary strategy to 2-DE (Goshe and Smith, 
2003; Tao and Aebersold, 2003). Most notably, a comparative study of these three 
proteomics methods found limited overlapping proteins between them, and iTRAQ 
was considered to be the more sensitive technology as compared to ICAT and 2-D 
DIGE (Wu et al., 2006). This underscored the importance of using various technology 
platforms for a more comprehensive proteomics study of complex biological samples. 
74 unique proteins were commonly identified from both iTRAQ and cICAT 
approach, which represented 9% and 54% of the total iTRAQ- and cICAT-identified 
proteins respectively. Based on the strict criteria applied for quantitation, such as the 
use of biological replicates, p values < 0.05, estimation of false positive identification 
rate and experimental determination of cut-off threshold, 105 and 58 differentially 
expressed proteins were identified from the iTRAQ and cICAT methods respectively 
(Figure 3.11, Table 3.5 and Table 3.6 for the number and list of differentially 
expressed proteins and relative ratios). Those proteins that were commonly identified 
from both approaches showed similar changes in expression levels (up-regulation, 
down-regulation or no change). Examples of proteins that showed differential 
expression in both approaches include galectin-1, HSP-90 alpha, Tu translation 
elongation factor, heterogeneous nuclear ribonucleoprotein F, malate dehydrogenase, 
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triosephosphate isomerase, ornithine aminotransferase, creatine kinase B-type, 
A-kinase anchor protein 12, epiplakin and filamin C. The identification of a greater 
number of proteins by the iTRAQ than cICAT method demonstrated that iTRAQ is a 
more sensitive technology. Furthermore, about half of the proteins identified by 
cICAT are found by iTRAQ. 
Interestingly, a subset of proteins found in this temporal study were also 
identified in our proteome analysis using 2-D DIGE, and they showed regulation in 
the similar manner by butyrate treatment. Such proteins included cytoskeletal 8, 
profilin-1, ornithine aminotransferase, cytochrome c oxidase polypeptide VIb, hnRNP 
K, hnRNP A1, translation initiation factor and Tu translation elongation factor. 
 
 
Figure 3.11 Venn diagram illustrating the number of proteins that were 
identified from the iTRAQ- and cICAT-labeled samples. ↑ represents number of 
protein that showed up-regulation, ↓ represents number of proteins that are 
down-regulated, and ≈ represents number of proteins that has no significant change in 














Table 3.5 List of iTRAQ-labeled proteins that showed temporal differential expresssion after butyrate treatment. Mean values and 
standard error (S.E.) of iTRAQ ratios were determined from the sample batches that identified the protein. S.E. values are not available for 
proteins identified in one sample batch. The p values were calculated based on t-test analysis of the iTRAQ ratio of peptides matched to the 






















Functions Protein Name 
Accession 
Number Functions 
24h Ratio ± 
S.E.(115/114) 
36h Ratio ± 
S.E.(116/114) 
48h Ratio ± 
S.E.(117/114) p Value 
NME1 9 kDa protein IPI00790856 Synthesis of nucleoside triphosphates 0.953 ± 0.093 0.828 ± 0.049 0.717 ± 0.087 0.0001 
CTPS CTP synthase 1 IPI00290142 Synthesis of nucleic acids and phospholipids 0.703 ± 0.001 0.603 ± 0.025 0.559 ± 0.014 0.0002 
PRIM2 Isoform 1 of DNA primase 
large subunit  IPI00027705 Replication of DNA 0.888  0.665  0.580  0.035 
MCM6 DNA replication licensing 
factor MCM6 IPI00031517 Initiation of eukaryotic genome replication 0.837  0.566  0.521  0.011 
MCM7 Isoform 1 of DNA 
replication licensing factor MCM7 IPI00299904 DNA replication 0.791  0.627  0.524  0.001 
CDC123 41 kDa protein IPI00514175 Cell division cycle 123 homolog 0.611  0.493  0.348  0.0009 
LOC389842 similar to Ran-specific 
GTPase-activating protein IPI00399212 Progression through the cell cycle 0.634 ± 0.064 0.571 ± 0.079 0.524 ± 0.022 0.0024 
CDC2 Hypothetical protein 
DKFZp686L20222 IPI00026689 Cell cycle transition 0.771 ± 0.020 0.683 ± 0.074 0.673 ± 0.157 0.0072 
SMC3 Structural maintenance of 
chromosomes protein 3 IPI00219420 Chromosome cohesion during cell cycle and in DNA repair. 0.723  0.628  0.605  0.0035 
CAPRIN1 Caprin-1 IPI00030910 Cytoplasmic activation/proliferation-associated protein 1 0.439 ± 0.076 0.253 ± 0.064 0.210 ± 0.074 0.0017 
RCC1;SNHG3-RCC1 Regulator of 
chromosome condensation IPI00747309
Regulation of onset of chromosome condensation in the S 
phase. 0.821  0.803  0.763  0.044 
NAP1L1 Nucleosome assembly 
























HDGF Hepatoma-derived growth 
factor IPI00020956 Cell growth 0.554  0.484  0.413  0.0035 
SUB1 Activated RNA polymerase 
II transcriptional coactivator p15 IPI00221222 Transcription 1.349 ± 0.108 1.481 ± 0.006 1.540 ± 0.001 0.00004 
TUFM Tu translation elongation 












































to eukaryotic translation elongation 
factor 1 b 
IPI00397392 Protein biosynthesis 0.898 ± 0.100 0.735 ± 0.154 0.739 ± 0.055 0.028 
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EIF3S3 Eukaryotic translation 
initiation factor 3 subunit 3 IPI00647650 Protein biosynthesis 0.817 ± 0.105 0.728 ± 0.012 0.717 ± 0.021 0.026 
LOC143244 similar to eukaryotic 
translation initiation factor 5A IPI00218084 Protein biosynthesis 0.902 ± 0.031 0.855 ± 0.110 0.799 ± 0.045 0.03 
NOLC1 Isoform Alpha of 
Nucleolar phosphoprotein p130 IPI00292387 Role in transcription catalyzed by rna polymerase i 0.727 ± 0.016 0.582 ± 0.007 0.454 ± 0.019 0.001 
RPL4 60S ribosomal protein L4 IPI00003918 Ribosomal protein 0.955 ± 0.006 0.856 ± 0.017 0.822 ± 0.028 9.87E-08 
RPLP2 60S acidic ribosomal 
protein P2 IPI00008529 Ribosomal protein 0.965 ± 0.021 0.886 ± 0.001 0.688 ± 0.106 - 
RPL5 Ribosomal protein L5 IPI00797983 Ribosomal protein 0.885  0.896  0.771  0.0048 
LOC388885 similar to 40S 
ribosomal protein S10 IPI00398673 Ribosomal protein 0.835 ± 0.016 0.803 ± 0.035 0.719 ± 0.032 0.002 
LOC730754 hypothetical protein 
LOC730754 IPI00642513 Similar to ribosomal protein S18 0.931 ± 0.114 0.791 ± 0.070 0.750 ± 0.092 0.0002 
RPS19 40S ribosomal protein S19 IPI00215780 Higher expression levels in some primary colon carcinomas 0.833 ± 0.026 0.804 ± 0.072 0.734 ± 0.058 0.0009 
RBM3 Putative RNA-binding 
protein 3 IPI00024320 RNA-binding protein family 0.988 ± 0.007 0.706 ± 0.050 0.561 ± 0.022 - 
LUC7L2 Isoform 2 of Putative 
RNA-binding protein Luc7-like 2 IPI00216804 Bind to RNA via its Arg/Ser-rich domain 0.794 ± 0.000 0.783 ± 0.019 0.704 ± 0.066 0.015 
DDX18 ATP-dependent RNA 
helicase DDX18 IPI00301323 DEAD box proteins 0.826  0.730  0.725  0.0008 
PRPF6 Pre-mRNA-processing 
factor 6 IPI00305068 pre-mRNA splicing 1.391 ± 0.172 1.399 ± 0.115 1.707 ± 0.083 0.024 
HNRPA1 Isoform A1-A of 
Heterogeneous nuclear 
ribonucleoprotein A1 
IPI00465365 pre-mRNA processing 0.812 ± 0.002 0.844 ± 0.053 0.786 ± 0.036 0.0012 
HNRPDL Isoform 1 of 
Heterogeneous nuclear 
ribonucleoprotein D-like 
IPI00011274 pre-mRNA processing 0.7965 ± 0.038 0.7645 ± 0.043 0.7205 ± 0.018 - 
HNRPD Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein D0 
IPI00220684 pre-mRNA processing 0.640  0.551  0.526  0.0015 
HNRPF Heterogeneous nuclear 
ribonucleoprotein F IPI00003881 pre-mRNA processing 0.776  0.791  0.774  0.041 
SYNCRIP Isoform 2 of 
Heterogeneous nuclear 
ribonucleoprotein Q 
IPI00402182 RNA interacting protein 0.845 ± 0.021 0.750 ± 0.044 0.772 ± 0.053 8.94E-06 
HNRPR HNRPR protein IPI00644055 pre-mRNA processing 0.819 ± 0.017 0.771 ± 0.027 0.742 ± 0.060 0.0046 
 105 
VAV2 Vav 2 oncogene IPI00472451 Regulation of Rho protein signal transduction 0.782 ± 0.032 0.789 ± 0.070 0.669 ± 0.062 - 
ANXA3 32 kDa protein IPI00745868 Regulation of cellular growth and in signal transduction pathways 0.815 ± 0.035 0.646 ± 0.020 0.572 ± 0.031 0.0009 
AKAP12 Isoform 1 of A-kinase 










PPM1G Protein phosphatase 1G IPI00006167 Serine/threonine phosphatases 0.856  0.815  0.712  0.014 
MT1X Metallothionein-1X IPI00008753 Induction by various anticancer agents 1.995  2.625  2.401  1.24E-06 
LGALS1 Galectin-1 IPI00219219 Induced by butyrate 1.227 ± 0.025 1.489 ± 0.028 1.456 ± 0.076 0.049 
RAP1A Ras-related protein 
Rap-1A precursor IPI00019345 Counteracts the mitogenic function of Ras 1.261 ± 0.101 1.233 ± 0.066 1.320 ± 0.073 0.039 



















SLC25A5 ADP/ATP translocase 2 IPI00007188 Adenine nucleotide translocator 2 (ANT2) 1.177  1.138  1.444  0.033 
NDUFA10 NADH dehydrogenase 
[ubiquinone] 1 alpha subcomplex 
subunit 10, mito 
IPI00029561 Complex I 1.283 ± 0.052 1.334 ± 0.077 1.682 ± 0.087 0.007 
SDHA Succinate dehydrogenase 
[ubiquinone] flavoprotein subunit, 
mitochondria 
IPI00305166 Complex II 1.292 ± 0.119 1.471 ± 0.190 1.691 ± 0.280 0.007 
COX5A Cytochrome c oxidase 
subunit 5A, mitochondrial 
precursor 
IPI00025086 Complex IV 1.136 ± 0.022 1.495 ± 0.144 1.575 ± 0.067 0.039 
COX6B1 Cytochrome c oxidase 



























ATP5B ATP synthase subunit beta, 
mitochondrial precursor IPI00303476 Complex V 1.256 ± 0.188 1.231 ± 0.173 1.345 ± 0.212 0.034 
HSPB1 Heat-shock protein beta-1 IPI00025512 Heat shock 27 kDa protein 0.877 ± 0.082 0.664 ± 0.056 0.596 ± 0.107 0.002 
HSPA4 Heat shock 70 kDa protein 
4 IPI00002966 Molecular chaperone 0.944 ± 0.070 0.933 ± 0.074 0.835 ± 0.005 0.037 
HSPA8 Isoform 2 of Heat shock 
cognate 71 kDa protein IPI00037070 Facilitate correct folding 0.961 ± 0.080 0.820 ± 0.038 0.808 ± 0.110 2.41E-06 
HSPA8 Isoform 1 of Heat shock 
cognate 71 kDa protein  IPI00003865 Facilitate correct folding 0.872  0.788  0.710  1.17E-05 
HSP90AA1 Heat shock protein 
HSP 90-alpha IPI00784295 Molecular chaperone 1.127 ± 0.052 1.026 ± 0.056 0.887 ± 0.056 1.96E-06 
HSP90AB2P Heat shock protein 
90Bb IPI00455599 Heat shock protein 90kDa alpha 1.080 ± 0.095 0.884 ± 0.100 0.742 ± 0.083 0.0027 
HSP90AB4P Heat shock protein 
90Bd IPI00555565 Heat shock protein 90kDa alpha 0.895 ± 0.082 0.818 ± 0.102 0.699 ± 0.052 9.45E-06 
HSP90AB1 Heat shock protein 































C6orf115 similar to Protein 
C6orf115 IPI00374316 Heat shock protein 0.621  0.470  0.392  0.012 
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CCT2 T-complex protein 1 subunit IPI00297779 Chaperonin containing TCP1 complex 0.832 ± 0.018 0.765 ± 0.045 0.722 ± 0.049 0.014 
P4HB Protein disulfide-isomerase 
precursor IPI00010796 Disulfide bonds formation 1.249 ± 0.088 1.472 ± 0.150 1.506 ± 0.141 3.3E-06 
PRDX5 Isoform Mitochondrial of 
Peroxiredoxin-5, mitochondrial 
precursor 
IPI00024915 Intracellular redox signaling 1.037 ± 0.146 1.423 ± 0.081 1.557 ± 0.139 - 
PRDX2 Peroxiredoxin-2 IPI00027350 Peroxiredoxin 2 1.340 ± 0.228 1.361 ± 0.075 1.560 ± 0.132 0.010 
PRDX1 11 kDa protein IPI00641244 Peroxiredoxin 1 1.273 ± 0.064 1.490 ± 0.058 1.415 ± 0.035 0.0011 
TXNDC4 Thioredoxin 
domain-containing protein 4 
precursor 
IPI00401264 Protein-disulfide isomerase 1.083 ± 0.145 1.196 ± 0.082 1.532 ± 0.137 0.002 
TXN Thioredoxin IPI00216298 Protein-disulfide isomerase 0.931 ± 0.046 0.865 ± 0.000 0.634 ± 0.019 0.0037 
PSME2 proteasome activator 
subunit 2 IPI00746205 Cleave peptides in an ATP/ubiquitin-dependent process 0.945 ± 0.061 0.837 ± 0.090 0.742 ± 0.012 0.025 
UBE1 Ubiquitin-activating enzyme 



































FBXO2 F-box only protein 2 IPI00007087 Ubiquitin protein ligase complex called SCFs 1.535  1.683  1.907  0.012 
MDH2 Malate dehydrogenase, 
mitochondrial precursor IPI00291006 Krebs Cycle malate to OAA 1.219 ± 0.075 1.387 ± 0.124 1.783 ± 0.220 0.0012 
SLC25A1 Tricarboxylate transport 
protein, mitochondrial precursor IPI00294159 Citrate-H+/malate exchange 0.876  0.980  1.488  0.0015 
OGDH oxoglutarate 
(alpha-ketoglutarate) 
dehydrogenase (lipoamide) isoform 
1 
IPI00098902 Krebs Cycle OAA to sunccinyl-CoA 1.205 ± 0.007 1.330 ± 0.057 1.629 ± 0.033 0.029 
IDH1 Isocitrate dehydrogenase 
[NADP] cytoplasmic IPI00027223 Citrate cycle (TCA cycle) 1.259 ± 0.178 1.208 ± 0.082 1.302 ± 0.158 0.0025 
TPI1 Isoform 1 of Triosephosphate 
isomerase IPI00797687 Glycolytic enzyme 1.300 ± 0.134 1.281 ± 0.163 1.289 ± 0.053 0.0016 
C12orf5 Uncharacterized protein 
C12orf5 IPI00006907 Pentose phosphate pathway 1.643 ± 0.046 1.844 ± 0.072 1.878 ± 0.053 3.50E-05 
TALDO1 similar to transaldolase 1 IPI00550488 Pentose phosphate pathway 1.900 ± 0.206 1.978 ± 0.249 2.511 ± 0.103 - 
TKT Transketolase IPI00643920 Pentose phosphate pathway 1.098  0.991  1.288  0.0029 
GANAB Isoform 1 of Neutral 
alpha-glucosidase AB precursor IPI00383581 n-linked oligosaccharide processing 1.119 ± 0.037 1.217 ± 0.066 1.409 ± 0.130 0.028 
ENO1 Isoform MBP-1 of 
Alpha-enolase IPI00759806 Glycolysis to and from phosphoglycerate 0.918 ± 0.050 0.911 ± 0.107 0.757 ± 0.038 7.66E-05 
ENO1 Isoform alpha-enolase of 






























OAT Ornithine aminotransferase, 
mitochondrial precursor IPI00022334 Arginine and ornithine enzyme 1.436 ± 0.127 1.811 ± 0.115 1.853 ± 0.103 0.019 
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ASNS Asparagine synthetase IPI00554777 Amino acid synthesis 1.223 ± 0.180 1.239 ± 0.138 1.382 ± 0.275 2.56E-06 
SARS Seryl-tRNA synthetase IPI00514587 Amino acid synthesis 1.473 ± 0.106 1.596 ± 0.096 1.471 ± 0.088 0.0002 
CARS Isoform 2 of 
Cysteinyl-tRNA synthetase, 
cytoplasmic 
IPI00158625 Amino acid synthesis 1.379  1.110  1.530  5.38E-05 
ASS1 Argininosuccinate synthase IPI00020632 Arginine biosynthetic pathway 1.487  1.443  1.542  - 
ALDH18A1 Isoform Short of Delta 
1-pyrroline-5-carboxylate 
synthetase 
IPI00218547 Amino acid synthesis proline, ornithine and arginine 1.077 ± 0.116 1.100 ± 0.125 1.436 ± 0.154 0.0078 
ECHS1 Enoyl-CoA hydratase, 
mitochondrial precursor IPI00024993 Beta-oxidation of fatty acids 1.401 ± 0.174 1.575 ± 0.321 1.710 ± 0.361 - 
DBI Isoform 2 of 
Acyl-CoA-binding protein IPI00218836 Lipid metabolism 1.157 ± 0.011 1.171 ± 0.033 1.304 ± 0.057 0.042 
CYB5R3 Isoform 1 of 
NADH-cytochrome b5 reductase 3 IPI00328415
Desaturation and elongation of fatty acids, cholesterol 
biosynthesis 1.241  1.550  1.722  - 
CKB Creatine kinase B-type IPI00022977 Energy transduction 1.350 ± 0.045 1.518 ± 0.069 1.618 ± 0.043 2.85E-08 
SEC22B Vesicle-trafficking protein 
SEC22b IPI00006865 Vesicle trafficking proteins 1.512 ± 0.181 2.126 ± 0.108 2.683 ± 0.413 - 
CLTC Isoform 2 of Clathrin heavy 
chain 1 IPI00455383 Trafficking of receptors and endocytosis 1.190 ± 0.002 1.253 ± 0.079 1.284 ± 0.027 0.0037 
RAB11B Ras-related protein 
Rab-11B IPI00020436
Secretory pathways, and may be involved in protein 
transport 1.511 ± 0.209 1.425 ± 0.083 1.504 ± 0.144 - 
NAPB NAPB protein IPI00748905 Vesicle targeting and docking 1.359 ± 0.029 1.248 ± 0.024 1.372 ± 0.024 0.013 
SAR1A SAR1 gene homolog A IPI00513941 Transport from the endoplasmic reticulum to the golgi apparatus 1.424  1.271  1.363  - 
ATP6V1A Vacuolar ATP synthase 



















SLC25A6 Solute carrier family 25 
(Mitochondrial carrier; adenine 
nucleotide translocator), member 6 
IPI00645646 Mitochondrial transport and apoptosis 1.063 ± 0.078 1.069 ± 0.017 1.274 ± 0.078 0.002 
KRT6L keratin 6L IPI00241841 Intermediate filament 1.137  1.402  1.630  0.00069 
KRT7 keratin 7 IPI00847342 Intermediate filament 1.346  1.583  1.909  0.030 
KRT8 Keratin, type II cytoskeletal 
8 IPI00554648 Intermediate filament 1.172 ± 0.042 1.334 ± 0.075 1.489 ± 0.075 3.33E-09 
KRT14 Keratin, type I cytoskeletal 
14 IPI00384444 Intermediate filament 2.000  2.330  2.625  0.018 
KRT18 Keratin, type I cytoskeletal 
18 IPI00784347 Intermediate filament 1.194 ± 0.065 1.392 ± 0.146 1.621 ± 0.239 0.0047 
KRT19 Keratin, type I cytoskeletal 
19 IPI00479145 Intermediate filament 1.419 ± 0.032 1.592 ± 0.040 1.777 ± 0.042 5.89E-06 
FLNC Isoform 2 of Filamin-C IPI00413958 Anchor and crosslink actin cytoskeleton 1.386  1.612  1.753  0.022 













































CFL1 24 kDa protein IPI00784459 Actin-depolymerizing activity 1.316  1.403  1.491  0.00023 
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Table 3.6 List of cICAT-labeled proteins that showed temporal differential expresssion after butyrate treatment. For cICAT, the change 























































PA2G4 20 kDa protein IPI00790307 PA2G4 proliferation-associated 2G4 - 0.449 - 
TUFM Tu translation elongation factor, 
mitochondrial IPI00027107 Protein biosynthesis - - 2.41 
EEF1A1 EEF1A1 protein IPI00025447 Protein synthesis Proto-oncogene - 0.438 - 
EEF1G Elongation factor 1-gamma IPI00000875 Highly expressed in pancreatic tumor tissue - 0.533 - 
EEF2 Elongation factor 2 IPI00186290 Protein synthesis 0.98 0.68 - 
EIF5A2 Eukaryotic translation initiation factor 
5A-2 IPI00006935 Proliferation-related function - 0.648 - 
PABPC1 Isoform 1 of Polyadenylate-binding 
protein 1 IPI00008524
Promote translation initiation and termination, recycling of 
ribosomes, and stability of the mRNA 0.894 0.813 0.545 
RPS6 40S ribosomal protein S6 IPI00021840 Control of cell growth and proliferation through the selective translation - 0.617 - 
RPL10A 60S ribosomal protein L10a IPI00412579 Ribosomal_L1 - 0.57 - 
30 kDa protein IPI00472119 Ribosomal_S3Ae 0.803 0.606 0.656 
RPS2 40S ribosomal protein S2  IPI00013485 Ribosomal_S5 - 0.601 - 
RPL14 60S ribosomal protein L14 IPI00002821 Component of the 60S subunit - 0.665 - 
LUC7L2 Isoform 1 of Putative RNA-binding 
protein Luc7-like 2 IPI00006932 Bind to RNA via its Arg/Ser-rich domain - 0.639 - 
HMGB2 High mobility group protein B2 IPI00219097 Chromatin structure modulation Overexpressed in malignant - 0.605 - 
CNBP Cellular nucleic acid binding protein 
beta variant 2 IPI00430813 Single stranded DNA-binding protein 0.477 - - 
NASP Isoform 1 of Nuclear autoantigenic 
sperm protein IPI00179953
DNA replication, normal cell cycle progression and cell 
proliferation - 0.386 - 
APEX1 DNA-(apurinic or apyrimidinic site) 











































SMARCC2 Isoform 2 of SWI/SNF-related 
matrix-associated actin-dependent regulator IPI00150057 ATP-dependent nucleosome remodeling - - 0.488 
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HMGB3 High mobility group protein B3 IPI00217477 High-mobility group box 3 - 0.605 - 
HNRPD Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein D0 IPI00028888 Pre-mRNA processing - 0.616 - 
HNRPF Heterogeneous nuclear 
ribonucleoprotein F IPI00003881 Pre-mRNA processing - 0.651 - 
HNRPK Isoform 1 of Heterogeneous nuclear 
ribonucleoprotein K IPI00216049 Pre-mRNA processing - 0.451 0.622 
SNRPB Isoform SM-B' of Small nuclear 
ribonucleoprotein-associated proteins IPI00027285 Pre-mRNA processing 2.235 - - 
RG9MTD1 RNA (guanine-9-) 
methyltransferase domain-containing protein 1 IPI00099996 RNA (guanine-9-) methyltransferase domain containing 1 1.474 1.816 2.869 
AKAP12 A-kinase anchor protein 12 isoform 
2 IPI00217683 Signaling scaffold for kinases - 0 - 
RHOC Rho-related GTP-binding protein 











PPM1G Protein phosphatase 1G IPI00006167 Serine/threonine phosphatases - 0.633 - 
LGALS1 Galectin-1 IPI00219219 Induced by butyrate 1.816 2.585 2.034 
VDAC1 Voltage-dependent anion-selective 



















RAN GTP-binding nuclear protein Ran IPI00643041 Ras-related nuclear protein, member RAS oncogene family - 0.439 - 
UQCRH Ubiquinol-cytochrome c reductase 



























ATP5A1 ATP synthase subunit alpha, 
mitochondrial precursor IPI00440493
ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit 1 - 2.13 - 
HSPD1 60 kDa heat shock protein, 
mitochondrial precursor IPI00784154 Molecular chaperone 0.999 1.229 1.479 
HSPA1B;HSPA1A Heat shock 70 kDa protein 
1 IPI00304925 Chaperone inhibit apoptosis - 0.642 0.582 
HSP90AA1 Heat shock protein HSP 90-alpha 
2 IPI00382470 Molecular chaperone - - 0.487 
HSPH1 Isoform Beta of Heat-shock protein 
105 kDa IPI00218993 Prevents the aggregation of denatured proteins - - 0.432 
CCT4 T-complex protein 1 subunit delta IPI00302927 Molecular chaperone - 0.664 - 
CCT7 T-complex protein 1 subunit eta IPI00018465 Molecular chaperone - 0.529 - 
CCT8 Chaperonin containing TCP1, subunit 8 































PRDX6 Peroxiredoxin-6 IPI00220301 Redox regulation - 0.497 - 
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MDH2 Malate dehydrogenase, mitochondrial 
precursor IPI00291006 Krebs Cycle malate to OAA - 1.796 - 
TPI1 Isoform 2 of Triosephosphate isomerase IPI00451401 Glycolysis 2.039 - 1.033 
G6PD Isoform Long of Glucose-6-phosphate 
1-dehydrogenase IPI00216008 Glycolysis pentose phosphate pathway - - 1.835 
DLD Dihydrolipoyl dehydrogenase, 
mitochondrial precursor IPI00015911 pyruvate and alpha-ketoglutarate dehydrogenase complexes. 1.522 1.366 2.185 
OAT Ornithine aminotransferase, 
mitochondrial precursor IPI00022334 Arginine and ornithine enzyme - 2.901 2476.13 
GOT2 Aspartate aminotransferase, 
mitochondrial precursor IPI00018206 Amino acid metabolism, urea and TCA cycle - 2.145 - 
GLUD1 Glutamate dehydrogenase 1, 



















CKB Creatine kinase B-type IPI00022977 Energy transduction 2.375 1.554 1.942 
SURF4 Isoform 1 of Surfeit locus protein 4 IPI00005737 Transport between the endoplasmic reticulum and Golgi compartments - - 2.281 
TMED7 Transmembrane emp24 
domain-containing protein 7 precursor IPI00032825 Membrane protein carrier activity - - 2426.419 




creates the electrochemical gradient of sodium and 
potassium ions, providing the energy for active transport of 
various nutrients 































ALB ALB protein IPI00216773 Albumin protein - 1.588 - 
EPPK1 Epiplakin IPI00010951 Integrity of intermediate filaments 5871.174 7123.541 7718.168 
FLNA Filamin-A IPI00333541 Anchor and crosslink actin cytoskeleton 2.656 1.484 1.483 
FLNB Isoform 1 of Filamin-B IPI00289334 Anchor and crosslink actin cytoskeleton - 2.347 - 












































LIMA1 Isoform Beta of LIM domain and 
actin-binding protein 1 IPI00008918
Cytoskeleton-associated protein inhibits actin filament 






3.7 Peptide Counts Per iTRAQ- and cICAT-Labeled Proteins 
Many of the iTRAQ-labeled proteins were identified by several peptides. 
About 54% of the proteins were matched to at least two peptides, and around 17% of 
the proteins were identified by more than three peptides (Figure 3.12). Compared to 
the iTRAQ data, fewer peptides were matched to each cICAT-labeled protein which 
exemplified the disparity in proteome coverage due to difference in their labeling 
chemistries. About 82% of the cICAT-labeled proteins were single-peptide based 
identifications, with only 1% of them matched to more than three peptides (Figure 
3.12). The vast difference in peptide counts per protein identified by iTRAQ and 
cICAT is attributed to the rarity of cysteinyl residues, as well as better fragmentation 
pattern and higher ionization efficiency of iTRAQ-labeled peptides (Hardt et al., 2005; 
Aggarwal et al., 2005). The number and amino acid sequence of peptides that are 
matched to the proteins (for both ≥ two peptides and single-peptide based protein 
identifications) are shown in the Appendix Data III to VI. 
 
3.7.1 Correlation of Peptide Counts and Protein Abundance in ‘Shotgun’ 
Proteomics 
The number of peptides matched per protein was found to correspond to the 
number of replicate runs that identified the particular protein (Figure 3.13A). On 
average, 5.7 peptides were matched to iTRAQ-labeled proteins that were identified in 
all 4 biological replicates whereas only 1.6 peptides were matched to those found in 
one experimental run. This may show that proteins of high abundance have greater 
peptide coverage than those of low abundance and hence were identified by MS more 
frequently from replicates analyses. Data from Link et al. (1999) and Washburn et al. 
(2001) had shown that ‘shotgun’ proteomics is not a comprehensive profiling 
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approach. Undoubtedly, ‘shotgun’ proteomics applied to complex biological samples 
such as cell or tissues lysate is unable to analyze all ions that are detected by MS (Liu 
et al., 2004; Gan et al., 2007). Data dependent acquisition in this LC-MS technique 
missed low-abundance peptides during tandem MS analysis. In this study, about 59% 
of the proteins can only be found from one run, and a decreasing number of proteins 
were commonly identified from more of the iTRAQ-labeled replicates analyzed 
(Figure 3.13B). As shown in Figure 3.13B, only about 5% of the iTRAQ-labeled 
proteins were identified from all the 4 experimental runs. 
In this study, labeling of the samples with cICAT reagents was based on a 
pair-wise analysis of each of the three time-point of butyrate treatment. On the other 
hand, the use of iTRAQ reagents allowed multiplexing of all the 4 samples (all three 
time-points) in a single LC-MS/MS run. Hence our work required three pair-wise 
cICAT analyses for the three time-course (24h, 26h and 48h) proteome profiling 
studies that we conducted in a single iTRAQ experiment (Figure 3.9B). This 
complicates our cICAT data analysis as different sets of peptides and proteins were 
identified from each LC-MS/MS run. Similar to the results obtained from the iTRAQ 
approach, cICAT data showed that the majority (about 70%) of the proteins were 
identified in only one time-point analysis (24h, 36h or 48h) whilst only 13% of the 
proteins were commonly identified across all the three time-points (Figure 3.13C). 
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Figure 3.12 Number of peptide counts per protein identified from the iTRAQ and cICAT approach. The difference in labeling chemistries 
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Figure 3.13A Number of peptide counts per protein identified from the different 
number of iTRAQ-labeled samples analyzed. Proteins that were identified from 
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Figure 3.13B Distribution of iTRAQ-labeled proteins identified from different 
number of biological replicates. About 55% of the identified proteins were present 
in only one sample and a decreasing percentage of common proteins were found as 






























Figure 3.13C cICAT-labeled proteins identified from the three time-points 
samples (24h, 36h and 48h butyrate-treated). A lesser number of proteins were 
commonly identified from all the three time-points than those that were found in only 
one time-point sample. 
 
3.8 Physicochemical Properties of the Proteins Identified 
3.8.1 Molecular Weight (Mr) and Isoelectric Point (pI) 
It is well known that proteins with extremes in molecular weight (Mr) and 
isoelectric point (pI) are poorly resolved by 2-DE. From our study, both the iTRAQ- 
and cICAT-labeled proteins were plotted according to their theoretical pI values and 
Mr (Figure 3.14). They were shown to be predominantly between pI 4 to 12 and with 
Mr less than 100kDa. Proteins with extreme Mr (Mr < 15kD or Mr > 100kDa), such as 
metallothionein-1X (8kDa), NME1 (10kDa), cytochrome c oxidase subunit VIb 
(13kDa), clathrin heavy chain (190kDa), A-kinase anchoring protein 12 (200 kDa), 
filamin A (300kDa) and epiplakin (500kDa) were detected from this “bottom-up” 
proteomics approach. Many of the alkaline proteins are involved in important 
fundamental cellular processes that are disrupted in carcinogenesis, such as DNA 
replication, transcription, and translation (Li et al., 2004d). Several proteins of high 
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basicity (pI > 10), such as ribosomal proteins and histones were found in this study. 
However, acidic proteins (pI < 4) were not identified from both the iTRAQ and 
cICAT approaches. This could be due to the low content or absence of lysine/arginine 




Membrane proteins, including G-protein coupled receptors (GPCRs), ion 
channels and transporters, account for more than 50% of drug targets (Hopkins and 
Groom, 2002). As resolution of hydrophobic proteins is one of the pitfalls in the 2-DE 
approach, we sought to search for such membrane and membrane-bound proteins by 
calculating the hydropathic indices (GRAVY score) (Kyte and Doolittle, 1982) and 
predicting transmembrane helixes (TMHs) (Hofmann and Stoffel, 1993) of the 
proteins identified in this study. About 5% of the total proteins identified have 
positive GRAVY score, suggesting that they are hydrophobic proteins (Figure 3.15). 
On the other hand, 70% of the proteins were predicted to possess at least one TMH 
(Figure 3.16). In addition, some of the membrane-associated proteins possess positive 
GRAVY score and several TMHs, such as SLC25A5 ADP/ATP translocase 2, ATP 
synthase subunit g, ATP synthase subunit beta, SLC25A6 solute carrier family 25, 







3.8.3 Cysteinyl Residues Content 
The use of ICAT labeling strategy in ‘shotgun’ proteomics reduces the 
complexity of peptide mixtures via selective tagging and isolation of 
cysteine-containing peptides. This enrichment step aimed to increase the potential of 
identifying low abundance proteins in the complex whole cell lysate (Han et al., 2001; 
Gygi et al., 2002). On the other hand, the tagging of all peptides by the iTRAQ 
reagents avoided the setback of ICAT in detecting only cysteine-containing proteins. 
Clearly, a much greater percentage of proteins containing no or less cysteinyl residues 
(0 to 2) were identified by iTRAQ than those found from cICAT labeling method 
(Figure 3.17). Examples of the proteins identified by iTRAQ that do not contain 
cysteinyl residues include prohibitin-2, cytoskeletal 8, cytoskeletal 18, cytoskeletal 19, 
ribosomal proteins and ATP synthase subunits. However, our results did not show that 
the cICAT approach identified significantly more proteins with high content of 
cysteinyl residues than iTRAQ. This could be due to the identification of a greater 



































































Figure 3.14 Distribution of predicted molecular weight (Mr) and isoelectric point 
(pI) of the proteins identified from (A) iTRAQ and (B) cICAT labeling 
methodologies. All the proteins have physicochemical properties between pI 4-12. 











































Figure 3.15 Histogram of hydropathic indices (GRAVY score) of the proteins identified from iTRAQ and cICAT approaches. No 
significant difference was observed between these two approaches. About 5% of the proteins have positive GRAVY score, indicating that they 







































Figure 3.16 Histogram of transmembrane helixes (TMHs) predicted for proteins identified from the iTRAQ and cICAT approaches. No 




Figure 3.17 Comparison of the number of cysteinyl residues per proteins identified from iTRAQ and cICAT approaches. Significantly 
higher number of proteins with low cysteinyl residues content was identified from iTRAQ-labeled than cICAT-labeled samples. 
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3.9 Butyrate-Regulated Pathways Identified by the Temporal Analysis of 
Butyrate Treatment 
As shown in Figure 3.18, the number of proteins exhibiting minor differential 
expression (relative ratios between 0.75 and 1.25) was higher at the 24h time-point 
compared to the 36h and 48h time-points. On the other hand, the proportion of 
proteins with significant changes in expression levels (relative ratio <0.75 or >1.25) 
increased as a function of time (48h > 36h > 24h). This showed that the expression 
levels of the proteins were regulated by butyrate in a time-dependent manner. 
In addition to providing insights into the mechanism underlying butyrate’s 
pleiotropic effects, our study of the time dynamics of butyrate treatment also shed 
light on potential therapeutic targets associated with the progression of cell maturation 
in cancer cells. From the list of differentially expressed proteins collated from this 
comparative proteomics approach, proteins that exhibited progressive up- or 
down-regulation on a temporal basis were clustered into groups on the bases of 
biological functions (Figure 3.19, Table 3.5 and Table 3.6). The temporal regulation 
of these proteins was related to four cellular processes affected by butyrate treatment, 
viz., A) growth arrest, B) apoptosis, C) metabolism, and D) metastasis. An overview 
of the temporal anti-cancer effects of butyrate treatment on the various cellular 
processes was shown in Figure 3.20. Some of the protein candidates that displayed 
up- or down-regulation upon butyrate treatment over the time-points were selected for 
validation using quantitative real-time PCR and/or western blotting techniques 





















































Figure 3.18 Change in expression levels of proteins as a function of butyrate treatment time. The proportion of proteins with significant 
changes in expression levels (relative ratio <0.75 or >1.25) increases as a function of time of treatment. 
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NME1 9 kDa protein
CTPS CTP synthase 1
PRIM2 Isoform 1 of DNA primase large subunit 
MCM6 DNA replication licensing factor MCM6
MCM7 Isoform 1 of DNA replication licensing factor
MCM7
CDC123 41 kDa protein
RANBP1 Ran-specific GTPase-activating protein
CDC2 Hypothetical protein DKFZp686L20222
SMC3 Structural maintenance of chromosomes protein 3
CAPRIN1 Caprin-1
RCC1;SNHG3-RCC1 Regulator of chromosome condensation
NAP1L1 Nucleosome assembly protein 1-like 1








































RAP1A Ras-related protein Rap-1A precursor
PHB2 Prohibitin-2




























NDUFA10 NADH dehydrogenase ubiquinone 1
alpha subcomplex
SDHA Succinate dehydrogenase [ubiquinone]
flavoprotein subunit, mitochondri
COX5A Cytochrome c oxidase subunit 5A,
mitochondrial precursor
COX6B1 Cytochrome c oxidase subunit VIb
isoform 1
ATP5B ATP synthase subunit beta, mitochondrial
precursor



































HSPB1 Heat-shock protein beta-1
HSPA4 Heat shock 70 kDa protein 4
HSPA8 Isoform 2 of Heat shock cognate 71 kDa protein
HSPA8 Isoform 1 of Heat shock cognate 71 kDa protein
HSP90AA1 Heat shock protein HSP 90-alpha
HSP90AB2P Heat shock protein 90Bb
HSP90AB4P Heat shock protein 90Bd
HSP90AB1 Heat shock protein HSP 90-beta
C6orf115 similar to Protein C6orf115
CCT2 T-complex protein 1 subunit beta
P4HB Protein disulfide-isomerase precursor



































PSME2 proteasome activator subunit 2
UBE1 Ubiquitin-activating enzyme E1






































MDH2 Malate dehydrogenase, mitochondrial precursor
OGDH oxoglutarate (alpha-ketoglutarate) dehydrogenase
(lipoamide) isoform 1
IDH1 Isocitrate dehydrogenase [NADP] cytoplasmic
C12orf5 Uncharacterized protein C12orf5
TALDO1 similar to transaldolase 1
ENO1 Isoform MBP-1 of Alpha-enolase
ENO1 Isoform alpha-enolase of Alpha-enolase
OAT Ornithine aminotransferase, mitochondrial precursor
ASNS Asparagine synthetase
ASS1 Argininosuccinate synthase
ALDH18A1 Isoform Short of Delta 1-pyrroline-5-
carboxylate synthetase
ECHS1 Enoyl-CoA hydratase, mitochondrial precursor
DBI Isoform 2 of Acyl-CoA-binding protein
CYB5R3 Isoform 1 of NADH-cytochrome b5 reductase 3





































KRT8 Keratin, type II cytoskeletal 8
KRT14 Keratin, type I cytoskeletal 14
KRT18 Keratin, type I cytoskeletal 18
KRT19 Keratin, type I cytoskeletal 19
FLNC Isoform 2 of Filamin-C
EPPK1 Epiplakin
CFL1 24 kDa protein
 
 
Figure 3.19 Identification of protein clusters in biological functions that showed similar trends of differential expression over time. These 
proteins exhibit progressive up- or down-regulation on a temporal basis and were clustered into groups of certain cellular processes modulated 
by butyrate: A) cell cycle progression B) apoptosis (B1-tumour suppressors, B2-oxidative phosphorylation, B3-HSPs and chaperones, 















































Figure 3.20 An overview of the temporal effects of butyrate treatment on the various cellular processes associated with the progression 
of cell maturation in cancer cells. The differential regulation of the proteins from each cellular process was summarized to illustrate the overall 











Cytochrome c oxidase Va Cytochrome c oxidase VIb Orinithine
aminotransferase


















































Figure 3.21 Validation of the iTRAQ results on selected proteins using real-time PCR. The results verified differential regulation of these 
proteins (down-regulated or up-regulated) upon butyrate treatment. Fold-change ratio assessed by real-time PCR was expressed as mean values 

















Figure 3.22 Western blots of proteins identified to have differential expression from iTRAQ data. A. Western blot confirmed differential 
expression of these proteins. GAPDH was used as the loading control. For AKAP12, decreased expression of full length protein (~200kDa) was 
detected but an increase in the presence of a protein fragment ~40kDa was seen over time. B. 2-DE (pH 3-10) western blot for AKAP12 was 









































Chapter 4      DISCUSSION   
 
4.1 2-D DIGE Analysis of Butyrate-Treated HCT-116 Cells – Identification of 
Proteins Involved in the Initiation of Growth Arrest and Apoptosis during Cell 
Maturation 
HCT-116 cells, a heterologous human colon carcinoma cell line with Ras 
mutation (Brattain et al., 1981), has been used in a series of studies to investigate the 
effects conferred by HDAC inhibitors (HDACi). These studies using drugs such as 
butyrate, suberoylanilide hydroxamic acid (SAHA) and trichostatin A (TSA) were useful 
in identifying protein targets and molecular pathways that mediate the biological effects 
of these anti-cancer drugs on colorectal cancer. For instance, the requirement for the 
histone hyperacetylation pathway (Hinnebusch et al., 2002), contribution of p21 and p53 
(Archer et al., 1998b; Mahyar-Roemer and Roemer, 2001), sensitization of 
TRAIL-pathway (Kim et al., 2004b), and the linear relationship of WNT activity to 
butyrate actions (Lazarova et al., 2004) have been investigated using this cell line. In 
addition, fractionation of HCT-116 cell lysates with a 2-D chromatographic technique by 
Yan et al. (2003) visualized ‘protein bands’ that were peninsularinone drug-regulated. In 
another context, HCT-116 cells were used to create a data-driven model of colon cancer 
cells using the Diagrammatic Cell Language (Christopher et al., 2004) to integrate 
networks in signaling pathways and gene expression.  
Previous work done by our lab has shown that physiological concentration of 
butyrate initiated growth arrest and apoptosis in HCT-116 cells at the 24h time-point 
treatment (Tan et al., 2002). Here, we aimed to use 2-D DIGE analysis to identify 
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proteins involved in the initiation of cell maturation by butyrate in cancer cells. 2-D 
DIGE is a fluorescent 2-DE technology used in comparative proteomics to overcome the 
technical limitation of non-reproducibility present in conventional 2-DE gels. Among the 
20 protein spots that showed differential expression upon initiation of growth arrest and 
apoptosis (24h post-treatment), only 6 of them were identified by MALDI-TOF MS 
(Figure 3.4 and Table 3.2). Subsequently, we prefractionated the cell lysate using heparin 
affinity chromatography prior to 2-D DIGE with the view to identify more proteins 
associated with butyrate-induced growth arrest and apoptosis. 
 
4.2 Improved Differential Analysis of Butyrate-Treated HCT-116 Cells Using 
Heparin Affinity Chromatography as a Prefractionation Step 
The sheer magnitude of cellular protein expression surpasses the sensitivity of 
current 2-DE technologies. Hence, 2-DE analyses of crude cells/tissues extracts are 
dominated by proteins of high abundance that obscure those with low copy numbers. 
These under-represented proteins such as transcription factors and regulatory proteins are 
important players in butyrate actions. The detection and identification of these proteins 
would necessitate the use of strategies for complexity reduction and protein enrichment in 
proteomics. Thus it is not surprising that 2-D DIGE of whole cell lysate of HCT-116 
detected only 20 differentially expressed protein spots, and only 6 of them were identified 
by MS analysis.  
Heparin affinity chromatography has been used successfully as a prefractionation 
step to enrich specific groups of proteins from biological samples. Heparin is a highly 
sulfated glucosaminoglycan that binds to a broad range of proteins, such as nucleic 
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acid-binding proteins, proteins involved in protein synthesis and growth factors, 
metabolic enzymes and coagulation factors (Conrad, 1998). Of the variety of 
perturbations induced by butyrate, inhibition of HDACs that led to changes in chromatin 
structure and regulation of specific subsets of genes is thought to be a major event (Marks 
et al., 2000; Hinnebusch et al., 2002). Many of the low-abundance nucleic acid-binding 
proteins such as transcriptional factors and RNA binding proteins which contained basic 
domains can thus be enriched by heparin affinity chromatography. This chromatographic 
procedure had also been used to identify several novel proteins from brain extract 
(Karlsson et al., 1999). Shefcheck et al. (2003) also evaluated the use of immobilized 
heparin chromatography for fractionation of cytosolic proteins from the human breast 
cancer cell line, MCF-7.  
We performed 2-D DIGE analysis of heparin-affinity enriched fractions of 24h 
butyrate-treated HCT-116 cells (Figure 4.1). Furthermore, we used two overlapping 
narrow range IPG strips (pH 4-7 and pH 6-11) to increase the spatial resolution in the pI 
range. The applications of sample pre-fractionation and narrow range IPGs in our study 
would provide a more comprehensive ‘window’ of the butyrate-treated proteome. 46 
differentially expressed protein spots were detected and 24 of them were identified by 
MALDI-TOF MS. As evident from the greater number of differentially regulated spots 
being identified in comparison to the whole cell lysate, this sub-proteomic approach has 
















Figure 4.1 Flow-chart illustrating the use of heparin affinity chromatography and narrow range IPGs for the differential 
analysis of butyrate-treated HCT-116 cells. 20 differentially expressed protein spots were detected from the whole cell lysate 
resolved on a 2-D DIGE gels with pH 3-10 IPGs. From the heparin-bound fraction, 22 and 24 differentially expressed protein spots 
were detected from the pH 4-7 and pH 6-11 2-DE gels respectively. As evident from the detection of a greater number of differentially 
regulated spots as compared to the whole cell lysate analysis, this sub-proteomics approach has enabled us to delve deeper into the 
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Table 4.1 The application of heparin affinity chromatography and overlapping 
narrow range IPG strips in 2-D DIGE had resulted in the detection and 
identification of a greater number of differentially expressed proteins as 
compared to the whole cell lysate. 
 
HCT-116 Cells Total Cell Lysate Heparin-Bound Fraction 
IPG pH range for 2-D DIGE pH 3-10 pH 4-7 pH 6-11 Total 
     
Number of Differentially 
Expressed Protein Spots 
Detected by DeCyder 
Analysis 
20 22 24 46 
     
Number of Protein Spots 
Identified by MS Analysis 6 10 14 24 
 
 
4.3 Proteins Differentially Expressed in HCT-116 Cells Following Butyrate 
Treatment 
4.3.1 Proteins Identified from the Acidic Range of 2-D DIGE 
Our data from heparin-affinity enriched fractions identified a number of 
proteins whose expressions were significantly altered following butyrate treatment. 
Here, we describe several of them pertaining to effects associated with butyrate such 
as transcriptional and translational modulations, and the induction of apoptosis in 
cancer cells. As listed in Table 3.3, 10 protein spots from the acidic range were 
identified to be differentially expressed. They included the down-regulated crk-like 
protein (crk-l), Ser/Thr protein phosphatase PP1, eukaryotic translation initiation 
factor 4E (eIF-4E), and up-regulated elongation factor Tu (EF-Tu) and cytochrome c 
oxidase VIb. 
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Crk-l is an oncogenic protein involved in various signaling systems. 
Integrin-based motility was shown to be significantly increased in cells 
overexpressing this oncoprotein (Hemmeryckx et al., 2001). In our study, we showed 
down-regulation of Crk-1 in HCT-116 cells following butyrate treatment. 
Concomitant with our findings, the integrin signaling pathway (Li et al., 2003b) has 
been reported to be defective in butyrate-treated colonic cells (Levy et al., 2003). We 
thus postulate that Crk-1 down-regulation following butyrate treatment of HCT-116 
cells may deter integrin-mediated cell motility. Similarly, down-regulation of PP1 
triggered by butyrate may also destabilize cell integrity and serve to induce ultrarapid 
capase-3 dependent apoptosis (Fladmark et al., 1999). In addition, PP1 has also been 
shown to be involved in other physiological processes associated with butyrate 
actions, such as the modulation of transcription factors, remodeling of chromatin 
structure, cell cycle progression and apoptosis (Klumpp and Krieglstein, 2002; 
Ceulemans and Bollen, 2004). Phosphorylation/dephosphorylation of anti-apoptotic 
and pro-apoptotic Bcl-2 proteins, caspases and their targets by protein phosphatases 
are important regulators of the apoptotic pathways.  
Initiation factor eIF-4E, a mRNA cap-binding protein, was shown to be 
down-regulated by butyrate in this study. eIF-4E is a tumorigenic protein and is 
overexpressed in a myriad of human tumors including colon carcinoma (De Benedetti 
and Graff, 2004). This eukaryotic initiation factor controls the synthesis of 
oncogenesis-associated proteins that participate in cell growth, transformation, 
angiogenesis, invasion and metastasis (Mamane et al., 2004). In contrast, EF-Tu, 
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which was responsible for conveying aminoacyl-tRNAs to ribosomes for protein 
synthesis was up-regulated by butyrate treatment. This corresponded to the findings 
that showed that protein synthesis is required for butyrate-induced apoptosis 
(Ruemmele et al., 1999; Della Ragione et al., 2001). 
Our data from the proteome analyses of whole cell lysate and heparin bound 
fraction showed that cytochrome c oxidase VIb was up-regulated by more than 3-fold. 
The activity of cytochrome c oxidase (COX) is crucial for oxidative phosphorylation. 
Corresponding to our findings, COX activity was reduced in colon cancers, and the 
expression levels of COX subunits were found to be decreased in colon adenomas and 
carcinomas as compared to normal colonic tissues (Heerdt et al., 1990). COX was 
also suggested to be associated with the efflux of cytochrome c in response to 
apoptosis in cancer cells (Wu et al., 2000). Furthermore, COX expression is 
up-regulated by apoptotic stimuli such as chemotherapeutic drugs in a dose-dependent 
manner along with the activation of mitochondrial respiratory chain (Sánchez-Alcázar 
et al., 2001; Chandra et al., 2002). Hence, the increased expression of COX VIb in 
HCT-116 cells may relate to the regulation of cellular metabolism and activation of 
mitochondrial-mediated apoptosis by butyrate. 
 
4.3.2 Proteins Identified from the Basic Range of 2-D DIGE 
From the basic range, 14 differentially expressed protein spots were identified. 
This included nucleoside diphosphate kinase B (NDPK B) and 
phosphotidylethalonamine-binding protein (PEBP), which were both down-regulated, 
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and carboxypeptidase A3 (CPA 3), which was up-regulated. NDPK B is one of the 
main NDPK isoforms in human, and has altered expression in colorectal cancer. 
NDPKs catalyze the transfer of phosphoryl group from nucleoside triphosphate to 
nucleoside diphosphate, and play pivotal functions in cell motility, signal transduction 
and regulation of gene expression (Fournier et al., 2003; Salerno et al., 2003; Postel, 
2003). Its down-regulation here correlated with its role as a transcriptional activator of 
c-myc oncogene (Agou et al., 1999) since c-myc expression is repressed by butyrate in 
colon cancer cells (Wilson et al., 2002). PEBP is a survival-promoting protein that 
was shown to be highly expressed in tumor cells. PEBP conferred resistance to TNF-α 
– signaling pathways and TNF-α – induced apoptosis in cancer cells (Wang et al., 
2004a). Its down-regulation shown in our data is also in line with the synergistic 
apoptotic effects of butyrate and TNF-α on intestinal epithelial cells (Jones et al., 
2004). Our proteomics study showed a 2-fold increase in the expression of CPA3 in 
HCT-116 colon cells following butyrate treatment. This paralleled genomic data in 
which induced expression of CPA3, a novel gene in the histone hyperacetylation 
pathway, was also demonstrated following treatment of prostrate epithelial cancer 
cells with HDAC inhibitors, butyrate and trichostatin A (Huang et al., 1999). 
 
4.4 hnRNP K and A1 are Altered by Butyrate Treatment 
One of the interesting groups of proteins identified to be differentially 
expressed from this work was the heterogeneous nuclear ribonucleoprotein (hnRNP) 
family. The hnRNP family (in mammalian cells) consists of more than 20 members, 
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all of which are able to associate with mRNA precursors and many influence mRNA 
biogenesis (Dreyfuss et al., 1993). In this work, hnRNP K was detected in the acidic 
range gels, while hnRNP A1 was identified in the basic range gels. 
hnRNP K was found to be up-regulated by 2.81-fold in HCT-116 after 24h 
butyrate treatment. hnRNP K is a multi-modular protein in the hnRNPs family which 
functioned as docking platform bridging multiple signaling cascades to regulation of 
DNA and RNA-directed processes (such as transcription, translation, pre-RNA 
splicing, mRNA trafficking and stability) for many genes (Bomsztyk et al., 2004). 
Altered mRNA metabolism is one of the characteristic of cancer cells (Perrotti and 
Neviani, 2007). The expression of hnRNP K is regulated by growth factor, and this 
protein is involved in tumourigenesis (Mandel et al., 2001; Ostrowski and Bomsztyk, 
2003). hnRNP K, which was shown to be up-regulated by butyrate in this study, could 
function as a transcription factor itself or interact with activators/ repressors of RNA 
polymerase II promoters (Tomonaga and Levens, 1996). In addition, chromatin 
remodeling which is a well-established outcome of HDAC inhibition by butyrate, is 
one aspect of the nucleic acid-directed regulation by hnRNP K. However, hnRNP K 
has been found to be over-expressed and associate with poor prognosis in colorectal 
cancer (Carpenter et al., 2006). Nonetheless, hnRNP K was also proposed to control 
early stages of cell spreading, a process required for cancer cells migration and 
invasion (de Hoog et al., 2004). Hence, up-regulation of hnRNP K by butyrate may 
regulate chromatin remodeling and affect downstream processes such as inhibition of 
cancer cells spreading. 
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4.4.1 Butyrate Treatment Decreases the Expression of hnRNP A1 in HCT-116 
Cells 
A recent report on sporadic colorectal cancers has detected an overexpression 
of hnRNP A1 (Ushigome et al., 2005), suggesting that hnRNP A1 played a role in 
tumorigenesis. The authors suggested that the increased expression of hnRNP A1 may 
contribute to the maintenance of telomere repeats in colorectal cancer cells or 
transformation of colon epithelial cells via transcriptional and translational 
perturbation. siRNA-mediated reduction of hnRNP A1 together with hnRNP A2 was 
able to promote apoptosis in several cell lines, including colon cancer cells (Patry et 
al., 2003). This corroborated with the down-regulation of full length forms of hnRNP 
A1 following apoptosis induced by butyrate, as seen here in our study. The protein 
spots that were identified as hnRNP A1 with native molecular weight (Mr of ~ 38 kDa) 
were down-regulated by butyrate, which was confirmed with western blot (Figure 
3.8A). Hence, our data showed that butyrate down-regulates hnRNP A1 during the 
initiation of growth arrest and apoptosis in HCT-116 cells. 
 
4.4.2 Phosphorylation Status of hnRNP A1 in HCT-116 Cells 
It was documented that the spot position of hnRNP A1 differed in several 
apoptotic cells implying differential post-translational modifications (Thiede et al., 
2002) and multiple phosphorylations were speculated to be responsible for the change 
in pI values seen. Butyrate induces apoptosis, along with the activation of signaling 
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pathways, such as of PKC and p38 MAP kinase which participated in cell death 
(McMillan et al., 2003). The activations of MAPK pathways by anti-neoplastic agents 
transduced therapeutic signals that regulate pathways in cell cycle progression, 
migration, differentiation, and apoptosis (Wada and Penninger, 2004). The activation 
of such signaling pathways could be potential chemotherapeutic routes for drug 
development (Olson and Hallahan, 2004). It is likely that hnRNP A1 may be 
phosphorylated as a target in these pathways. This hypothesis corroborated with a 
similar report by Allemand et al. (2005). They showed that cells under osmotic stress 
activate the MKK3/6-p38 signaling pathway, which resulted in subsequent 
phosphorylation and accumulation of hnRNP A1 in the cytoplasm (Allemand et al., 
2005). As seen in our anti-phosphoprotein immuno-blots, we showed that the several 
hnRNP A1 protein spots are phosphorylated isoforms of hnRNP A1. However, this 
study demonstrated that butyrate treatment did not affect the phosphorylation status of 
hnRNP A1 (Figure 3.8A). 
 
4.5 Butyrate Treatment Induces Cleavage and Cytosolic Localization of hnRNP 
A1 
Redistribution of proteins between cellular compartments plays a crucial part 
in apoptosis (Porter, 1999), either with or without cleavage by caspases. Some 
members of hnRNP families, including hnRNP A1, shuttle between the cytoplasm 
and nucleus. The trafficking of hnRNPs may be associated with a role in RNA 
processing (Dreyfuss et al., 2002). Furthermore, nuclear import of hnRNP A1 is 
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dependent on the rate of transcription. The close relation between its localization and 
role as splicing factor was further supported by the relocation of hnRNP A1 to 
cytoplasm when splicing was inhibited by snRNA-specific oligonucleotide 
(Lichtenstein et al., 2001). The localization of hnRNP A1 is also closely tied with 
proliferation, differentiation and apoptosis of both normal and tumorigenic cells. For 
example, mRNA export activity of nuclear hnRNP A1 was shown to be required for 
proliferation, survival, and tumorigenesis of acute phase CML blasts and BCR/ABL 
leukemogenesis (Iervolino et al., 2002). Nuclear proteome study showed 
up-regulation of hnRNP A1 in proliferative intestinal epithelial cells and repressed 
expression in differentiated cells (Turck et al., 2004). Both native and cleaved forms 
of hnRNPs translocate between cellular compartments in Fas-induced apoptotic cells, 
and cleavage of hnNRP A1 during apoptosis may affect its import into the nucleus 
(Thiede et al., 2002). Interestingly, caspase 3, which is essential for the induction of 
cell death by butyrate in colonic cells, was found to be responsible for the cleavage of 
hnRNP A1 during apoptosis in a human Burkitt lymphoma cell line (Brockstedt et al., 
1998). Anti-hnRNP A1 western blot analysis of the cytosolic proteins of HCT-116 
cells detected a cleaved isoform of hnRNP A1 (Mr ~ 26kDa) after butyrate treatment 
(Figure 3.8B). The decrease in whole cell expression of full length forms of hnRNP 
A1, presence of phosphorylations as its post-translational modifications, and the 
cytoplasmic retention of the cleaved protein observed in our study shedded new 
insight on the multi-faceted roles and regulation of hnRNP A1 in the cellular response 
to butyrate treatment. 
 147
 
4.6 The study of the Progression of Cell Maturation Mediated by Butyrate Using 
iTRAQ and cICAT Labeling Approaches 
The stimulation of cell maturation pathway by butyrate in colonic cancer cells 
follows a temporal ordered sequence. This physiological regulator initiates growth 
arrest at G0-G1 (at 12-24h post-treatment), followed by the early phase activation of 
apoptotic cascades and subsequent morphological changes in the cancer cells (Heerdt 
et al., 1994; Heerdt et al., 1997; Mariadason et al., 2000). A complex cascade of 
cellular processes will be triggered by butyrate during the progression of cell 
maturation. Since butyrate is a remarkable chemopreventive and chemotherapeutic 
agent, identification of the proteins and pathways induced by butyrate during cell 
maturation will aid in the development of anti-cancer drugs. We have earlier 
identified several proteins based on the proteome analysis of 24h butyrate treatment 
using 2-D DIGE. The study of a single time-point butyrate treatment may be 
insufficient to fully elucidate the mechanism of butyrate’s anti-cancer actions. Hence, 
a temporal analysis of butyrate treatment using proteomics was adopted with the view 
to better understand the complex nature of butyrate’s therapeutic properties. The 
iTRAQ labeling methodology which enabled multiplexing of four different samples is 
suitable for such temporal studies. 
Proliferation and apoptotic assays conducted on HCT-116 colorectal cancer 
cells demonstrated the cell line’s sensitivity to butyrate-induced growth inhibition and 
apoptosis in a time- and dose-dependent manner (Tan et al., 2002). At 24h and 72h 
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post-treatment with butyrate, 22.5% and 66.7% of HCT-116 cells underwent 
apoptosis, respectively (Figure 3.1). By monitoring the spontaneous growth arrest and 
apoptosis we had shown that control cells at 24h did not differ significantly from 
those at 36h and 48h (Tan et al., 2002; data not shown). Thus, in this work, the 
proteome profile of HCT-116 cells treated with butyrate after 24h, 36h, and 48h 
(labeled with iTRAQ Tag115, Tag116 and Tag117 respectively), were compared to the 
control cells at 24h (labeled with Tag114) (Figure 3.9A). Each of the cell extracts was 
digested by trypsin and labeled with the respective iTRAQ tags. Following this, the 
four labeled samples were pooled and analyzed by 2-D LC MALDI-TOF/TOF MS for 
protein identification and quantification. Four separately cultured batches of HCT-116 
cells, acting as biological batches, were analyzed instead of any technical replicates 
since biological variation was recently shown to account for most of the deviation 
from published iTRAQ data (Gan et al., 2007). 
Unlike iTRAQ that labels all peptides, cICAT selectively tags only 
cysteine-containing proteins/peptides. Selective enrichment of cICAT-labeled 
peptides will simplify the complex peptide mixtures leading to an increase in the 
probability of identifying low abundance proteins. Relative quantitation of protein 
abundance by the iTRAQ approach relies on the reporter ions (low mass region: m/z 
114, 115, 116, 117) generated in the MS/MS spectra whilst the cICAT method 
quantitates relative protein abundance in the MS mode by comparing the pair of 
labeled-peptides with the unique 9Da mass-shift (Figure 3.10). As illustrated by the 
greater number of protein identities and peptide counts per protein detected by iTRAQ 
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as compared with cICAT, it showed that iTRAQ is a more sensitive technology than 
cICAT. However, no one method was able to profile exhaustively all the differentially 
expressed proteins (Figure 3.11 and Figure 3.12). Hence we decided to use both 
technologies to acquire data for the temporal analysis of butyrate treatment. 
 
4.7 High-Throughput Proteome Analysis using Offline 2-D LC 
MALDI-TOF/TOF MS Platform 
In this work, a 2-D LC – MALDI-TOF/TOF MS platform was utilized which 
provided high-throughput chromatographic separation, followed by simultaneous 
protein quantitation and identification in tandem MS. The 2-D LC separation of the 
iTRAQ- and cICAT-labeled peptides was coupled offline to a MALDI-TOF/TOF MS 
system. The peptides prefractionated by strong cation exchange chromatography were 
automatically separated in the second dimension with a reverse phase column. The 
LC – MALDI interface system was used where the RPLC eluate was directly 
deposited onto the MALDI plates to enhance peptide recovery and minimize sample 
loss. Moreover, the transfer and storage of the entire chromatogram onto MALDI 
targets allowed precursor selection and result dependent analysis. Unlike online 
LC-ESI MS that has a limited time for MS/MS analysis, the offline approach does not 
have this problem and it allows optimization of workflow and sample re-analysis. 
Data acquisition during the MS analysis is biased against ions of weak signal 
intensity which arose from low abundance peptides. This was illustrated by Washburn 
et al. (2001) who showed that low abundant proteins were identified by one or two 
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peptides whereas abundant proteins were matched to multiple (>2) peptides. Peptide 
hits and spectral counts have been proposed to correlate with protein abundance in the 
sample. Due to the random sampling of ions selection during MS/MS analysis, and 
the huge dynamic range of protein expressions, peptides from high abundance 
proteins are detected more frequently than those of lower abundance in a ‘shotgun’ 
proteomics experiment (Liu et al., 2004). Hence, the iTRAQ-labeled proteins that 
were identified from multiple experimental analyses are present at a higher abundance 
than those that can be found in only one sample run. This explained the low peptide 
counts for proteins that were identified in a single iTRAQ-labeled sample whilst 
proteins that were found in all the replicates were matched to multiple peptides. For 
example, in this study, HSP-90 and cytoskeletal protein 8 were matched to several 
peptides and identified in all four replicates. Proteins of extreme Mr (<15kDa or 
>100kDa) or hydrophobicity (with TMHs or positive GRAVY score) were identified 
from iTRAQ-labeled and cICAT-labeled samples. Such proteins are difficult to be 
identified by 2-DE analysis as they are poorly resolved by 2-DE gels. 
   
4.8 A Model to Illustrate the Temporal Regulation of Cellular Processes and 
Pathways by Butyrate 
The coordinated involvement of various cellular processes initiated by 
butyrate during cell maturation follows a temporal order. We showed a temporal 
orchestration of various cellular processes and the associated proteins during the 
stimulation of cell maturation by butyrate (Figure 3.19 and Figure 3.20). This study 
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used temporal expression profiling of butyrate-treated cancer cells to identify clusters 
of proteins in pathways that correlate protein expression changes with the induction of 
anti-cancer effects. The synergistic influence of each cluster of proteins resulted in the 
overall phenotypic response to butyrate. We proposed a model illustrating the 




Figure 4.2 A proposed model depicting pathways initiated by butyrate in mediating growth arrest and apoptosis in HCT-116 cells. (A) 
Reduced expression of cell cycle regulatory proteins and nucleotides biosynthesis proteins led to growth arrest induced by butyrate. (B) Butyrate 
increased the expression of tumour suppressors, proteins associated with mitochondrial transition pore (MTP) for the translocation of 
cytochrome c, and modulated the expression of chaperones and proteasome pathways, resulting in the activation of apoptosis cascades. (C) 
Metabolic machinery of the cells was altered with an increased expression of several metabolic enzymes. (D) Expression of 
cytoskeleton-associated proteins was increased to strengthen cytoskeletal scaffold and to lower the metastasis potential of HCT-116 cells. ER, 
endoplasmic reticulum; hnRNPs, heterogeneous nuclear ribonucleoproteins; ETC, electron transport chain; ECM, extracellular matrix; meta, 
metabolism. 
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4.8.1 Cluster A: Growth arrest 
Cell cycle progression. Butyrate is known to regulate several cell cycle genes 
including c-myc, p16 and p21 (Archer et al., 1998b). Among the list of 
down-regulated proteins identified here, several function in nucleotide biosynthesis, 
cell cycle progression and cellular proliferation (Figure 3.19). These proteins include 
DNA replication licensing factor MCM7, Ran-specific GTPase-activating protein, 
caprin 1 and nucleosome assembly protein 1-like 1. The down-regulation of these cell 
cycle regulatory proteins is in concordance with the inhibition of DNA replication, 
hindrance of cell division and hence blockage of cell cycle progression by butyrate, as 
shown in Cluster A of our proposed model (Figure 4.2). For example, DNA 
replication licensing factor MCM 6 and MCM7 function as the replication fork 
helicase during the initiation of DNA replication in the cell cycle (Ishimi et al., 1997; 
Labib et al., 2000). Suppression of caprin 1, also known as cytoplasmic 
activation/proliferation-associated protein-1, was reported to reduce proliferation rate 
which demonstrated its role in cellular proliferation (Wang et al., 2005). Similarly, 
nucleosome assembly protein 1-like 1 is involved in the induction of cell proliferation 
(Simon et al., 1994) and was shown to be down-regulated by butyrate in this study. 
Our temporal analysis showed that butyrate induced an early reduction in the 
expression of these proteins, which plateaued after the 36h time-point (Figure 3.19 
and 3.20). 
 
Signaling. A-kinase anchoring protein 12 (AKAP12), a scaffold protein for 
kinases (Michel and Scott, 2002) that possessed tumour suppressor activity, was 
found to be dramatically down-regulated in both iTRAQ and cICAT data (Figure 
3.21). Multiple intracellular kinases in the oncogenic or survival signaling pathways 
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have been illustrated to be key-points in butyrate actions (McMillan et al., 2003; 
Orchel et al., 2005). Western blotting using monoclonal antibody against the 
C-terminal of AKAP12 showed decreased expression of the full length protein and an 
appearance of a truncated isoform at Mr ~40kDa over time (Figure 3.22). MS/MS 
spectra of AKAP12 matched only sequences from the N-terminal part of the protein, 
supporting the decreased presence of native AKAP12 which was verified as a western 
blot band at ~200kDa. The 2-DE western blot clearly verified the increased 
abundance of the fragmented protein of ~40kDa (Figure 3.22). This preliminary data 
may indicate that targeting of kinases by AKAP12 may be regulated by butyrate, thus 
affecting downstream growth-associated signaling cascades. On the other hand, the 
N-terminal fragment of AKAP12 may contribute to the tumour suppressor property of 
this protein. This awaits further investigations. 
 
4.8.2 Cluster B: Apoptosis 
As demonstrated in Figure 4.2, the proteins in Cluster B function as tumour 
suppressors, heat shock proteins and chaperones, players in the oxidative 
phosphorylation pathway, or ubiquitination-proteasome pathway respectively. The 
temporal changes in expression of these proteins contributed to the initiation of 
apoptosis by butyrate in HCT-116 cells. 
 
Tumour suppressors. As shown in Figure 3.19, tumour suppressors, such as 
galectin-1, metallothionein-1X, prohibitin-2, and Ras-related protein Rap-1A, 
displayed a temporal increase in expression level upon butyrate treatment in this study. 
These proteins contribute to tumour growth suppression by butyrate. For example, 
galectins are multifunctional β-galactoside lectins with roles including cell adhesion, 
 155
growth regulation, invasion, and apoptosis (Liu, 2000). The identification of 
up-regulated galectin-1 here (Figure 3.22) corroborated with previous work that 
showed its association with butyrate’s actions (Ohannesian et al., 1994; Gaudier et al., 
2004). We also found metallothionein-1X was markedly up-regulated by butyrate, and 
this was confirmed by real-time PCR (Figure 3.21). The expression of 
metallothioneins is not universal to all tumours. For instance, this protein was 
over-expressed in bladder cancer but down-regulated in advanced prostate cancer 
(Garrett et al., 2000; Somji et al., 2001). Although other metallothioneins have been 
found to be up-regulated by butyrate in a paradigm of increased resistance to toxic 
metals in tetracarcinoma and hepatoma cells (Birren and Herschman, 1986; Andrews 
and Adamson, 1987), this is the first report on the regulation of metallothioneins by 
butyrate in colorectal cancer cells. Metallothioneins have a high metal binding affinity 
for metal homeostasis and detoxification. Exposure to metals such as chromium, 
nickel, iron, copper and manganese has been shown to promote carcinogenesis. Thus, 
the increased expression of metallothionein by butyrate may relate to the regulation of 
metals associated with colorectal carcinogenesis. 
Similarly, our results also showed that voltage-dependent anion-selective 
channel protein 1 and 2 (VDAC1 and VDAC2), ADP/ATP translocase 2 (ANT2) 
were found to be concurrently up-regulated by butyrate. Their expression levels were 
shown to increase, particularly after the 36h time-point (Figure 3.19). These proteins 
are candidate regulators of cytochrome c release via the mitochondrial transition pore 
(MTP) for activation of apoptotic cascades. Since mitochondria played a pivotal role 
in apoptosis (Kroemer and Reed, 2000; Desagher and Martinou, 2000), the release of 
proapoptotic proteins, like cytochrome c, apoptosis-inducing factor, and Smac/Diablo 
from the mitochondria is crucial in mediating apoptosis by chemotherapeutic agents. 
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The extrinsic apoptotic pathway mediated by cytochrome c release was activated by 
butyrate treatment (Natoni et al., 2005). VDAC1 has an increased expression level as 
seen from the cICAT results (Table 3.6). It played an essential role in the 
translocation of apocytochrome c for the activation of downstream caspases. 
Over-expression of this mitochondrial protein has been found to induce cell death 
(Abu-Hamad et al., 2006). ANT2 catalyzed the exchange of ADP/ATP across the 
mitochondrial membrane, and have been implicated in apoptosis mediated through the 
mitochondrial transition pore as well (Belzacq et al., 2002). The increased expression 
of these regulators of MTP may contribute to the activation of cytochrome c mediated 
apoptotic cascades by butyrate. The measurement of these tumour suppressors in 
cancer cells could thus serve as monitors of the efficacy of pro-apoptotic drug 
treatment. 
 
 Oxidative phosphorylation. Our results clearly reflected a trend of increased 
expression of the electron transport chain (ETC) complexes (Figure 3.19). The 
increase in expression levels of these proteins were further enhanced after 36h of 
butyrate treatment. Amongst the proteins, differential expression of cytochrome c 
oxidase Va and VIb were verified with real-time-PCR (Figure 3.21). Cytochrome c 
oxidase VIb was also reported to be up-regulated by butyrate in our 2-D DIGE 
analysis of total cell lysate and heparin bound fractions, and western blotting 
confirmed the result here (Figure 3.22). The increased expression of proteins in the 
oxidative phosphorylation pathway may be related to the enhanced mitochondrial 
activity by butyrate, and subsequent growth arrest and apoptosis in the colonic 
epithelial cells (Heerdt et al., 1997). Our study has also shown the up-regulation of 
several ATP synthase subunits of Complex V upon butyrate treatment. For example, 
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ATP synthase was down-regulated in colorectal carcinoma as an avoidance 
mechanism towards reactive oxygen species (ROS) – mediated cell death (Cuezva et 
al., 2002). The study by Giardina et al. (1999) had shown a role for butyrate influence 
on ROS generation in colon carcinogenesis. The changes in the expression levels of 
ETC complexes, such as complex I, II, IV and V, as seen here may result in unstable 
mitochondrial membrane potential and an increase in ROS production. Hence, in 
addition to possible generation of ATP from the enhanced oxidative phosphorylation 
for the energy-dependent apoptosis, cytotoxic mitochondrial ROS production could 
sensitize butyrate-treated cells to oxidative stress-mediated cell death (Figure 4.2, 
Cluster B). 
 
Heat shock proteins (HSPs) and Chaperones. A temporal decrease in the 
expression of chaperones, such as heat shock protein HSP90, heat shock cognate 
71kDa protein, heat shock 105kDa protein and thioredoxin, was detected in 
butyrate-treated HCT-116 cells (Figure 3.19). The degree of down-regulation was 
shown to be reduced after the 36h time-point. HSPs act as molecular chaperones, thus 
playing an indispensable role in defense against cellular stress such as 
chemotherapy-induced apoptosis (Creagh et al., 2000). HSP90, one of the 
down-regulated chaperones identified here, was advocated as a novel anticancer target 
(Isaacs et al., 2003). Its inhibitor 17-allylaminogeldanamycin (17AAG) is currently in 
an anti-cancer clinical trial. HSP90 is also responsible for maintaining the stability of 
many oncogenic proteins with biological functions in cellular proliferation and 
apoptosis. For example, HSP90 is known to be dysfunctional in tumours (Workman, 
2004; Whitesell and Lindquist, 2005), and was detected to be up-regulated in 
transformed cells. Inhibitors of this anti-apoptotic protein triggered cancer cell death 
 158
synergistically with butyrate treatment (Rahmani et al., 2003). The reduced 
expression of chaperones as shown here would deter proper protein folding, thus 
leading to protein aggregation which ultimately resulted in cell death in cancer cells. 
 
Ubiquitination-Proteasome pathway. Proteasome activator subunit 2, 
S-phase kinase-associated protein 1A and ubiquitin-activating enzyme E1 are some of 
the proteins in the ubiquitination-proteasome pathway that were also noted to be 
differentially regulated by butyrate, as shown in Figure 3.19. Degradation of proteins 
via the ATP/ubiquitin-dependent pathway mediated apoptosis (Orlowski, 1999). 
Targets of the 26S proteasome include proteins in heat shock response and cell cycle 
control (Hershko and Ciechanover, 1998; Hohfeld et al., 2001); both systems were 
found to be down-regulated in this study (Figures 3.19 and 4.2). The butyrate-induced 
apoptotic cascades were associated with the ubiquitin-degradation system, and 
inhibitors of the proteasome act synergistically with butyrate in anti-carcinogenic 
therapy. In support of this, Pei et al. (2004) found that the simultaneous application of 
a proteasome inhibitor and butyrate could induce apoptosis. Both Giuliano et al. 
(1999) and Yu et al. (2003) showed similar synergistic effects between proteasome 
activity and butyrate. Hence, butyrate-regulated ubiquitination-proteasome pathway 
would affect the levels of survival- and apoptosis-related proteins in cancer cells. 
 
4.8.3 Cluster C: Metabolism 
Our data identified a repertoire of biosynthetic enzymes, including those 
involved in the Krebs cycle and pentose phosphate pathway, to be up-regulated by 
butyrate in a time-dependent manner (Figure 3.19). The change in the expression 
levels for most of these proteins was shown to be more pronounced after 36h of 
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treatment. Examples of these metabolic enzymes were malate dehydrogenase, 
oxoglutarate (alpha-ketoglutarate) dehydrogenase, transaldolase and transketolase. 
This suggested that butyrate altered the metabolic machinery of HCT-116 cells. Most 
tumours including CRC depend on enhanced glycolysis instead of oxidative 
phosphorylation for ATP production, even in the presence of oxygen, a phenomenon 
known as the “Warburg effect” (Warburg, 1956). The metabolic enzymes found to be 
up-regulated by butyrate in this study are involved in various glucose metabolic 
pathways which thus promote glucose metabolism. However, unlike other metabolic 
enzymes, alpha-enolase was shown to be down-regulated by butyrate. This may retard 
the rate of glycolysis since enolase catalyzed the formation of phosphoenolpyruvate, a 
precursor of glycolytic end-product pyruvate. Furthermore, several enzymes 
functioning in the oxidative phosphorylation pathway were up-regulated by butyrate 
(as discussed earlier). 
Butyrate demonstrated phenotypical specificity whereby it caused growth 
arrest followed by differentiation and/or apoptosis in carcinoma cells but promoted 
proliferation in normal cells (Comalada et al., 2006). Colonic carcinoma cells derive 
energy via metabolism of glucose whereas normal colonic epithelial cells oxidize 
butyrate as the key fuel source for cellular proliferation (Roediger, 1982; Ardawi and 
Newsholme, 1985; Hague et al., 1996). Butyrate had been reported to induce 
apoptosis in the presence of glucose and pyruvate but promote growth in the absence 
of these alternative energy sources (Singh et al., 1997). It has been reasoned that 
metabolism of other fuels permit butyrate to effect its anti-cancer actions. Herein, 
butyrate altered the metabolic profile of cancer cells, resulting from an enhanced 
expression of several metabolic enzymes. Metabolism of other energy sources as fuel 
thus availed butyrate to effect its anti-cancer actions in HCT-116 cells. 
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In addition, proteins functioning in amino acid and lipid/cholesterol metabolic 
pathways, such as ornithine aminotransferase, asparagine synthetase, 
argininosuccinate synthase, delta 1-pyrroline-5-carboxylate synthetase, lipoamide 
acyltransferase and enoyl-CoA hydratase, were also up-regulated in this study. 
Leschelle et al. (2000) and Tabuchi et al. (2006) had demonstrated stimulated 
lipogenesis by butyrate. Ruemmele et al. (1999) and Della Ragione et al. (2001) 
found that inhibiting protein synthesis by cycloheximide blocked butyrate-induced 
apoptosis. In this work, vesicular transport proteins, which function in protein 
synthesis such as vesicle trafficking protein SEC22b, coatomer subunit beta and 
N-ethylmaleimide-sensitive factor attachment protein-β (NAPB) protein, were 
identified to be up-regulated. These pathways were grouped under Cluster C in the 
proposed model (Figure 4.2). 
 
4.8.4 Cluster D: Metastasis 
Cytoskeleton-associated proteins. In correlation to previous reports on 
cytoskeletal organization of cancer cells (Kruh, 1982, Zeng and Briske-Anderson, 
2005), the data here showed increased expression of various cytoskeleton-related 
proteins by butyrate (Figure 3.19). The overall increase in the expression level of 
these proteins was higher after the 36h time-point. The concerted temporal 
up-regulation of these proteins such as cytoskeletal 8, cytoskeletal 18, cytoskeletal 19, 
epiplakin and filamins may lead to a strengthened cytoskeletal scaffold and reduced 
metastasis potential of carcinoma cells (Cluster D in Figure 4.2). Several of these 
identified proteins function as crosslinkers in the intermediate filament network, 
modulating cell adhesion, motility and invasiveness. Real-time PCR was conducted 
for cytoskeletal 19 (Figure 3.21). LIM domain and actin-binding protein, also known 
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as the elevated expression of epithelial protein lost in neoplasm (EPLIN), identified 
by cICAT, diminished the invasiveness of cancer cells. EPLIN is a 
cytoskeleton-associated protein whose down-regulation in cancer cells may facilitate 
motility of these cancer cells (Maul et al., 2003). Our results showed that the 
anti-metastasis effect was induced as a latter event, after growth inhibition and 
apoptosis (Figure 3.19 and 3.20). The anti-metastasis effect shown here corresponded 
to the in vivo study performed by Velazquez et al. (1996) who demonstrated the 
inhibition of seeding and growth of colorectal metastases to the liver by intravenous 
infusion of butyrate in mice. Butyrate is currently evaluated in clinical trials and has 

















Chapter 5       CONCLUSION  
 
Butyrate is suggested to be responsible for the chemopreventive properties of 
fiber-rich diet against colorectal cancer cells. Butyrate stimulates cell maturation via 
inducing growth arrest, differentiation and/or apoptosis in cancer cells. A better 
understanding of the mechanism whereby butyrate mediates its anti-cancer effects 
would certainly aid in the design of better therapeutic intervention. We employed 
several proteomics platforms to elucidate the ‘blueprint’ of butyrate’s 
chemopreventive role in this disease. 
2-D DIGE was used to identify proteins involved in the initiation of growth 
arrest and apoptosis by butyrate at 24h treatment. Using whole cell lysate, very few 
proteins were found to be regulated by butyrate treatment. However, we showed that 
the application of an enrichment step using heparin affinity chromatography, and 
overlapping narrow range IPGs in 2-D DIGE had enhanced the detection and 
identification of more proteins for proteome analysis. Using this approach, we 
discovered that full length forms of hnRNP A1 were down-regulated and cleaved after 
butyrate treatment. A cleaved form of hnRNP A1 was also shown to be retained in the 
cytoplasm of butyrate-treated cells. These observations may relate to the role and 
regulation of hnRNP A1 in the cellular response to butyrate.  
The proteins identified by a single time-point treatment may be inadequate to 
fully understand the cellular processes involved during the progression of cell 
maturation induced by butyrate. Hence, we performed multiplexed quantitative 
proteomics using stable isotope labeling strategies (iTRAQ and cICAT) to study the 
temporal effects of butyrate treatment in HCT-116 cells. Differentially expressed 
proteins identified from this study were grouped according to their biochemical 
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functions. A model was proposed to illustrate the temporal orchestration of four 
integrated cellular processes, viz. cell cycle progression, apoptosis, metabolism, and 
metastasis, during the stimulation of cell maturation by butyrate. The coordinated and 
synergistic influence of each pathway would result in the overall anti-cancer effects of 
butyrate. 
Our study demonstrated that butyrate mediated cell cycle blockage at the early 
stage which tapered off after the 36h time-point. The regulation of HSPs and 
ubiquitination-proteasome pathway by butyrate was less significant. On the other 
hand, the expression levels of proteins that function in oxidative phosphorylation, 
metabolism, or as tumour suppressors increased on a temporal basis following a 
similar trend. Moreover, there was a greater increase in their expression levels after 
the 36h time-point. The synergistic up-regulation of these proteins induced apoptosis 
in HCT-116 cells. The anti-metastasis effect of butyrate was most significant, and this 
was strongly accentuated at the late phase of treatment. The temporal and synergistic 
effects of each pathway would lead to the anti-proliferative and pro-apoptotic 
properties of butyrate. 
From the various proteomics approaches described earlier, this study had also 
identified several mediators (proteins and cellular processes) responsible for 
butyrate’s anti-proliferative and pro-apoptotic effects. The characterization of these 
players in butyrate’s anti-cancer actions would help in the design of effective and 
novel molecular-targeted chemotherapeutic agents. Lastly, the signature clusters of 
proteins and cellular processes associated with the time dynamics of butyrate 
treatment could also serve as potential therapeutic targets or proteomics biomarkers to 
monitor pro-apoptotic drugs’ efficacy or toxicity. 
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Chapter 6      FUTURE STUDIES 
 
Using various proteomics approaches, this study has identified several 
butyrate-responsive proteins and pathways that could serve as potential therapeutic 
targets for colorectal cancer. For example, we have demonstrated that butyrate 
treatment altered the expression levels of proteins that function in cell cycle 
progression, oxidative phosphorylation, metabolism, apoptosis and metastasis. These 
effects of butyrate treatment have also been validated via real-time PCR and western 
blotting techniques, but future work would encompass clinical translational research 
on the targets identified in this study. 
As outlined in Figure 3.19, our work had shown several biochemical pathways 
that are affected by butyrate treatment. However, our laboratory is interested in 
studying protein candidates involved in cancer metastasis as butyrate is currently 
undergoing phase II clinical trials for its anti-metastatic effect. Furthermore, 
intravenous infusion of butyrate was shown to inhibit the seeding and growth of 
colorectal metastases to liver in mice. Since we showed that butyrate’s anti-metastatic 
effect was mediated by up-regulation of cytoskeleton-associated proteins, future work 
would therefore involve (a) validating the specificity of the identified 
cytoskeleton-associated proteins as therapeutic targets for colorectal cancer using cell 
lines and clinical tissues, (b) performing siRNA knockdown and over-expression to 
assess the role of these proteins in mediating butyrate’s anti-metastasis effect, and (c) 
conducting in vivo studies using nude mice. These approaches could also be applied to 
other classes of identified proteins involved in other cellular processes, to study their 
roles in mediating cellular transformation in colorectal cancer cells. 
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(a) Clinical Validation 
The expression levels of these cytoskeleton-associated proteins (e.g. epiplakin, 
filamins and cytokeratins) would first be validated in other butyrate-treated colorectal 
cancer cell lines. If confirmed, they would be analyzed in clinically well characterized 
tissue samples (normal versus colonic tumour tissues) using immunohistochemistry or 
tissue microarray to check for their expression levels. Furthermore, colonic tumours 
derived from patients at an advanced stage with invasive and metastatic neoplasia 
would be included for this analysis. It is expected that the expressions of these 
proteins in metastatic colon tumour tissues would be lower than that in normal colonic 
tissues since butyrate treatment induced an increase in their expression levels. This 
would show that the proteins were indeed involved in metastasis, and their 
up-regulation by butyrate treatment would verify their roles in this process. 
 
(b) Functional Validation 
Future work would also include functional studies to validate these selected 
butyrate-regulated proteins as putative targets for cancer therapies. These proteins 
would be over-expressed or knockdown to assess their role in cancer cells 
invasiveness. It is expected that over-expression of these proteins would enhance 
butyrate’s anti-metastatic effect whilst knockdown of them would reduce it. As we 
showed that butyrate induced chemotherapeutic effects via various mediators, 
simultaneous knockdown or over-expression of several cytoskeleton-associated 
proteins could be performed to study the synergistic effects of these proteins on 
metastasis. For example, multiple knockdown or over-expression of the identified 
proteins (i.e. epiplakin, filamins, and cytokeratins) can be performed on the cell lines. 
In addition, we could also study the synergistic effects of cytoskeleton-associated 
proteins and those involved in other cellular processes such as cell cycle progression 
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(e.g. MCM7, caprin 1), oxidative phosphorylation (e.g. cytochrome c oxidase), and 
apoptosis (e.g. mitochondrial ANT, VDAC). 
 
(c) In Vivo Studies 
Lastly, in vivo studies using nude mice would be conducted using those 
mutant cell lines with over-expressed or knockdown protein(s) that were validated to 
contribute to butyrate’s anti-metastasis effect. These cell lines would be injected into 
nude mice, and the size and metastatic potential of the tumour(s) formed by these 
cancer cells would be affected if these protein candidates play important roles in 
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Appendix Data I 
 
Minimum ion score thresholds that were used following false positive rate measurements for multi-peptide and single peptide based 
protein identifications. 
 
Minimum ion score thresholds that were used following false positive rate 
measurements 
iTRAQ-Labeled Samples cICAT-Labeled Samples  
Batch 1 Batch 2 Batch 3 Batch 4 24h 36h 48h 
Multi-peptide based protein 
identifications 24 24 21 21 21 21 21 
Single peptide based protein 






















Appendix Data II 
 
Determination of the cutoff threshold of fold changes for proteins with single peptide match. 2 equal amounts of tryptic digested six protein 
mixtures were labeled with iTRAQ reagent 114 and 117 respectively, and analyzed with 1-D LC MALDI-TOF/TOF MS. The standard deviation 
(S.D.) based on the ratios of all the identified peptides was 0.15. 1.3 (1 + 2 S.D.) was determined to be the significant (p < 0.05) cutoff threshold 








































Appendix Data III 
 
List of differentially expressed proteins that were labeled with iTRAQ and identified by at least 2 peptides. The ratios and sequences of 
peptides that were identified were shown. All the proteins that matched to the same set of peptide sequences were also shown. 
 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 1 Batch 1 Batch 1 Protein Name Accession No. 
115/114 115/114 115/114 115/114 115/114 115/114 115/114 115/114 115/114 115/114 115/114 115/114
NME1 9 kDa protein 
NME1-NME2 protein 
NME1;NME2 Nucleoside 






























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 























































































































































































MCM6 DNA replication 







Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 














CDC123 41 kDa protein 
CDC123 21 kDa protein 









0.055 - - - - - - - - - 
 IV 
protein 123 homolog 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 













- - - - - - - - - 














Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
























Regulator of chromosome 
condensation 
RCC1 regulator of chromosome 
condensation 1 isoform a 
RCC1 regulator of chromosome 








0.226 - - - - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 














- - - - - - 
NAP1L1 Nucleosome assembly 
protein 1-like 1 
NAP1L1 43 kDa protein 
NAP1L1 16 kDa protein 
NAP1L1 20 kDa protein 
NAP1L1 20 kDa protein 
NAP1L1 22 kDa protein 






















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 



















































0.036 - - - - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
2 - 2 - - 
GYPHWPAR 






0.449 - - - - - - 
TUFM Tu translation 
elongation factor, 
mitochondrial 























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 












































































































































































































































Similar to eukaryotic 

















EEF1B2 Elongation factor 
1-beta 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 












































EIF3S3 Eukaryotic translation 













Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 






























LOC143244 similar to 
eukaryotic translation initiation 
factor 5A EIF5A Isoform 1 of 
Eukaryotic translation 
initiation factor 5A-1 
EIF5A Isoform 2 of Eukaryotic 
translation initiation factor 
5A-1 
EIF5A2 Eukaryotic translation 






















0.143 - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





























































- - - 
NOLC1 Isoform Alpha of 
Nucleolar phosphoprotein p130 
NOLC1 Isoform Beta of 
Nucleolar phosphoprotein p130 
IPI00292387 













Number of unique peptides identified and No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
 VII 
sequences 





























































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 


























































































































RPL5 Ribosomal protein L5 
RPL5 60S ribosomal protein L5 
IPI00797983 













Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





































LOC388885 similar to 40S 
ribosomal protein S10 
RPS10 40S ribosomal protein 
S10 























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





















































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 












































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
















































































































































LUC7L2 Isoform 2 of Putative 
RNA-binding protein Luc7-like 
2 


















0 0.77 ± 0
 IX 
RNA-binding protein Luc7-like 
2 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 




















































HNRPA1 Isoform A1-A of 
Heterogeneous nuclear 
ribonucleoprotein A1 
HNRPA1 HNRPA1 protein 
HNRPA1 Isoform A1-B of 
Heterogeneous nuclear 
ribonucleoprotein A1 


















0.439 - - - - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
































































































































































































HNRPAB Isoform 1 of 
Heterogeneous nuclear 
ribonucleoprotein A/B 
HNRPAB 36 kDa protein 
HNRPAB Isoform 2 of 
Heterogeneous nuclear 
ribonucleoprotein A/B 
HNRPAB Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein A/B 












0.151 - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 














- - - 
D0HNRPD Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein D0 










0.153 - - - - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 


















- - - - - - 
HNRPF Heterogeneous nuclear 







Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
3 - - - 3 










SYNCRIP Isoform 2 of 
Heterogeneous nuclear 
ribonucleoprotein Q 
SYNCRIP Isoform 1 of 
Heterogeneous nuclear 
ribonucleoprotein 
QSYNCRIP Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein Q 
SYNCRIP Isoform 4 of 
Heterogeneous nuclear 
ribonucleoprotein Q 

































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
















































































































































HNRPR HNRPR protein 
HNRPR Heterogeneous nuclear 
ribonucleoprotein R 
IPI00644055 



















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





























































































ANXA3 32 kDa protein 
ANXA3 Annexin A3 
IPI00745868 













Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 

































































AKAP12 Isoform 1 of A-kinase 
anchor protein 12 
AKAP12 A-kinase anchor 



























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
































































































MT1G Isoform 1 of 
Metallothionein-1G 























0.184 - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 













































- - - 

















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 






























































RAP1A Ras-related protein 
Rap-1A precursor 
RAP1A RAP1A, member of 
RAS oncogene family 



























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 









































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 



































dehydrogenase (Ubiquinone) 1 
beta subcomplex, 8, 19kDa 
NDUFB8 NADH 
dehydrogenase (Ubiquinone) 1 
beta subcomplex, 8, 19kDa 
NDUFB8 NADH 
dehydrogenase [ubiquinone] 1 
















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 



























56 kDa protein 
SDHA SDHA protein 
SDHALP1 27 kDa protein 
























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
 XV 




















































COX5A Cytochrome c oxidase 
subunit 5A, mitochondrial 
precursor 























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 









































































































COX6B1 Cytochrome c oxidase 
subunit VIb isoform 1 





















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 


















































































ATP5B ATP synthase subunit 

























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 



























































































































































































































































































































































































ATP6V1A Vacuolar ATP 



















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
















































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
3 1 - 5 3 




















































HSPA4 Heat shock 70 kDa 













Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 












































HSPA8 Isoform 2 of Heat shock 
cognate 71 kDa protein 
HSPA8 Heat shock 70kDa 






















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 






















































































































































































HSPA8 Isoform 1 of Heat shock 






0.131 - - - 
 XVIII 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 














































































































































- - - 
HSP90AA1 Heat shock protein 
HSP 90-alpha 
HSP90AA1 Heat shock protein 



























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
 XIX 


































































































































































































































































































































































































































































































































































































































































































































































































































































HSP90AB2P Heat shock 

























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 



































































































































HSP90AB4P Heat shock 



















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





































































































































HSP90AB1 Heat shock protein 
HSP 90-beta 



























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 




























































































































































































































































































































































































































































































































































































































































































































































































































































































CCT2 T-complex protein 1 













Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
6 - - 8 14 












































































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 







































































































































































































































































































































PRDX1 11 kDa protein 
PRDX1 Peroxiredoxin-1 
IPI00641244 













Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 













































domain-containing protein 4 
precursor 











Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 








































0.102 - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 












































- - - 
PSME2 proteasome activator 
subunit 2 
PSME2 Proteasome activator 
complex subunit 2 
IPI00746205 













Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 



























































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 






















MDH2 Malate dehydrogenase, 



















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 































































































































0.359 0.294 0.487 0.225 0.22 0.332 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 


























































TPI1 Isoform 1 of 
Triosephosphate isomerase 
TPI1 Triosephosphate 















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 























































































TKT Hypothetical protein 
DKFZp686J13123 









0.231 - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 




































GANAB Isoform 1 of Neutral 
alpha-glucosidase AB precursor 
GANAB 107 kDa protein 
GANAB Isoform 2 of Neutral 
alpha-glucosidase AB precursor 
GANAB Isoform 3 of Neutral 























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 































































































0.445 - - - - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 







































































- - - - - - 
ENO1 Isoform alpha-enolase of 













Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
12 - - 52 27 



























































































































































































































































































































































































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 













































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





























































































SARS Seryl-tRNA synthetase 






















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 






































































































CARS Isoform 2 of 
Cysteinyl-tRNA synthetase, 
cytoplasmic 




synthetase isoform c 
CARS cysteinyl-tRNA 










Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
2 - - - 2 
VTWYCCGPTVYDASHM GHAR 







ALDH18A1 Isoform Short of 
Delta 1-pyrroline-5-carboxylate 
synthetase 

















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 



























































DBI Isoform 2 of 
Acyl-CoA-binding protein 
DBI Isoform a 1 of 
Acyl-CoA-binding protein 























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 

























































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 

































































































































































































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 























CLTC Isoform 2 of Clathrin 
heavy chain 1 
CLTC Isoform 1 of Clathrin 
heavy chain 1 
IPI00455383 













Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 














































































































































SLC25A6 Solute carrier family 
25 (Mitochondrial carrier; 
adenine nucleotide 
translocator), member 6 
IPI00645646 
















Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





































































0.357 - - - - - - - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 

























- - - - - - - - - 
KRT7 keratin 7 
KRT7 Keratin, type II 
cytoskeletal 7 
IPI00847342 







Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 


















KRT8 Keratin, type II 

























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































KRT18 Keratin, type I 
cytoskeletal 18  



























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 



























































































































































































































































































































































































KRT19 Keratin, type I 

























Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





















































































































































































































































































































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
11 2 - 11 8 














































































































































FLNC Isoform 2 of Filamin-C 
FLNC Gamma filamin variant 









Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 







































Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 





























































































































































































































































CFL1 24 kDa protein 
CFL1 Cofilin-1 
IPI00784459 






0.336 - - - 
Number of unique peptides identified and 
sequences No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 































































Appendix Data IV 
 
List of differentially expressed proteins that were labeled with iTRAQ and identified by a single-peptide. The sequence, precursor m/z and 
E-value of the peptide matched to the proteins were shown. The precursor charge of all the peptides is +1. The numbers of iTRAQ-labeled 
peptides used for quantitation for the each of the sample batches were indicated. 
 
No. Protein Name Accession Number Sequence of Peptide Identified Precursor m/z E-value 
1 CTPS CTP synthase 1 IPI00290142 VPLLLEEQGVVDYFLR 2034.123500 2.8e-005 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 1 Batch 1 Batch 1 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 











No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 3 5 


























PRIM2 Isoform 1 of DNA 
primase large subunit  
PRIM2 58 kDa protein  
IPI00027705 
IPI00794173 IPFADALDLFR 1421.790400 4.9e-005 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 






0.037 0.58 ± 0.028
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 2 2 












MCM7 Isoform 1 of DNA 
replication licensing factor 
MCM7 
IPI00299904 RFELYFQGPSSNKPR 2114.126700 4.5e-006 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - 0.615 ± 0.012 0.66 ± 0.075 0.696 ± 0.3 0.791 ± 0 0.627 ± 0 0.524 ± 0 
 XL 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 2 1 




0.996 0.791 0.627 0.524 
4 
LOC389842 similar to 
Ran-specific 




IPI00414127 AWVWNTHADFADECPKPELLAIR 3016.463400 9.4e-007 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
0.466 ± 0.13 0.594 ± 0.166 
0.569 ± 









No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 



































chromosomes protein 3 
IPI00219420 SIMELMNVLELR 1591.864900 4e-005 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 





No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - - 2 








component chromosome 11 
surface marker 1 isoform 1 
CAPRIN1 73 kDa protein 





LNEQYEHASIHLWDLLEGK 2583.362300 1e-009 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
0.67 ± 0.325 0.746 ± 0.104 
0.628 ± 




0.057 0.363 ± 0 0.189 ± 0 0.137 ± 0 
 XLI 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 














0.236 0.363 0.189 0.137 
7 









IPI00455831 EYWMDPEGEMKPGRK 2285.137000 2.4e-006 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 






0.195 1.457 ± 0.45 1.487 ± 0.35
1.541 ± 
0.468 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 


























8 RPLP2 60S acidic ribosomal protein P2 IPI00008529 ILDSVGIEADDDRLNK 2061.090800 1.4e-011 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
0.944 ± 0 0.887 ± 0 0.582 ± 0 - - - 0.986 ± 0 0.884 ± 0 0.795 ± 0 - - - 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
1 - 1 - 
0.944 0.887 0.582 - - - 0.986 0.884 0.795 - - - 
9 RBM3 Putative RNA-binding protein 3 IPI00024320 YYDSRPGGYGYGYGR 1874.855800 0.00052 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - 0.981 ± 0 0.656 ± 0 0.539 ± 0 0.995 ± 0.062 
0.755 ± 
0.094 0.582 ± 0.08
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 1 2 








RNA helicase DDX18 
DDX18 Hypothetical protein 
(Fragment) 




GHALLILRPEELGFLR 1978.176500 1.7e-005 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - 0.826 ± 0.005 0.73 ± 0.163
0.725 ± 
0.175 - - - 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 2 - 









LOC653889 similar to U5 
snRNP-associated 102 kDa 
protein 
IPI00305068 
IPI00739440 IDSDLGDAWAFFYK 1935.958000 2.8e-005 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - 1.219 ± 0 1.284 ± 0 1.624 ± 0 1.563 ± 0.091 1.514 ± 0.12 1.79 ± 0.148
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 1 2 






HNRPDL Isoform 1 of 
Heterogeneous nuclear 
ribonucleoprotein D-like 
HNRPDL Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein D-like 
HNRPAB Isoform 4 of 
Heterogeneous nuclear 
ribonucleoprotein A/B 
HNRPAB Isoform 1 of 
Heterogeneous nuclear 
ribonucleoprotein A/B 











FGEVVDCTIK 1444.735100 0.00013 
 XLIII 
HNRPAB Isoform 3 of 
Heterogeneous nuclear 
ribonucleoprotein A/B 
HNRPAB 36 kDa protein 
HNRPDL Isoform 2 of 
Heterogeneous nuclear 
ribonucleoprotein D-like 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 




0.062 0.834 ± 0 0.722 ± 0 0.703 ± 0 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 3 1 










0.834 0.722 0.703 
13 
VAV2 Vav 2 oncogene 
VAV2 97 kDa protein 
VAV2 Protein vav-2 





NSELFDPFDLFDVR 1857.917500 0.0013 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 





No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 1 2 





14 PPM1G Protein phosphatase 1G IPI00006167 LPLPYGFSAMQGWR 1766.909900 6.7e-008 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 






0.042 0.856 ± 0 0.815 ± 0 0.712 ± 0 - - - - - - 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 






1.12 0.856 0.815 0.712 - - - - - - 
15 NDUFA10 NADH dehydrogenase [ubiquinone] 
IPI00029561 
IPI00103509 YGMWHFLLGDK 1654.867300 6e-005 
 XLIV 
1 alpha subcomplex subunit 
10, mito 
NDUFA10 NADH 




1 alpha subcomplex, 10, 
42kDa varia 






Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 











No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
1 - 2 3 















C6orf115 similar to Protein 
C6orf115 
C6orf115 similar to Protein 
C6orf115 
IPI00374316 
IPI00740277 CANLFEALVGTLK 1712.929700 1.3e-005 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - - - - 0.621 ± 0.043 0.47 ± 0.022
0.392 ± 
0.092 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - - 2 










PRDX5 peroxiredoxin 5 
precursor, isoform b 
PRDX5 peroxiredoxin 5 











Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
0.891 ± 0 1.503 ± 0 1.696 ± 0 - - - - - - 1.182 ± 0 1.342 ± 0 1.418 ± 0 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
1 - - 1 
0.891 1.503 1.696 - - - - - - 1.182 1.342 1.418 
18 
PRDX2 Peroxiredoxin-2 
PRDX2 16 kDa protein 






KEGGLGPLNIPLLADVTR 2151.259000 1.9e-007 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
















0.192 - - - 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 























IPI00294159 FGMFEFLSNHMR 1659.796100 9.9e-005 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 




0.064 0.98 ± 0.223
1.488 ± 
0.279 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 2 2 















IPI00027223 LIFPYVELDLHSYDLGIENR 2550.339800 8.6e-007 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
0.953 ± 0 1.408 ± 0 1.546 ± 0 - - - 1.436 ± 1.291 ± 1.46 ± 0.725 1.081 ± 1.126 ± 1.144 ± 
 XLVI 
0.022 0.226 0.317 0.145 0.229 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
1 - 2 3 














21 C12orf5 Uncharacterized protein C12orf5 IPI00006907 SLFDYFLTDLK 1649.892000 2.7e-008 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 






0.293 1.93 ± 0.13 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 3 3 
























IPI00744692 TIVMGASFR 1125.621700 0.0055 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - 1.694 ± 0 2.226 ± 0 2.614 ± 0 2.105 ± 0 1.729 ± 0 2.408 ± 0 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 1 1 











EFVEEFIWPAIQSSALYEDR 2573.262700 8.3e-005 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 





No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - - 2 










IPI00024993 SLAMEMVLTGDR 1466.733600 0.00048 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - 1.575 ± 0 1.897 ± 0 2.071 ±0 1.227 ± 0 1.254 ± 0 1.349 ± 0 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 1 1 
- - - - - - 1.575 1.897 2.071 1.227 1.254 1.349 
25 
CYB5R3 Isoform 1 of 
NADH-cytochrome b5 
reductase 3 




IPI00446235 FKLWYTLDR 1529.868700 0.0012 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - - - - 1.241 ± 0.062 1.55 ± 0.082
1.722 ± 
0.156 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - - 2 










RAB11A 24 kDa protein 





STIGVEFATR 1224.672200 0.00025 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - 1.72 ± 0 1.508 ± 0 1.648 ± 0 1.302 ± 0 1.343 ± 0 1.361 ± 0 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 1 1 
- - - - - - 1.72 1.508 1.648 1.302 1.343 1.361 
27 
NAPB NAPB protein 
NAPA CDNA FLJ44555 fis, 
clone UTERU3007640, 
highly similar to Homo 
sapiens 
IPI00748905 
IPI00445144 LDQWLTTMLLR 1533.850600 0.00041 
 XLVIII 
N-ethylmaleimide-sensitive 
factor attachment protein, 
alpha 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 









No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - 3 3 



















28 SAR1A SAR1 gene homolog A IPI00513941 ELNARPMEVFMCSVLK 2201.112300 0.0022 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 





No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - - 2 






KRT14 Keratin, type I 
cytoskeletal 14 
KRT14 27 kDa protein 




ADLEMQIESLKEELAYLK 2555.410400 0.00055 
Average iTRAQ Ratio ± S.D. 
Batch 1 Batch 2 Batch 3 Batch 4 
115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 115/114 116/114 117/114 
- - - - - - - - - 2 ± 0.14 2.33 ± 0.118 2.625 ± 0.197 
No. of iTRAQ labeled peptides for quantification and respective iTRAQ ratio 
- - - 2 










Appendix Data V 
 
List of differentially expressed proteins that were labeled with ICAT and identified by at least 2 peptides. The ratios and sequences of 
peptides that were identified were shown. All the proteins that were matched to the same set of peptide sequences were also shown. 
 
Average cICAT Ratio ± S.D. Protein Name Accession Number 24h 24h 24h 
PA2G4 20 kDa protein 






- 0.449 ± 0.003 - 
Number of unique peptides identified and sequences No. of ICAT labeled peptides for quantification and respective ICAT ratio 
2 - 2 - 
VAHSFNCTPIEGMLSHQL K 
GIAFPTSISVNNCVCHFS PLK - 
0.451 
0.447 - 
EEF2 Elongation factor 2 IPI00186290 0.98 ± 0.001 0.68 ± 0.14 - 
Number of unique peptides identified and sequences No. of ICAT labeled peptides for quantification and respective ICAT ratio 

















30 kDa protein 
RPS3A 40S ribosomal protein S3a 
IPI00472119 
IPI00419880 0.803 ± 0.09 0.606 ± 0.047 0.656 ± 0.005 
Number of unique peptides identified and sequences No. of ICAT labeled peptides for quantification and respective ICAT ratio 

















CNBP Cellular nucleic acid 
binding protein beta variant 2 
CNBP Isoform 3 of Cellular 
nucleic acid-binding protein 




0.477 ± 0.226 - - 
Number of unique peptides identified and sequences No. of ICAT labeled peptides for quantification and respective ICAT ratio 










LGALS1 Galectin-1 IPI00219219 1.816 ± 0.05 2.585 ± 0.589 2.034 ± 0.472 
Number of unique peptides identified and sequences No. of ICAT labeled peptides for quantification and respective ICAT ratio 





















HSPD1 60 kDa heat shock protein, 
mitochondrial precursor 
HSPD1 61 kDa protein 
IPI00784154 
IPI00472102 0.999 ± 0.009 1.229 ± 0.51 1.479 ± 0.13 
Number of unique peptides identified and sequences No. of ICAT labeled peptides for quantification and respective ICAT ratio 

















MDH2 Malate dehydrogenase, 
mitochondrial precursor IPI00291006 - 1.796 ± 0.529 - 
Number of unique peptides identified and sequences No. of ICAT labeled peptides for quantification and respective ICAT ratio 









ALB ALB protein 
ALB Isoform 1 of Serum albumin 
precursor 




- 1.588 ± 0.087 - 
Number of unique peptides identified and sequences No. of ICAT labeled peptides for quantification and respective ICAT ratio 






FLNA Filamin A, alpha 




2.656 ± 1.08 1.484 ± 0.324 1.483 ± 0.121 
Number of unique peptides identified and sequences No. of ICAT labeled peptides for quantification and respective ICAT ratio 






















Appendix Data VI 
 
List of differentially expressed proteins that were labeled with ICAT and identified by a single-peptide. The sequence, precursor m/z and 
E-value of the peptide matched to the proteins were shown. The precursor charge of all the peptides is +1.  
 




GNB2L1 Lung cancer oncogene 7 
GNB2L1 Proliferation-inducing gene 21  
GNB2L1 33 kDa protein 
GNB2L1 25 kDa protein 
GNB2L1 26 kDa protein 







TNHIGHTGYLNTVTVSPDGSLCASGGK 2913.419400 0.0011 
2 TUFM Tu translation elongation factor, mitochondrial IPI00027107 HYAHTDCPGHADYVK 1949.946200 0.0045 
3 
EEF1A1 EEF1A1 protein 
EEF1A1 Elongation factor 1-alpha 1 
Eukaryotic translation elongation factor 1 alpha-like 3 





SGDAAIVDMVPGKPMCVESFSDYPPLGR 3165.494400 0.00018 
4 
EEF1G Elongation factor 1-gamma 
EEF1G;LOC729998 similar to Elongation factor 1-gamma 




WFLTCINQPQFR 1779.903900 0.027 
5 
EIF5A2 Eukaryotic translation initiation factor 5A-2 
LOC143244 similar to eukaryotic translation initiation factor 5A 
EIF5A Isoform 2 of Eukaryotic translation initiation factor 5A-1 





KYEDICPSTHNMDVPNIK 2331.113800 0.25 
6 PABPC1 Isoform 1 of Polyadenylate-binding protein 1 PABPC4 Isoform 1 of Polyadenylate-binding protein 4 
IPI00008524
IPI00012726 ALYDTFSAFGNILSCK 1976.982900 0.00011 
7 RPS6 40S ribosomal protein S6 RPS6 Ribosomal protein S6 
IPI00021840
IPI00640929 MKLNISFPATGCQK 1764.931000 0.025 
8 
RPL10A 60S ribosomal protein L10a 
25 kDa protein 




FSVCVLGDQQHCDEAK 2233.011700 0.094 
9 RPS2 40S ribosomal protein S2  31 kDa protein 
IPI00013485
IPI00478002 KLLMMAGIDDCYTSAR 2014.954700 0.34 
10 
RPL14 60S ribosomal protein L14 
RPL14 RPL14 protein 




CMQLTDFILKFPHSAHQK 2371.198700 0.0033 
11 LUC7L2 Isoform 1 of Putative RNA-binding protein Luc7-like 2 LUC7L2 Isoform 2 of Putative RNA-binding protein Luc7-like 2 
IPI00006932
IPI00216804 SHLLNCCPHDVLSGTR 2206.089100 0.14 
12 HMGB2 High mobility group protein B2 IPI00219097 MSSYAFFVQTCR 1666.758700 0.024 
13 NASP Isoform 1 of Nuclear autoantigenic sperm protein IPI00179953 KPTDGASSSNCVTDISHLVR 2314.174300 0.0054 
 LII 
NASP Isoform 2 of Nuclear autoantigenic sperm protein 
NASP nuclear autoantigenic sperm protein isoform 1 




14 APEX1 DNA-(apurinic or apyrimidinic site) lyase APEX1 Protein 
IPI00215911
IPI00792538 KPLVLCGDLNVAHEEIDLR 2361.258100 6.9e-005
15 
SMARCC2 Isoform 2 of SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin 
SMARCC2 Isoform 1 of SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin 
IPI00150057
IPI00216047 TQDECILHFLR 1601.807600 0.15 
16 HMGB3 High mobility group protein B3 HMGB3 Non-histone chromosomal protein 
IPI00217477
IPI00411540 MSAYAFFVQTCR 1666.758700 0.026 
17 
HNRPD Isoform 1 of Heterogeneous nuclear ribonucleoprotein D0 
HNRPD Isoform 2 of Heterogeneous nuclear ribonucleoprotein D0 
HNRPD Isoform 3 of Heterogeneous nuclear ribonucleoprotein D0 
HNRPD Isoform 4 of Heterogeneous nuclear ribonucleoprotein D0 






GFCFITFKEEEPVK 1900.941900 0.13 
18 HNRPF Heterogeneous nuclear ribonucleoprotein F IPI00003881 DLSYCLSGMYDHR 1786.793600 0.12 
19 
HNRPK Isoform 1 of Heterogeneous nuclear ribonucleoprotein K 
HNRPK Isoform 2 of Heterogeneous nuclear ribonucleoprotein K 
HNRPK Heterogeneous nuclear ribonucleoprotein K 
HNRPK Heterogeneous nuclear ribonucleoprotein K 
HNRPK Heterogeneous nuclear ribonucleoprotein K 







LFQECCPHSTDR 1889.881200 0.029 
20 
SNRPB Isoform SM-B' of Small nuclear ribonucleoprotein-associated proteins 
SNRPN Small nuclear ribonucleoprotein-associated protein N 
SNRPB Isoform SM-B1 of Small nuclear ribonucleoprotein-associated proteins 
SNRPB Small nuclear ribonucleoprotein B' 
SNRPB Isoform SM-B of Small nuclear ribonucleoprotein-associated proteins B 
SNRPN Small nuclear ribonucleoprotein polypeptide N variant 








HMNLILCDCDEFR 2081.010000 0.0015 
21 RG9MTD1 RNA (guanine-9-) methyltransferase domain-containing protein 1 IPI00099996 NVDPFHIYFCNLK 1845.932000 0.0024 
22 AKAP12 A-kinase anchor protein 12 isoform 2 AKAP12 Isoform 1 of A-kinase anchor protein 12 
IPI00217683
IPI00237884 SSEKNEDFAAHPGEDAVPTGPDCQAK 2927.335400 0.016 
23 
RHOC Rho-related GTP-binding protein RhoC precursor 
RHOA Transforming protein RhoA precursor 
RHOA Ras homolog gene family, member A variant 
RHOC Ras homolog gene family, member C 
RHOC Ras homolog gene family, member C 







HFCPNVPIILVGNKK 1906.062600 0.0018 
24 PPM1G Protein phosphatase 1G IPI00006167 GTEAGQVGEPGIPTGEAGPSCSSASDKLPR 3082.463900 0.00034 
25 VDAC1 Voltage-dependent anion-selective channel protein 1 VDAC1 20 kDa protein 
IPI00216308
IPI00790304 EHINLGCDMDFDIAGPSIR 2339.128700 0.00063 
26 RAN GTP-binding nuclear protein Ran RAN 11 kDa protein 
IPI00643041
IPI00788997 VCENIPIVLCGNKVDIK 2311.237100 0.23 
 LIII 
RAN 15 kDa protein 
RAN 26 kDa protein 






27 UQCRH Ubiquinol-cytochrome c reductase complex 11 kDa protein, mitochondria IPI00296022 SHTEEDCTEELFDFLHAR 2415.105200 0.26 
28 ATP5A1 ATP synthase subunit alpha, mitochondrial precursor ATP5A1 54 kDa protein 
IPI00440493
IPI00797044 LYCIYVAIGQKR 1662.940400 0.26 
29 
HSPA1B;HSPA1A Heat shock 70 kDa protein 1 
HSPA6 Heat shock 70 kDa protein 6 
HSPA1B;HSPA1A Heat shock 70kDa protein 1A 
HSPA1B;HSPA1A heat shock 70kDa protein 1A 






FEELCSDLFR 1485.693600 0.0031 
30 
HSP90AA1 Heat shock protein HSP 90-alpha 2 
HSP90AA1 Hsp89-alpha-delta-N 
HSP90AA1 Heat shock protein HSP 90-alpha 





CLELFTELAEDKENYK 2172.047900 0.00045 
31 
HSPH1 Isoform Beta of Heat-shock protein 105 kDa 
HSPH1 Isoform Alpha of Heat-shock protein 105 kDa 




KPVTDCVISVPSFFTDAER 2338.180200 0.017 
32 CCT4 T-complex protein 1 subunit delta IPI00302927 AKIGLIQFCLSAPK 1715.974100 0.22 
33 CCT7 T-complex protein 1 subunit eta CCT7 chaperonin containing TCP1, subunit 7 isoform b 
IPI00018465
IPI00552072 QLCDNAGFDATNILNKLR 2233.129600 0.11 
34 CCT8 Chaperonin containing TCP1, subunit 8 (Theta) variant CCT8 T-complex protein 1 subunit theta 
IPI00302925
IPI00784090 KAHEILPNLVCCSAK 2080.102500 0.13 
35 PRDX6 Peroxiredoxin-6 IPI00220301 DINAYNCEEPTEKLPFPIIDDR 2819.395000 0.0014 
36 
TPI1 Isoform 2 of Triosephosphate isomerase 
TPI1 Triosephosphate isomerase 1 variant 
TPI1 30 kDa protein 
TPI1 22 kDa protein 








G6PD Isoform Long of Glucose-6-phosphate 1-dehydrogenase 
G6PD Isoform Short of Glucose-6-phosphate 1-dehydrogenase 




LQFHDVAGDIFHQQCK 2122.056200 0.096 
38 DLD Dihydrolipoyl dehydrogenase, mitochondrial precursor IPI00015911 VCHAHPTLSEAFR 1703.886200 6.2e-005
39 OAT Ornithine aminotransferase, mitochondrial precursor IPI00022334 KYFDFLSSYSAVNQGHCHPK 2564.243400 4.4e-008
40 GOT2 Aspartate aminotransferase, mitochondrial precursor IPI00018206 NLDKEYLPIGGLAEFCK 2146.123000 0.0045 
41 GLUD1 Glutamate dehydrogenase 1, mitochondrial precursor GLUD2 Glutamate dehydrogenase 2, mitochondrial precursor 
IPI00016801
IPI00027146 IIKPCNHVLSLSFPIR 2073.212600 0.45 
42 CKB Creatine kinase B-type IPI00022977 FCTGLTQIETLFK 1736.925200 0.00047 
43 
SURF4 Isoform 1 of Surfeit locus protein 4 
SURF4 Surfeit 4 




LCLISTFLEDGIR 1715.943800 0.0018 




ATP1A1 Isoform Long of Sodium/potassium-transporting ATPase subunit alpha-1 
polypeptide 
ATP1A1 Isoform Short of Sodium/potassium-transporting ATPase subunit alpha-1 
polypeptide 
IPI00006482
IPI00414005 IISANGCKVDNSSLTGESEPQTR 2642.408000 0.0042 
46 EPPK1 Epiplakin IPI00010951 YLEGTSCIAGVLVPAKDQPGR 2410.288600 0.0089 
47 
FLNB Isoform 1 of Filamin-B 
FLNB Isoform 2 of Filamin-B 
FLNB Isoform 3 of Filamin-B 
FLNB Isoform 6 of Filamin-B 
FLNB Filamin B 







VHSPSGAVEECHVSELEPDKYAVR 2874.396200 0.0057 
48 
FLNC Isoform 1 of Filamin-C 
FLNC Isoform 2 of Filamin-C 




DSPFIAHILPAPPDCFPDKVK 2543.340800 0.00039 
49 
LIMA1 Isoform Beta of LIM domain and actin-binding protein 1 
LIMA1 Epithelial protein lost in neoplasm beta variant 
LIMA1 Isoform Alpha of LIM domain and actin-binding protein 1 
LIMA1 67 kDa protein 






IYCKPHFNQLFK 1773.939500 0.026 
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2-D DIGE Analysis of Butyrate-Treated HCT-116 Cells after
Enrichment with Heparin Affinity Chromatography
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Butyrate, a 4-carbon short chain fatty acid, is responsible for the protective effects of fiber in colorectal
cancer prevention. To better understand the ‘blueprint’ of butyrate’s chemopreventive role in this
disease, we performed 2-dimensional difference gel electrophoresis (2-D DIGE) of butyrate-treated HCT-
116 colorectal cancer cells after pre-fractionation using heparin affinity chromatography. A combination
of this enrichment step with overlapping narrow range IPGs (pH 4-7 and pH 6-11) in 2-D DIGE resulted
in the detection of 46 differentially expressed spots. Twenty-four of these were identified by MS analyses,
and 5 spots were found to be heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). Three isoforms
of 38kDa were down-regulated while two with Mr  26 kDa were up-regulated. These represent
phosphorylated isoforms of hnRNP A1 as verified by immunoblotting with anti-phosphotyrosine and
anti-phosphoserine antibodies. Using 2-DE, subcellular fractionation and western blot analysis, we
further showed that full-length hnRNP A1 underwent down-regulation, cleavage and cytoplasmic
retention upon butyrate treatment. These indicate that modulations of hnRNP A1 may play a significant
role in the mediation of growth arrest and apoptosis by butyrate.
Keywords: HCT-116 colorectal cancer cells ¥ butyrate ¥ apoptosis ¥ heparin affinity chromatography ¥ 2-D DIGE ¥
narrow range IPG ¥ hnRNP A1 ¥ subcellular fractionation
Introduction
Colorectal cancer is among the most common cancers in
developed countries1 and has become the most commonly
diagnosed malignancy among the Singapore population. Stud-
ies have shown that environmental factors, especially dietary
habits, contribute to colorectal cancer with intake of fiber-rich
food associated with a reduced risk.2,3 It was discovered that
short chain fatty acids (SCFAs), particularly butyrate, derived
from the fermentation of fiber, mediated the protective effect.
Physiological concentrations of butyrate induce growth arrest,
differentiation, and stimulate apoptotic cascades in various
cancer cells.4-6 Work has been done to identify global targets
of butyrate, in the hope of elucidating the complete molecular
mechanism and regulatory pathways to discover potential
therapeutic targets.7-9
Proteomics is the systematic analysis of the proteome, which
is defined as the totality of proteins expressed by a genome.10
Two-dimensional gel electrophoresis (2-DE) coupled with
protein identification by mass spectrometry (MS) has been the
mainstay proteomics platform for differential expression studies
in diseases or treatment with drugs.11 2-D difference gel
electrophoresis (2-D DIGE) introduced by Unlu et al.12 enables
comparative expression analysis via the use of spectrally
resolvable amine reactive fluorescent dyes to pre-label different
protein populations prior to 2-DE. The ability to multiplex
different samples overcomes the pitfall of inter-gel nonrepro-
ducibility inherent in conventional 2-DE gels. In addition, a
Cy2-labeled “standard” run on every gel boosts the statistical
confidence in detecting and quantifying true biological changes.
Although 2-DE provides an exquisite resolution in protein
separation, the great complexity and dynamic range of cellular
proteins expression result in bias toward the visualization of
resident high abundant proteins.13,14 Hence, functionally im-
portant proteins of low abundance tend to be masked when
resolved on 2-DE without any pre-enrichment steps. In prin-
ciple, there are two major approaches advocated for sample
simplification and protein enrichment, viz., (i) subcellular
fractionation and (ii) protein pre-fractionation. Subcellular
proteomics allows a more focused proteome analysis, also
giving insight to their cellular distributions and functions.15 The
use of chromatographic strategies based on various physico-
chemical characteristics has also been successfully applied for
fractionation of complex protein mixtures.16,17 Heparin affinity
chromatography operates through the unique combination of
affinity binding and ion pairing to target a particular group of
proteins, and was aptly used as pre-fractionation route to
enrich proteins of interest.18,19
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A functional proteomics approach was undertaken herein
to identify candidate proteins regulated by butyrate in HCT-
116 colorectal cancer cells. Differential proteomics was initially
analyzed on crude cell extract of butyrate-treated HCT-116 cells
using 2-D DIGE. Subsequently, heparin affinity chromatogra-
phy was adopted as a pre-fractionation step prior to 2-D DIGE
analysis. The advent of narrow range immobilized pH gradient
(IPG) gels has greatly improved the resolving power of 2-DE.20,21
Undoubtedly, sample pre-fractionation techniques coupled
with narrow range IPG gels will provide a more in-depth
‘window’ of the proteome.22 In this study, heparin-bound
proteins from HCT-116 cells were resolved using two overlap-
ping narrow range IPG gels (pH 4-7 and pH 6-11) in 2-D DIGE
to enhance the proteome coverage for differential expression
analysis. Several proteins were identified in response to bu-
tyrate-mediated growth arrest and apoptosis. Further charac-
terization of an identified protein, hnRNP A1 was conducted
using subcellular fractionation, 2-DE and western blot analysis.
The results shown here may underscore its multifaceted
involvement in butyrate actions in this cell line.
Materials and Methods
Cell Culture. HCT-116 human colorectal carcinoma cell line
(American Type Culture Collection, Rockville, MD) was cultured
in McCoy’s 5A media (Sigma, St. Louis, MO) supplemented with
10% fetal bovine serum (Invitrogen, CA) and antimycotic
antibiotics (Sigma) in a humidified incubator (37 °C, 5% CO2).
Upon reaching 60% confluency, the media were changed to
fresh media or media containing 5 mM sodium butyrate
(Sigma). The cells were harvested via trypsinization after 24 h
of treatment with butyrate.
Sample Preparation. Control and butyrate-treated cells were
disrupted with a cocktail solution containing 7 M urea (USB,
Cleveland, USA), 2 M thiourea (Fluka, Buchs, Switzerland), 4%
CHAPS (USB), 40 mM Tris (J. T. Baker, Phillipsburg, USA), 1
mM PMSF (Sigma), 50 íg/mL DNase 1 and RNase A (Roche
Diagnostic, Mannheim, Germany). Total cell lysates were
centrifuged at 18 800  g, 15 °C for 1 h to obtain the
supernatants for 2-D DIGE.
For heparin affinity chromatography, harvested control and
butyrate-exposed HCT-116 cells were resuspended in 10 mM
sodium phosphate buffer (pH 7.0) (Merck, Darmstadt, Ger-
many), 1 Halt protease inhibitor cocktail (Pierce, Rockford,
IL), 50 íg/mL DNase 1 and RNase A. The cells were lysed by
sonication, and cell lysates were then centrifuged at 100 000 
g for 2 h at 15 °C to obtain the supernatants for chromato-
graphic separation.
Heparin Affinity Chromatography. A 1-mL portion (con-
taining 2 mg) of clarified control and butyrate-treated HCT-
116 cell lysates was fractionated by a HiTrap Heparin HP
column connected to the A‹ KTA purifier liquid chromatography
system (GE Healthcare, formally known as Amersham Bio-
sciences, Uppsala, Sweden). The column was equilibrated with
5 column volumes of 10 mM sodium phosphate, pH 7.0 at a
flow-rate of 1.0 mL/min prior to sample loading. Flow-through
fractions which contained the unbound proteins were collected
till the optical density at 214 nm returned to the baseline level.
Bound proteins were then fractionated via stepwise elution
using 10 mM sodium phosphate, pH 7.0 containing 0.4 M, 0.8
M, 1.2 M, 1.6 M, and 2.0 M NaCl. The eluates from each salt
concentration were pooled and transferred to Amicon Ultra 4
centrifugal filter devices (nominal molecular weight cutoff of
10kDa) (Millipore Corporation, Billerica, USA) for desalting and
concentration.
Protein Assay. Protein concentration was measured using
Coomassie Plus protein assay kit (Pierce) with bovine serum
albumin (BSA) as standard.
2-D DIGE. Protein labeling for 2-D DIGE was performed
according to the protocol in the Ettan DIGE User Manual (GE
Healthcare). Cy3 and Cy5 were used to label the control and
butyrate-treated sample, respectively. A total of 320 pmol of
each dye was added to 40 íg of protein from each sample. An
equal amount of Cy2 was added to a mixture of the control
and treated sample (each contributing 20 íg of protein), to act
as internal standard for image matching and cross-gel statistical
analysis.
The 18 cm IPG strips were rehydrated passively overnight
with rehydration buffer consisting of 7 M urea, 2 M thiourea,
4% CHAPS, 20 mM dithiothreitol (DTT) (Bio-Rad, Hercules, CA),
0.2% IPG buffer (GE Healthcare), and trace bromophenol blue
(Merck). Labeled samples containing 20 mM DTT and 0.5% IPG
buffer were then loaded using a sample loading cup on a
universal strip holder, and focused on the IPGphor IEF unit
(GE Healthcare). Whole cell lysates were fractionated with pH
3-10 NL IPG strips, while pH 4-7 L and pH 6-11 L IPG strips
were used to fractionate samples obtained from heparin affinity
chromatography. Focusing parameters for the wide range (pH
3-10) and narrow range (pH 4-7 and pH 6-11) IPG strips were
as followed respectively: (i) 200 V, 200 Vhr; (ii) 500 V, 500 Vhr:
(iii) 1000 V, 500 Vhr; (iv) 1000-8000 V, 2250 Vhr; and (v) 8000
V, 32 000 Vhr and (i) 100 V, 50 Vhr; (ii) 200 V, 1200 Vhr; (iii)
500 V, 250 Vhr; (iv) 1000 V, 500 Vhr; (v) 1000-8000 V, 2250 Vhr;
(vi) 8000 V, 32000 Vhr. A two-step equilibration procedure was
used to reduce and alkylate the IPG strips prior to SDS-PAGE
as described in Liang et al., 23 except that 12.5% polyacrylamide
gels were used.
Protein Visualization and DeCyder Imaging Analysis for
2-D DIGE. Fluorescent images of the 2-D DIGE gels were
obtained using the Typhoon Variable Mode Imager 9400 (GE
Healthcare) and viewed using the ImageQuant software v5.0
(Molecular Dynamics, Sunnyvale, CA). Computerized evalua-
tions of the 2-D DIGE gels patterns were performed using
DeCyder v5.02 (Amersham Biosciences) as described in the
Ettan DIGE User Manual; Differential In-gel Analysis (DIA) and
Biological Variation Analysis (BVA) modules were used. The
spots were also manually screened to ensure correct matching
across gels. A threshold limit of 2.0-fold difference was set as
the statistically significant quantitative change and only spots
that were present in at least 3 of the 4 gels run for each
experiment were selected. Student’s t-test at 95% statistical
confidence (significance level, p < 0.05) was set. The gels were
silver-stained, and followed by in-gel tryptic digestion as
described in Neo et al.24
Mass Spectrometry Analysis and Database Searching. Pep-
tide digests from each gel spot were spotted onto a 100-well
MALDI sample plate and mixed with equal volume of CHCA
matrix solution (10 mg/mL R-cyano-4-hydroxy-cinnamic acid
in 0.1% TFA, 50% ACN). Peptide mass spectra were obtained
using a MALDI-TOF Voyager-DE STR mass spectrometer (Ap-
plied Biosystems). Laser intensity was set at 2400 with 100 shots
per spectrum over the window of m/z 700 to m/z 3000. The
mass spectrometric automatic data acquisition was performed
in delayed extraction and reflector mode. Instrumental calibra-
tion was performed internally using two trypsin autodigest ions
(m/z 842.51, m/z 2211.104).
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Proteins of interest were identified by peptide mass finger-
printing using the ProteinProspector MS-Fit software (http://
prospector.ucsf.edu/ucsfhtml4.0/msfit.htm, Protein Prospector;
UCSF, San Francisco, CA). Human and rodent subsets of
SWISS-PROT databases were used in the MS-Fit search. The
search parameters allowed oxidation of methioine, N-terminal
acetylation, carboxyamidomethylation of cysteine, and phos-
phorylation of serine, threonine, and tyrosine, and mass
tolerance was set at 50 ppm. The apparent Mr and pI were
estimated using an in-house program.
Subcellular Fractionation. The cytosolic fraction of HCT-
116 cells was prepared according to Thiede et al.25 except that
a series of three freeze-thawing processes was incorporated
prior to homogenization.
Western Blot. Proteins from the cytosolic samples were
precipitated using the 2-D Cleanup kit (GE Healthcare) and
resolubilized in the same cocktail solution used to generate
whole cell lysate. 120ug of whole cell lysate and cytosolic
fractions were resolved in 2-DE gels of 6-11 range. Upon
completion of electrophoresis, the gels were rinsed in Towbin
transfer buffer of 25 mM Tris, 192 mM glycine (USB), 0.1% SDS,
20% methanol (Merck). Proteins were then blotted onto
nitrocellulose membrane (Bio-Rad) using a HoeferTE 70 Series
Semi-Phor Semi-dry Transfer Unit (GE Healthcare). After
transfer, blots were blocked using 5% (w/v) BSA in TBS-T
(20mM Tris-HCl, 137mM NaCl, 0.1% Tween 20, pH 7.5)
overnight. Goat anti-hnRNP A1 and rabbit HRP-conjugated
anti-goat IgG antibodies (Santa Cruz, CA) were used at a
dilution of 1:500 and 1:100 000 in TBS-T with 1% BSA, respec-
tively. 3 washes in TBS-T were performed between each
antibody incubation. Immuno-detections of phosphoproteins
in the 2-DE blot of whole cell lysate were conducted using
mouse anti-phosphotyrosine IgG2b PY20 (BD Biosciences) and
mouse anti-phosphoserine IgM (Calbiochem) at 1:1000 and
1:200 dilutions, respectively. Subsequent visualization was
performed using enhanced chemiluminescence (ECL) (GE
Healthcare).
Results and Discussion
2-D DIGE on Butyrate-Treated HCT-116 Cells. HCT-116
cells, a heterologous human colon carcinoma cell line with ras
mutation,26 have been used in a series of studies to investigate
the effects conferred by HDAC inhibitors. These studies using
drugs such as butyrate, suberoylanilide hydroxamic acid and
trichostatin A were useful in identifying protein targets and
molecular pathways that mediate the biological effects of these
drugs on colorectal cancer. For instance, the requirement for
the histone hyperacetylation pathway,27 contribution of p21 and
p53,28,29 sensitization of TRAIL-pathway,30 and the linear rela-
tionship of WNT activity to butyrate actions31 have been
investigated using this cell line. In addition, fractionation of
HCT-116 cells lysate with a 2-D chromatographic technique
by Yan et al.32 visualized ‘protein bands’ that were peninsu-
larinone drug-regulated. In another context, HCT-116 cells were
used to create a data-driven model of colon cancer cell using
the Diagrammatic Cell Language33 to integrate networks in
signaling pathways and gene expression. Our previous study
had shown that upon 24 h post-treatment with physiological
concentration (5 mM) of sodium butyrate, HCT-116 cells
demonstrated significant growth inhibition and sensitivity to
butyrate-induced apoptosis.8
In this current work, 2-D DIGE was used to generate protein
expression maps as an unbiased method to uncover participat-
ing players in butyrate actions on HCT-116 cells. 2-D DIGE
approach has circumvented the technical bottleneck of inter-
gel variations in 2-DE, ensuring more accurate and reproduc-
ible results during comparative expression profiling. Differential
analysis of HCT-116 whole cell extract with 2-D DIGE gels in
quadruplicates revealed expression modulation of 20 protein
spots upon treatment, and peptide mass fingerprinting identi-
fied 6 of them (Table 1).
Improved Differential Analysis of HCT-116 Cells Using
Heparin Affinity Chromatography as a Prefractionation Step
Prior to 2-D DIGE. To enable us to delve deeper into the
Table 1. List of Proteins Identified to Be Differentially Expressed by Butyrate as Analyzed from 2-D DIGE of HCT-116 Whole Cell
Lysatea













1 Cytokeratin 8 P05787 134-148, 161-176, 214-225,
226-233, 234-252, 265-273,
329-341, 353-362, 382-392
30 2.15 3.9e-007 53.7/5.5 54.8/5.1




30 2.16 2.4e-006 53.7/5.5 55.5/5.2





37 2.26 1.0e-007 53.7/5.5 56.5/5.4




32 2.77 3.0e-009 53.7/5.5 55.5/5.3
5 Ornithine
aminotransferase
P04181 17-31 (2PO4), 33-46, 50-64,
67-76, 170-180, 275-292




P14854 21-28, 29-39, 48-59 36 3.55 7.2e-007 10.2/6.5 11.3/5.6
a Average volume ratio and student’s t-test p value were derived from DeCyder analysis (Mr is in kDa). b Represents accession numbers from Swiss-Prot
database. c A positive value signifies up-regulation and a negative value signifies down-regulation in terms of fold differences.
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proteome, we subsequently performed heparin affinity chro-
matography as a sample pre-fractionation step prior to 2-D
DIGE and MS analyses. As shown in the chromatogram (Figure
1), almost all the proteins were eluted in the first three fractions,
i.e., (I) unbound proteins (flow-through), (II) 0.4 M NaCl
fraction, and (III) 0.8 M NaCl fraction. Heparin is a highly
sulfated glucosaminoglycan that binds to a broad range of
proteins, such as nucleic acid-binding proteins, growth and
protein synthesis factors, metabolic enzymes and coagulation
factors.34 Of the variety of perturbations induced by butyrate,
inhibition of histone deacetylases that leads to changes in
chromatin structure and regulation of specific subsets of genes
was known to be a key event.27 Many of the low-abundance
nucleic acid-binding proteins such as transcriptional factors
and RNA binding proteins which contain basic domains can
thus be enriched by heparin affinity chromatography. This
chromatographic procedure had also been used to identify
several novel proteins from brain extract.18 Recently, Shefcheck
et al. also evaluated the use of immobilized heparin chroma-
tography for fractionation of cytosolic proteins from the human
breast cancer cell line, MCF-7.19 From the three eluted fractions,
only fraction II was used for 2-D DIGE analysis. The protein
content in fraction III was too low to permit further investiga-
tion. Two overlapping narrow-range IPG strips (pH 4-7 and
pH 6-11) were used for 2-D DIGE instead of the wide range
pH 3-10 IPG strip used in the study of total cell lysate. This
provided a better spatial resolution in the pI range, thus
minimizing the possibility of comigration of spots.35 22 spots
from the acidic range gels (pH 4-7) and 24 spots in the basic
range gels (pH 6-11) were detected as differentially regulated
with 10 and 14 spots identified from each range, respectively
(Figure 2 and Table 2). As deduced from the identification of a
greater number of differentially regulated spots in comparison
to the whole cell lysate analysis, this sub-proteomic approach
has greatly enhanced the resolution and detection sensitivity,
thus facilitating a more comprehensive analysis.
Proteins Differentially Expressed in HCT-116 Cells Follow-
ing Butyrate Treatment. Our data from heparin-affinity en-
riched fractions identified a number of proteins whose expres-
sion were significantly altered following butyrate treatment.
Here, we describe several of them pertaining to effects associ-
ated with butyrate such as transcriptional and translational
modulations, and the induction of apoptosis in cancer cells.
As listed in Table 2, 10 protein spots from the acidic range were
identified to be differentially expressed. They included the
down-regulated crk-like protein (crk-l), Ser/Thr protein phos-
phatase PP1, eukaryotic translation initiation factor 4E (eIF-
4E), and up-regulated elongation factor Tu (EF-Tu).
Crk-l is an oncogenic protein. Integrin-based motility was
shown to be significantly increased in cells overexpressing this
oncoprotein.36 In our study, we showed downregulation of
Crk-1 in HCT-116 cells following butyrate treatment. Concomi-
tant with our findings, the integrin signaling pathway37 has been
reported to be defective in butyrate-treated colonic cells.38 We
thus postulate that Crk-1 downregulation following butyrate
treatment of HCT-116 cells may deter integrin-mediated cell
motility. Similarly, down-regulation of PP1 triggered by butyrate
may also destabilize cell integrity and serve to induce ultra-
rapid capase-3 dependent apoptosis.39 In addition, PP1 has also
been shown to be involved in other physiological processes
associated with butyrate actions, such as the modulation of
transcription factors and remodeling of chromatin structure.40
Initiation factor eIF-4E, a mRNA cap-binding protein, was
shown to be down-regulated by butyrate in this study. eIF-4E
is a tumorigenic protein and is overexpressed in a myriad of
human tumors including colon carcinoma.41 In contrast, EF-
Tu, which was responsible for conveying aminoacyl-tRNAs to
ribosomes for protein synthesis was up-regulated. The dif-
ferential effects exhibited by these 2 proteins involved in protein
synthesis may be responsible for the selectivity mediated by
butyrate on protein expression.
Figure 1. Heparin affinity chromatography profile of control and butyrate-treated HCT-116 cell lysates. Step-wise elution gradient was
applied and three pools of fractions (I, II, and III) were collected.
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Figure 2. Silver-stained 2-D DIGE gel of fraction II obtained by heparin affinity chromatography of HCT-116 cell lysate resolved on a
(A) pH 4-7 and (B) pH 6-11 IPG gel. 10 and 14 protein spots identified from pH 4-7 and pH 6-11 gel are indicated with their spot
numbers, respectively. V represents down-regulated and v represents up-regulated proteins.
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From the basic range, 14 differentially expressed protein
spots were identified. This included nucleoside diphosphate
kinase B (NDPK B) and phosphotidylethalonamine-binding
protein (PEBP), which were both downregulated, and carbox-
ypeptidase A3 (CPA 3), which was upregulated. NDPK B is one
of the main NDPK isoforms in human, and has altered
expression in colorectal cancer. NDPKs play pivotal functions
in cell motility, signal transduction and regulation of gene
expression.42-44 Its down-regulation here correlates with its role
as a transcriptional activator of c-myc oncogene45 since c-myc
expression is repressed by butyrate in colon cancer cells.46 PEBP
is a survival-promoting protein that was shown to be highly
expressed in tumor cells. PEBP confers resistance to TNF-R -
signaling pathways and induces apoptosis in cancer cells.47 Its
Table 2. List of Proteins Identified from 2-D DIGE Analysis (pH 4-7 and pH 6-11) of Fraction II (Heparin Affinity Chromatography
























P33316 104-115 (1Met-ox), 156-169,
195-206, 217-224, 225-241
25 -4.22 7.80 e-009 26.7/9.6 24.1/5.8
1204 Ser/Thr protein phosphatase PP1 P36873 27-36, 61-74, 114-122, 247-260 19 -2.40 1.10 e-006 37.0/6.1 41.1/5.9
1121 Crk-like protein P46109 12-21, 40-57, 58-69, 90-104,
269-282
22 -2.30 0.00034 33.8/6.3 42.2/6.6
1462 Eukaryotic translation initiation
factor 4E
P06730 22-36, 163-173, 174-181,
193-206
22 -2.08 0.00083 25.1/5.8 31.2/5.9
up-
regulated
2454 Cytochrome c oxidase
polypeptide VIb
P14854 21-28, 29-39, 48-59 36 3.36 0.00076 10.2/6.5 11.8/5.9
930 Heterogeneous nuclear
ribonucleoprotein K
Q07244 70-86, 140-148, 149-163,
180-191, 208-219, 306-316,
317-325
18 2.81 9.40 e-005 51.0/5.4 51.2/6.4
925 Ornithine aminotransferase P04181 33-46, 50-64, 67-76, 170-180 11 2.60 0.0035 48.5/6.6 51.4/6.4
1092 RGS19-interacting protein 1 O14908 11-24, 58-72, 217-224, 225-240,
249-263, 268-279, 296-307
32 2.43 9.60 e-005 36.1/5.9 42.4/6.4
1049 Acyl-CoA dehydrogenase P45954 160-170, 270-284, 285-294,
326-347, 385-396
16 2.22 1.30 e-005 47.5/6.5 44.4/6.1
1265 Elongation factor Tu P49411 210-227, 239-252, 253-271 11 2.01 0.00034 49.5/7.3 36.8/6.3
basic range (pH 6-11)
down-
regulated
824 40kDa peptidyl-prolyl cis-trans
isomerase
Q08752 18-28, 57-69, 103-111, 115-125,
146-154, 175-185, 186-195, 196-
214, 228-235, 236-244, 314-321,
322-331
34 -2.91 1.50 e-005 40.8/6.8 42.9/6.9
1462 Dihydrofolate reductase P00374 20-29, 57-64, 72-78, 82-92, 110-
123, 124-133, 159-174
46 -2.85 2.80 e-005 21.5/6.9 26.6/7.0
1972 Profilin-1 P07737 57-70, 76-89 (1Met-ox), 117-126,
128-136,
34 -2.53 1.80 e-006 15.1/ 8.4 15.4/8.4
1081 Heterogeneous nuclear
ribonucleoprotein A1
P09651 16-31, 32-47, 93-105, 114-122,
123-130, 131-140 (1Met-ox), 147-
161, 167-178,353-370
38 -2.52 0.0058 38.8/9.3 38.7/9.7
1128 Heterogeneous nuclear
ribonucleoprotein A1
P09651 16-31, 32-47, 93-105, 114-122,
123-130, 131-140, 147-161,
167-178
29 -2.33 0.017 38.8/9.3 37.7/8.0
1127 Heterogeneous nuclear
ribonucleoprotein A1
P09651 16-31, 32-47 (1Met-ox), 93-105,
114-122, 123-130, 131-140
(1Met-ox), 147-161, 167-178,
29 -2.29 0.0071 38.8/9.3 37.7/7.9
1476 Phosphotidylethalonamine-
binding protein
P30086 40-47, 48-62, 63-76, 83-93, 94-113,
120-132, 133-141, 162-179,
180-187
62 -2.06 0.00017 21.1/7.0 26.4/8.3
1977 Profilin-1 P07737 57-70, 76-89 (1Met-ox), 92-105,
117-126, 128-136 (1Met-ox)
43 -2.04 0.0011 15.1/8.4 15.2/8.6
1767 Nucleoside Diphosphate
kinase B
P22392 7-18, 57-66, 89-105, 106-114 31 -2.01 6.10 e-005 17.3/8.5 20.6/8.4
up-
regulated
591 Pre-B cell enhancing factor
precursor
P43490 33-40, 89-99, 100-107, 108-117,
118-127, 175-189, 190-196, 197-
216, 235-255, 290-296, 303-323,
343-349, 393-400, 401-415, 435-
447, 448-463, 470-477, 479-491
46 2.96 7.50 e-007 55.5/6.7 59.9/7.0
596 Pre-B cell enhancing factor
precursor
P43490 33-40, 89-99, 100-107, 108-117,
118-127, 175-189, 190-196, 197-
216, 235-255, 290-296, 303-323,
343-349, 470-477, 479-491
34 2.38 0.00014 55.5/6.7 58.1/6.9
1406 Heterogeneous nuclear
ribonucleoprotein A1
P09651 16-31, 32-47, 93-105, 114-122,
123-130, 131-140, 141-161,
167-178
26 2.21 0.0052 38.8/9.3 26.8/7.0
732 Carboxypeptidase A3 Q9UI42 21-28, 149-162, 171-183, 184-196,
245-257, 290-297 (1PO4), 411-417,
18 2.04 0.013 47.4/6.4 50.4/6.5
1416 Heterogeneous nuclear
ribonucleoprotein A1
P09651 16-31, 32-47 (1Met-ox), 93-105, 114-
122, 123-130, 131-140 (1Met-ox),
147-161, 167-178
29 2.03 7.40 e-005 38.8/9.3 26.8/8.1
a Mr in kDa. Spot no., t-test, and avg. vol. ratio were obtained from DeCyder differential analysis software. b Represents accession numbers from Swiss-Prot
database. c A positive value signifies up-regulation and a negative value signifies down-regulation in terms of fold-differences.
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down-regulation shown in our data is also in line with the
synergistic apoptotic effects of butyrate and TNF-R on intestinal
epithelial cells.48 Our proteomics study shows a 2-fold increase
in the expression of CPA3 in HCT-116 colon cells following
butyrate treatment. This parallels genomic data in which
induced expression of CPA3, a novel gene in the histone
hyperacetylation pathway, was also demonstrated following
treatment of prostrate epithelial cancer cells with HDAC
inhibitors, butyrate and Trichostatin A.49
hnRNP K and A1 are Altered and Undergo Post-transla-
tional Modifications with Butyrate Treatment. One of the
interesting groups of proteins identified to be differentially
expressed from this work was the heterogeneous nuclear
ribonucleoprotein (hnRNP) family. The hnRNP family (in
mammalian cells) consists of more than 20 members, all of
which are able to associate with mRNA precursors and many
influence mRNA biogenesis.50 In this work, hnRNP K was
detected in the acidic range gels, while hnRNP A1 was identified
in the basic range gels.
hnRNP K is a multi-modular protein in the hnRNPs family
which functions as docking platform bridging multiple signaling
cascades to regulation of DNA and RNA-directed processes
(such as transcription, translation, pre-RNA splicing, mRNA
trafficking and stability) for many genes.51 This protein, which
was shown to be up-regulated by butyrate in this study, could
function as a transcription factor itself or interact with activa-
tors/repressors of RNA polymerase II promoters.52 In addition,
chromatin remodeling which is a well-established outcome of
HDAC inhibition by butyrate, is one aspect of the nucleic acid-
directed regulation by hnRNP K.
Intriguingly, 5 differentially regulated spots with different pIs
(Figure 2B, spot number 1081, 1127, 1128, 1406, and 1416) on
Figure 3. Selected area of the ImageQuant view of CyDye image and its corresponding silver stained pH 6-11 2-DE gel showing the
5 protein spots identified as hnRNP A1. Red circles represent proteins that are up-regulated following butyrate treatment. Green circles
represent proteins down-regulated with butyrate treatment.
Figure 4. Western blot analysis of hnRNP A1 changes in HCT-116 cells 24 h after butyrate treatment. 120 íg of proteins were loaded
on a pH 6-11 18 cm strip. (A) Western blot with anti-hnRNP A1 antibodies illustrated a decrease in expression of all isoforms of
hnRNP A1 in butyrate-treated HCT-116 cells. Analyses using anti-phosphotyrosine and anti-phosphoserine antibodies confirmed that
these isoforms were due to phosphorylation of tyrosine and serine residues in hnRNP A1. However, there were no significant changes
in the phosphorylation status of hnRNP A1 between the control and butyrate-treated cells. (B) Immuno-blotting of the cytosolic fraction
of HCT-116 cells showed an appearance of the protein spot at the low molecular weight of the treated cells but not in the control cells.
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the 2-D DIGE gel (pH 6-11) were positively identified as hnRNP
A1. Three of the spots with apparent Mr of 38 kDa were down-
regulated and the other two spots with Mr of 26 kDa were
found to be up-regulated (Figure 3). The detailed diagrammatic
analysis by DeCyder software of the 5 hnRNP A1 protein spots
regulated with butyrate treatment is available in the Supporting
Information.
A recent report on sporadic colorectal cancers has detected
an overexpression of hnRNP A1,53 suggesting that hnRNP A1
plays a role in tumorigenesis. Reduction of hnRNP A1 together
with hnRNP A2 was able to promote apoptosis in several cell
lines.54 This corroborates with the down regulation of full length
forms of hnRNP A1 following apoptosis induced by butyrate,
as seen here in our study.
It was documented that the spot position of hnRNP A1 differs
in several apoptotic cells implying differential post-translational
modifications25 and multiple phosphorylations were speculated
to be responsible for the change in pI values seen. 2-DE and
Western blot analysis were done to validate the change in
expression patterns of hnRNP A1 following butyrate treatment.
Our results showed a train of hnRNP A1 immuno-reactive spots
with reduced intensities in HCT-116 cells treated with butyrate
(Figure 4A). This indicates that hnRNP A1 exists in several
isoforms probably due to post-translational modifications.
Indeed, hnRNP A1 is known to undergo post-translational
modifications such as phosphorylation55, sumoylation,56 and
ubiquitinylation.57
Butyrate induces apoptosis, along with the activation of
signaling pathways, such as of PKC and p38 MAP kinase which
participate in cell death.58 It is likely that hnRNP A1 may be
phosphorylated as a target in these pathways. This hypothesis
corroborates with a similar report by Allemand et al. They
showed that cells under osmotic stress activate the MKK3/6-
p38 signaling pathway, which resulted in subsequent phos-
phorylation and accumulation of hnRNP A1 in the cytoplasm.55
An anti-phosphoprotein immuno-blot performed confirmed
that the hnRNP A1 isoforms seen in our blots were due to
phosphorylations at tyrosine and serine residues. However,
there were no significant changes in phosphorylation status
following treatment with butyrate (Figure 4A).
In our results, the expression level of full-length hnRNP A1
protein was shown to be decreased and a smaller form was
detected only in butyrate-treated HCT-116 cells. It is possible
that the native hnRNP A1 undergoes cleavage upon butyrate
treatment. Indeed, an immuno-reactive spot was shown to be
induced in the treated sample, as detected at the lower
molecular weight (Mr  26 kDa) region. It has been suggested
that during apoptosis hnRNP A1 can be cleaved and localized
to the cytoplasm.25 To explore this, we studied the expression
level of hnRNP A1 in the cytosolic fraction of HCT-116 cells.
We carried out subcellular fractionation of HCT-116 cells to
conduct anti-hnRNP A1 Western blot analysis on the cytosolic
proteins. We detected an immuno-reactive spot at a low
molecular weight region of the gel in the cytosol of butyrate-
treated cells, which was absent in the counterpart control
(Figure 4B). This supports the hypothesis that butyrate induced
the formation of a cleaved hnRNP A1 in the cytosol of HCT-
116 cells.
Redistribution of proteins between cellular compartments
plays a crucial part in apoptosis,59 either with or without
cleavage by caspases. Some members of hnRNP families,
including hnRNP A1, shuttle between the cytoplasm and
nucleus. The trafficking of hnRNPs may be associated with a
role in RNA processing.60 The close relation between its
localization and role as splicing factor was further supported
by the relocation of hnRNP A1 to cytoplasm when splicing was
inhibited by snRNA-specific oligonucleotide.61 The localization
of hnRNP A1 is also closely tied with proliferation, differentia-
tion and apoptosis of both normal and tumorigenic cells.
Nuclear proteome study showed up-regulation of hnRNP A1
in proliferative intestinal epithelial cells and repressed expres-
sion in differentiated cells62 Both native and cleaved forms of
hnRNPs translocate between cellular compartments in Fas-
induced apoptotic cells, and cleavage of hnNRP A1 may affect
its import into the nucleus.25 Interestingly, caspase 3, which is
essential for the induction of cell death by butyrate in colonic
cells, was found to be responsible for the cleavage of hnRNP
A1 during apoptosis in a human Burkitt lymphoma cell line.63
The decrease in whole cell expression of full length forms of
hnRNP A1, presence of phosphorylations as its post-transla-
tional modifications, and the cytoplasmic retention of the
cleaved protein observed in our study sheds new insight on
the multi-faceted roles and regulation of hnRNP A1 in the
cellular response to butyrate treatment.
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Quantitative and Temporal Proteome Analysis
of Butyrate-treated Colorectal Cancer Cells*□S
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Colorectal cancer is one of the most common cancers in
developed countries, and its incidence is negatively asso-
ciated with high dietary fiber intake. Butyrate, a short-
chain fatty acid fermentation by-product of fiber induces
cell maturation with the promotion of growth arrest, dif-
ferentiation, and/or apoptosis of cancer cells. The stimu-
lation of cell maturation by butyrate in colonic cancer cells
follows a temporal progression from the early phase of
growth arrest to the activation of apoptotic cascades.
Previously we performed two-dimensional DIGE to iden-
tify differentially expressed proteins induced by 24-h bu-
tyrate treatment of HCT-116 colorectal cancer cells.
Herein we used quantitative proteomics approaches us-
ing iTRAQ (isobaric tags for relative and absolute quanti-
tation), a stable isotope labeling methodology that en-
ables multiplexing of four samples, for a temporal study of
HCT-116 cells treated with butyrate. In addition, cleavable
ICAT, which selectively tags cysteine-containing pro-
teins, was also used, and the results complemented
those obtained from the iTRAQ strategy. Selected
protein targets were validated by real time PCR and
Western blotting. A model is proposed to illustrate our
findings from this temporal analysis of the butyrate-
responsive proteome that uncovered several integrated
cellular processes and pathways involved in growth ar-
rest, apoptosis, and metastasis. These signature clus-
ters of butyrate-regulated pathways are potential tar-
gets for novel chemopreventive and therapeutic drugs
for treatment of colorectal cancer. Molecular & Cellular
Proteomics 7:1174–1185, 2008.
In developed countries, colorectal cancer is a prevalent
disease with high mortality and morbidity rates (1). This dis-
ease has emerged as the top malignancy in Singapore. Envi-
ronmental factors are responsible for about 80% of the cases,
whereas genetic predisposition accounts for the minority 20%
of cases. Epidemiological evidence suggests that high intake
of dietary fiber reduces the incidence and risk of this neo-
plasm (2, 3). A wealth of studies has shown that butyrate
produced from anaerobic fermentation of indigestible carbo-
hydrate is the molecule responsible for the chemopreventive
properties of a fiber-rich diet (4–6).
Although butyrate serves as an energy source for normal
colonocytes, in vivo and in vitro studies have shown that at
physiological concentrations this natural short-chain fatty
acid mediates cell maturation with the promotion of growth
arrest followed by differentiation and/or apoptosis of cancer
cells (7–11). These biological effects are crucial in colorectal
cancer therapy as colonic transformation is characterized by
multistage alterations of tissue homeostasis resulting in aber-
rant cell division and/or cell death (12, 13). Butyrate has been
purported as a potential anticancer agent. This initiated nota-
ble research in identifying proteins that contribute to its bio-
logical effects (14, 15). However, most of these investigations
focused on one target at any one time and were thus unable
to systematically elucidate the mode of actions of butyrate in
an integrated manner.
Through the use of DNA microarray technology, Mariada-
son et al. (16) showed that butyrate induced maximal genetic
reprogramming after 16 h of treatment on colorectal cancer
cells. In our earlier work, a functional proteomics approach
using a prefractionation strategy coupled with two-dimen-
sional (2-D)1 DIGE analysis was undertaken to identify candi-
date proteins regulated by 24-h butyrate treatment in HCT-
116 cells (17). We have also demonstrated the high sensitivity
of the cell line to butyrate-induced growth inhibition and apo-
ptosis in a time- and dose-dependent manner (18). Therefore,
the stimulation of cell maturation by butyrate implicated a
temporal orchestration of various cellular processes.
In this study, we carried out a comparative proteome anal-
ysis of HCT-116 cells treated with butyrate at three time
points with the aim to identify clusters of proteins (and path-
ways) that showed a consistent trend of differential expres-
sion over time. The synergistic influence of each cluster of
proteins may result in the overall phenotypic response to
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butyrate. Herein the chosen period of treatment (24, 36, and
48 h) spans from the induction of growth arrest and early
phase of apoptosis until the late phase of cell death. In addi-
tion to providing insights into the mechanism underlying the
pleiotropic effects of butyrate, our study of the time dynamics
of butyrate treatment could lead to the discovery of potential
therapeutic targets associated with the progression of cell
maturation in cancer cells. As the iTRAQmethodology permits
multiplexing of four samples in a single experiment, it is well
suited for the evaluation of the dynamic cellular response to
butyrate in a time course study (19). Here we show the first
experimental iTRAQ data for butyrate-treated HCT-116 cells
carried out at 24, 36, and 48 h.
EXPERIMENTAL PROCEDURES
Cell Culture—HCT-116 colorectal cancer cells were cultured and
treated with 5 mM sodium butyrate as reported previously except that
three treatment time points (24, 36, and 48 h) were used (17).
iTRAQ Labeling—Four batches each of control cells (24-h mock-
treated) and cells treated with 5 mM sodium butyrate for 24, 36, and
48 h, respectively, were harvested. 500 mM triethylammonium bicar-
bonate, 1.0% (w/v) SDS was used for extraction and denaturation of
cellular proteins by boiling at 100 °C for 10 min. Cellular debris were
removed after centrifugation at 18,800  g for 1 h at 23 °C. iTRAQ
labeling of each sample was performed according to the manufac-
turer’s protocol (Applied Biosystems, Foster City, CA). 100 g of
protein was reduced with 5 mM tris-(2-carboxyethyl)phosphine at
60 °C for 1 h and subsequently alkylated with 10 mM methyl meth-
anethiosulfonate for 10 min. After cysteine blocking, each sample was
diluted to 0.05% (w/v) SDS prior to trypsinization at 37 °C for 16 h.
Following this, each tryptic digest was labeled for 1 h with one of the
four isobaric amine-reactive tags as follows: Tag114, 24-h control;
Tag115, 24-h treated; Tag116, 36-h treated; and Tag117, 48-h treated
samples. These four iTRAQ-derivatized samples were then pooled
and passed through a strong cation exchange cartridge as recom-
mended by the manufacturer (Applied Biosystems). This eluate (from
the ion exchange step) was desalted using a Sep-Pak cartridge
(Millipore), vacuum-dried, and reconstituted for 2-D LC.
cICAT Labeling—The control and treated cells harvested from the
three time points (24, 36, and 48 h) were lysed in 50 mM Tris, 1.0%
(w/v) SDS, pH 8.5, and boiled at 100 °C for 10 min. They were then
subjected to centrifugation at 18,800  g for 1 h at 23 °C to remove
cell debris. cICAT labeling and processing of the samples followed
standard protocols (Applied Biosystems). 100 g of protein from the
control and butyrate-treated cell lysate of each time point was each
reduced with 1.25 mM tris-(2-carboxyethyl)phosphine and subse-
quently labeled with the respective isotopic light and heavy forms of
the cICAT reagents for 2 h at 37 °C. Each pair of heavy and light
cICAT-derivatized proteins from each time point was then pooled and
trypsinized at 37 °C for 16 h. Upon completion of in situ digestion, the
digested peptide mixture was cleaned up with a strong cation ex-
change cartridge and then enriched with an avidin affinity cartridge.
The cICAT-labeled peptides were then dried by speed vacuuming,
dissolved in cleaving reagents, and incubated at 37 °C for 2 h. After
the removal of biotin, peptides were brought to dryness again before
being reconstituted for 2-D LC.
2-D LC Separation of Labeled Peptides—Each of the iTRAQ- and
cICAT-labeled peptide mixtures was separated using an UltimateTM
dual gradient LC system (Dionex-LC Packings) equipped with a
ProbotTM MALDI spotting device. A 2-D LC separation was performed
as follows. The labeled peptide mixture was dissolved in 2% ACN
with 0.05% TFA and injected into a 0.3  150-mm strong cation
exchange column (FUS-15-CP, POROS 10S) (Dionex-LC Packings)
for the first dimensional separation. Mobile phase A was 5 mM
KH2PO4 buffer, pH 3, 5% ACN, and mobile phase B was 5 mM
KH2PO4 buffer, pH 3, 5% ACN, 500 mM KCl, respectively. The flow
rate was 6 l/min. Nine fractions were obtained using step gradients
of mobile phase B: unbound, 0–5, 5–10, 10–15, 15–20, 20–30, 30–
40, 40–50, and 50–100%. The eluting fractions were captured alter-
natively onto two 0.3  1-mm trap columns (3-m C18 PepMap
TM,
100 Å) (Dionex-LC Packings) and washed with 0.05% TFA followed
by gradient elution in a 0.2  50-mm reverse phase column (mono-
lithic polystyrene-divinylbenzene) (Dionex-LC Packings). The mobile
phases used for this second dimensional separation were 2% ACN
with 0.05% TFA (A) and 80% ACN with 0.04% TFA (B). The gradient
elution step was 0–60% B in 15 min at a flow rate of 2.7 l/min. The
LC fractions were mixed directly with MALDI matrix solution (7 mg/ml
-cyano-4-hydroxycinnamic acid and 130 g/ml ammonium citrate in
75% ACN) at a flow rate of 5.4 l/min via a 25-nl mixing tee (Upchurch
Scientific) before they were spotted onto a 192-well stainless steel
MALDI target plate (Applied Biosystems) using a Probot Micro Pre-
cision Fraction Collector (Dionex-LC Packings) at a speed of 5 s/well.
50 fmol of ACTH(18–39) peptide (m/z  2465.199) was spiked into
each well as internal standard.
Mass Spectrometry Analysis—The samples on the MALDI target
plates were analyzed using a 4700 Proteomics Analyzer mass spec-
trometer (Applied Biosystems). MS/MS analyses were performed us-
ing nitrogen at a collision energy of 1 kV and a collision gas pressure
of 1  106 torr. The GPS ExplorerTM software version 3.6 (Applied
Biosystems) was used to create and search files with the MASCOT
search engine (version 2.1; Matrix Science) for peptide and protein
identifications in both the cICAT- and iTRAQ-labeled samples. The
International Protein Index (IPI) human database (version 3.30, 67,922
sequences) (20) was used for the search, and this was restricted to
tryptic peptides.
iTRAQ-labeled Samples—One thousand shots were accumulated
for each MS spectrum. For MS/MS, 6,000 shots were combined for
each precursor ion with signal to noise (S/N) ratio greater or equal to
100. For precursors with S/N ratio between 50 and 100, 10,000 shots
were acquired. The resolution used to select the parent ion was 200.
No smoothing was applied before peak detection for both MS and
MS/MS, and the peaks were deisotoped. For MS/MS, only the peaks
from 60 to 20 Da below each precursor mass and with S/N 10 were
selected. Peak density was limited to 30 peaks per 200 Da, and the
maximum number of peaks was set to 125. Cysteine methanethiola-
tion, N-terminal iTRAQ labeling, and iTRAQ-labeled lysine were se-
lected as fixed modifications; methionine oxidation was considered
as a variable modification. One missed cleavage was allowed. Pre-
cursor error tolerance was set to 100 ppm; MS/MS fragment error
tolerance was set to 0.4 Da. Maximum peptide rank was set to 2.
iTRAQ quantification was performed using the GPS Explorer software
and normalized among samples. iTRAQ ratios were calculated based
on the cluster areas of the iTRAQ reporter fragment peaks (114, 115,
116, and 117), and the calculation of ratios included only peptides
identified with C.I. percent above cutoff thresholds as described
below.
The average iTRAQ ratio and S.D. were determined using the GPS








where R is the average iTRAQ ratio, Xi is the natural log of the iTRAQ
ratio of each iTRAQ pair, and N is the number of peptides with
non-zero iTRAQ ratio.
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where log S  sd and R is the average iTRAQ ratio.
sd
i  1N xi log R2
N 1
(Eq. 4)
where sd is the iTRAQ standard deviation and Xi is the natural log of
the iTRAQ ratio of each peptide.
In this work, four biological replicates of iTRAQ-labeled samples
were analyzed. Student’s t test was performed, and the p values
based on the iTRAQ ratios of peptides matched to each protein (48-h
time point versus control) were used to assess the significance of
temporal differential expression. Proteins that have p values 0.05 in
at least one data set and showed consistent changes in all data sets
were considered as significantly altered in the expression level.
To determine the cutoff threshold of -fold changes for proteins with
a single peptide match, two equal amounts of trypsin-digested six-
protein mixtures (Applied Biosystems) were labeled with iTRAQ re-
agents 114 and 117, respectively, and analyzed with 1-D LC MALDI-
TOF/TOF MS (reverse phase liquid chromatography; similar to that
mentioned above). The S.D. based on the ratios of all the identified
peptides was 0.15; thus 1.3 (1  2 S.D.) was determined to be the
significant cutoff threshold (p  0.05) for the up-regulated proteins,
and reciprocally 0.77 was the cutoff threshold for the down-regulated
proteins (data are shown in the supplemental data). Similar cutoff
thresholds have been used in other iTRAQ studies (21, 22).
cICAT-labeled Samples—For MS analysis, typically 1,000 shots
were accumulated for each sample well. MS/MS acquisition was
performed in a result-dependent manner. Only cICAT pairs with a
normalized ratio (normalized against the median ratio of all the cICAT
pairs detected) greater than 40% were selected for fragmentation.
Singletons were also selected as precursor ions. Stop conditions
were implemented so that 3,000–6,000 shots were accumulated
depending on the quality of the spectra. The resolution used for
parent ion selection was 200. Peak processing and detection proce-
dures were the same as those mentioned above. Heavy and light
cICAT-labeled cysteine, N-terminal acetylation and pyroglutamation
(Glu and Gln), and methionine oxidation were selected as variable
modifications. One missed cleavage was allowed. Precursor error
tolerance was set to 100 ppm, and MS/MS fragment error tolerance
was set to 0.3 Da. Maximum peptide rank was set to 5. cICAT
quantification was performed using GPS Explorer software and nor-
malized against the median ratio obtained from all the cICAT peptide
pairs detected in one sample. The ratios were calculated by compar-
ison of the cluster area of the heavy ICAT-labeled peptide with that of
the light ICAT-labeled peptide. Two equal amounts of trypsin-di-
gested BSA were labeled with heavy and light cICAT tags and sub-
jected to 1-D LC MALDI-TOF/TOF MS. The S.D. based on the ratios
of all the identified cICAT-labeled peptides was 0.12; thus 1.36 (1 
3 S.D.) was determined as the significant cutoff threshold (p  0.01)
for the significantly up-regulated proteins, and reciprocally 0.74 was
the cutoff threshold for the down-regulated proteins.
Estimation of False Positive Rate to Determine Cutoff Score—In
addition to the IPI human database, a randomized database (67,922
sequences) generated using IPI human database version 3.30 (gen-
erated using a Pearl script downloaded from Matrix Science) was also
used to search both the iTRAQ- and cICAT-labeled samples. The
false positive rate was calculated by comparing the peptide hits
obtained from these two databases at different ion score C.I. per-
cent (peptide). The minimum ion score C.I. percent was set such
that no more than a 5% false positive rate is achieved. Based on
this cutoff threshold, all the proteins identified from the random
database search were single peptide-matched. Hence proteins
identified from the human database that are matched to at least two
peptides are statistically confident. For single peptide-matched
proteins, only those with ion score C.I. percent greater than the
highest C.I. percent attained from the random database search
were selected. With these cutoff thresholds, we essentially
achieved a 0% false positive identification rate at the protein level.
In addition, those single peptide-matched proteins must be identi-
fied based on a peptide that has been detected several times in one
run or in replicate runs. The minimum ion score thresholds that were
used for each iTRAQ- and cICAT-labeled sample are shown in the
supplemental data.
Real Time PCR—RNA was isolated from two batches of harvested
HCT-116 cells using the RNeasy Plus minikit (Qiagen, Chatsworth,
CA) according to the manufacturer’s instructions. Purified RNA was
quantified by UV spectrophotometry (A260 of 1  40 g/ml) and
assessed using denaturing agarose gel electrophoresis. MultiScribeTM
reverse transcriptase (Applied Biosystems) was used to reverse tran-
scribe RNA from each sample to cDNA following the manufacturer’s
protocol. Primers specific for each gene target were designed using
Primer Express software (Applied Biosystems) and synthesized by 1st
Base Pte. Ltd. (Singapore). Basic Local Alignment Search Tool
(BLAST) searches for all primer sequences were performed to confirm
gene specificity. For quantification of each gene in the samples,
amplification was performed in triplicates with SYBR Green PCR
Master Mix (Applied Biosystems) on the ABI PRISM 7000 Sequence
Detection System instrument according to the manufacturer’s in-
structions. Non-template controls were included for each run. Glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the
endogenous control reference for normalization. Thermal cycling pa-
rameters were as follows: denaturation at 95 °C for 10 min followed
by 40 cycles at 95 °C for 15 s and 60 °C for 1 min.
Two-dimensional Gel Electrophoresis (2-DE)—2-DE was performed
as described previously (17). Briefly harvested cells were lysed in the
extraction buffer and clarified with centrifugation. 10 g of each
sample was then loaded onto rehydrated 7-cm pH 3–10 non-linear
IPG strips and separated on the IPGphor unit (GE Healthcare) using
the following parameters: (i) 100 V, 50 V-h; (ii) 200 V, 100 V-h; (iii) 500
V, 250 V-h; (iv) 1,000 V, 500 V-h; (v) 1,000–8,000 V, 2,250 V-h, and (vi)
8,000 V, 12,000 V-h. A two-step equilibration procedure using DTT
and iodoacetamide was used to reduce and alkylate the separated
proteins in the IPG strips, respectively, before the second dimensional
SDS-PAGE step.
Western Blot—Equal aliquots of proteins extracted from both con-
trol and treated cells of each time point were resolved by 1-D SDS-
PAGE. Upon completion of electrophoresis, the proteins were elec-
troblotted onto nitrocellulose membranes (Bio-Rad). The blots were
then blocked using 5% (w/v) nonfat dry milk in TBS with 0.1% Tween
20 (TBS-T) overnight prior to immunoprobing with antibodies diluted
in TBS-T with 1% (w/v) milk for 1 h each. The membranes were
incubated with rabbit anti-GAPDH (1:200) from Santa Cruz Biotech-
nology, Inc., mouse anti-heat shock protein (HSP) 90- (1:1,000) from
Stressgen, mouse anti-galectin-1 (1:500), mouse anti-AKAP12 (1:
500), mouse anti-SEC22b (1:750), or mouse anti-cytochrome c oxi-
dase VIb (1:750) from Abnova. HRP-conjugated anti-rabbit IgG (1:
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2,500) from Santa Cruz Biotechnology, Inc., HRP-conjugated anti-
mouse IgG (1:5,000) from GE Healthcare, or HRP-conjugated anti-
mouse IgM (1:5,000) from Pierce were used as secondary antibodies.
Three washes in TBS-T were carried out between each antibody
incubation. Subsequent visualization was performed using ECL (GE
Healthcare) with GAPDH levels as the loading control.
FIG. 1. Identification of protein clusters based on biological functions that showed similar trends of differential expression over time.
These proteins exhibit progressive up- or down-regulation on a temporal basis and were clustered into groups of certain cellular processes
modulated by butyrate: Cluster A, cell cycle progression; Cluster B, apoptosis (Cluster B1, tumor suppressors; Cluster B2, oxidative
phosphorylation; Cluster B3, HSPs and chaperones; Cluster B4, ubiquitination-proteasome pathway); Cluster C, metabolism; and Cluster D,
metastasis.
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Protein Identification from iTRAQ- and ICAT-labeled
Peptides
783 unique proteins were identified from a total of 3,116
tryptic peptides for the iTRAQ-labeled samples. On the other
hand, 137 unique proteins were identified from a total of 241
peptides obtained from cICAT (see supplemental data for the
lists of iTRAQ- and ICAT-labeled proteins that showed tem-
poral differential expression after butyrate treatment). Be-
cause of the difference in labeling chemistry, the result ob-
tained from the cICAT approach complements the iTRAQ
data. Recently quantitative proteomics incorporating stable
isotope tagging such as postisolation labeling using ICAT or
iTRAQ was demonstrated to be a strategy complementary to
2-DE (23, 24). Most notably, a comparative study of these
three proteomics methods found limited overlapping proteins
between them, and iTRAQ was considered to be the more
sensitive technology as compared with ICAT and 2-D DIGE
(25). This underscored the importance of using various tech-
nology platforms for a more comprehensive proteomics study
of complex samples.
Interestingly a subset of proteins found in this study had
also been identified in our previous work using 2-D DIGE (17),
and they showed regulation in a similar manner by butyrate
treatment. Such proteins include cytoskeletal 8, ornithine ami-
notransferase, cytochrome c oxidase polypeptide VIb, and Tu
elongation factor.
Temporal Analysis of Proteins following Butyrate
Treatment
From the list of differentially expressed proteins obtained
from this temporal study, proteins that exhibited progressive
up- or down-regulation were clustered into groups on the
bases of their biological functions. They could be grouped
into four cellular processes, viz. Cluster A, growth arrest;
Cluster B, apoptosis; Cluster C, metabolism; and Cluster D,
FIG. 2. Validation of the iTRAQ re-
sults on selected proteins using real
time PCR. The results verified differen-
tial regulation of these proteins upon bu-
tyrate treatment. -Fold change ratio as-
sessed by real time PCR was expressed
as mean values  S.E. of two batches of
cells performed in triplicates.
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metastasis (Fig. 1; also see the supplemental data for the
complete list of differentially expressed proteins). Subse-
quently some of these protein candidates were validated us-
ing quantitative real time PCR and/or Western blotting. These
results are shown in Figs. 2 and 3, and they are in accord with
the proteomics results.
An overview of the temporal anticancer effects of butyrate
treatment on the various cellular processes is shown in Fig. 4.
These data were obtained from the iTRAQ ratios of the pro-
teins grouped under each cellular process at each time point.
As seen here and discussed further below, our temporal anal-
ysis showed that butyrate induced a blockage of cell cycle
FIG. 3. Western blots of proteins
identified to have differential expres-
sion from iTRAQ data. a, Western blot
confirmed differential expression of
these proteins. GAPDH was used as the
loading control. For AKAP12, decreased
expression of full-length protein (	200
kDa) was detected, but an increased
presence of a protein fragment (	40
kDa) was seen over time. b, 2-DE (pH
3–10) Western blot for AKAP12 was
performed to confirm the increased ex-
pression of the fragment protein at 	40
kDa (circled in b). COX, cytochrome c
oxidase.
FIG. 4. An overview of the temporal
effects of butyrate treatment on the
various cellular processes. The differ-
ential regulation of the proteins from
each cellular process was summarized
to illustrate the overall temporal effects
of butyrate treatment on HCT-116 cells.
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progression as an early event (24 h), whereas the antimetas-
tasis effect was most apparent at the later stage (48 h) of
treatment.
Temporal Regulation of the Cellular Processes and
Pathways Induced by Butyrate
This study has clearly identified clusters of proteins in path-
ways that correlate protein expression changes with the in-
duction of anticancer effects. The synergistic influence of
each cluster of proteins results in the overall phenotypic
response to butyrate. On the bases of these observations,
we propose a model to illustrate the integrated cellular
mechanism initiated by butyrate in colorectal cancer cells
(Fig. 5).
Cluster A: Growth Arrest
Cell Cycle Progression—Butyrate regulates several cell cycle
genes including c-myc, p16, and p21 (14). Among the list of
down-regulated proteins identified here, several function in nu-
cleotide biosynthesis, cell cycle progression, and cellular prolif-
eration (Fig. 1). These proteins include DNA replication licensing
factor MCM7, Ran-specific GTPase-activating protein, caprin 1,
and nucleosome assembly protein 1-like 1 (the latter two proteins
were verified by real time PCR). The down-regulation of these cell
cycle regulatory proteins is in concordance with the inhibition of
DNA replication, hindrance of cell division, and hence blockage of
cell cycle progression by butyrate as represented in Cluster A
of our proposedmodel (Fig. 5). Our temporal analysis showed that
butyrate induced an early reduction in the expression of these
proteins, which plateaued after the 36-h time point (Fig. 4).
Signaling—Protein kinase A-anchoring protein 12, a scaf-
fold protein for kinases (26) that possesses tumor suppres-
sor activity, was found to be dramatically down-regulated in
both iTRAQ and cICAT data (also verified by real time PCR;
Fig. 2). Multiple intracellular kinases in the oncogenic or
survival signaling pathways have been illustrated to be key
players in butyrate actions (27, 28). Western blotting using
monoclonal antibody against the C terminus of AKAP12
showed decreased expression of the full-length protein and
an appearance of a truncated isoform at a molecular mass
FIG. 5. A model depicting pathways initiated by butyrate in mediating growth arrest and apoptosis in HCT-116 cells is proposed.
A, reduced expression of cell cycle regulatory proteins and nucleotides biosynthesis proteins led to growth arrest induced by butyrate. B,
butyrate increased the expression of tumor suppressors and proteins associated with MTP for the translocation of cytochrome c and
modulated the expression of chaperones and proteasome pathways, resulting in the activation of apoptosis cascades. C, the metabolic
machinery of the cells was altered with an increased expression of several metabolic enzymes. D, expression of cytoskeleton-associated
proteins was increased to strengthen the cytoskeletal scaffold and lower the metastasis potential of HCT-116 cells. ER, endoplasmic
reticulum; hnRNPs, heterogeneous nuclear ribonucleoproteins; ETC, electron transport chain; ECM, extracellular matrix; meta,
metabolism.
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of 	40 kDa over time (Fig. 3). Peptides from the MS/MS
spectra of AKAP12 matched to only sequences from the
N-terminal part of the protein, supporting the decreased
presence of native AKAP12, which was verified in the West-
ern blot band at 	200 kDa. The 2-DE Western blot clearly
verified the increased abundance of the fragmented protein
of 	40 kDa (Fig. 3). These preliminary data may indicate
that targeting of kinases by AKAP12 may be regulated by
butyrate, thus affecting downstream growth-associated sig-
naling cascades. On the other hand, the N-terminal frag-
ment of AKAP12 may contribute to the tumor suppressor
property of this protein. These await further investigations.
Cluster B: Apoptosis
As demonstrated in Fig. 5, the proteins in Cluster B function
as tumor suppressors, heat shock proteins, or chaperones,
players in the oxidative phosphorylation pathway or ubiquiti-
nation-proteasome pathway. The temporal changes in ex-
pression of these proteins contribute to the initiation of apo-
ptosis by butyrate in HCT-116 cells.
Tumor Suppressors—As shown in Fig. 1, tumor suppres-
sors, such as galectin-1, metallothionein-1X, prohibitin-2, and
Ras-related protein Rap-1A, displayed a temporal increase in
expression level upon butyrate treatment in this study. These
proteins contribute to tumor growth suppression by butyrate.
For example, galectins are multifunctional -galactoside lec-
tins with roles including cell adhesion, growth regulation, in-
vasion, and apoptosis (29). The identification of up-regulated
galectin-1 here (validated with Western blot in Fig. 3) corrob-
orated with previous work that showed its association with the
actions of butyrate (30, 31). We also found that metallothion-
ein-1X was markedly up-regulated by butyrate, and this was
confirmed by real time PCR (Fig. 2). The regulation of metal-
lothioneins is not uniform in all tumors. For instance, this
protein was overexpressed in bladder cancer but down-reg-
ulated in advanced prostate cancer (32, 33). Although other
metallothioneins have been found to be up-regulated by bu-
tyrate in a paradigm of increased resistance to toxic metals in
tetracarcinoma and hepatoma cells (34, 35), this is the first
report on the regulation of metallothioneins by butyrate in
colorectal cancer cells. Metallothioneins have a high metal
binding affinity for metal homeostasis and detoxification. Ex-
posure to metals such as chromium, nickel, iron, copper, and
manganese has been shown to promote carcinogenesis.
Thus, the increased expression of metallothionein by butyrate
may be related to the regulation of metals associated with
colorectal carcinogenesis.
Similarly our results also showed that voltage-dependent
anion-selective channel protein 1 (VDAC1) and ADP/ATP
translocase 2 (ANT2) were found to be concurrently up-reg-
ulated by butyrate. Their expression levels were shown to
increase particularly after the 36-h time point (Figs. 1 and 4).
These proteins are candidate regulators of cytochrome c re-
lease via the mitochondrial transition pore (MTP) for activation
of apoptotic cascades. Mitochondria play a pivotal role in
apoptosis (36, 37), and the release of proapoptotic proteins
like cytochrome c, apoptosis-inducing factor, and Smac/Dia-
blo from mitochondria is crucial in mediating apoptosis by
chemotherapeutic agents. The extrinsic apoptotic pathway
mediated by cytochrome c release was activated by butyrate
treatment (38). VDAC1 has an increased expression level as
seen from the cICAT results. It plays an essential role in the
translocation of apocytochrome c for the activation of down-
stream caspases. Overexpression of this mitochondrial pro-
tein has been found to induce cell death (39). ANT2 catalyzes
the exchange of ADP/ATP across the mitochondrial mem-
brane and has been implicated in apoptosis mediated through
the mitochondrial transition pore as well (40). The increased
expression of these regulators of MTP may contribute to the
activation of cytochrome c-mediated apoptotic cascades by
butyrate. The measurement of these tumor suppressors in
cancer cells could thus serve as monitors of the efficacy of
proapoptotic drug treatment.
Oxidative Phosphorylation—Our results clearly reflected a
trend of increased expression of the electron transport chain
complexes (Fig. 1). The rise in expression levels of these
proteins was further increased after 36 h of butyrate treat-
ment. Among the proteins, differential expression of cyto-
chrome c oxidases Va and VIb were verified with real time
PCR (Fig. 2). Cytochrome c oxidase VIb was also reported to
be up-regulated by butyrate in our previous work (17), and
Western blotting confirmed the result here (Fig. 3). The in-
creased expression of proteins in the oxidative phosphoryla-
tion pathway may be related to the enhanced mitochondrial
activity by butyrate and subsequent growth arrest and apo-
ptosis in the colonic epithelial cells (41). Our study has also
shown up-regulation of the ATP synthase subunit of Complex
V upon butyrate treatment. ATP synthase was down-regu-
lated in colorectal carcinoma as an avoidance mechanism
toward reactive oxygen species (ROS)-mediated cell death
(42). The study by Giardina et al. (43) has shown a role for
butyrate influence on ROS generation in colon carcinogene-
sis. The changes in the expression levels of electron transport
chain complexes, such as Complexes I, II, IV, and V, as seen
here may result in unstable mitochondrial membrane potential
and an increase in ROS production. Hence in addition to
possible generation of ATP from the enhanced oxidative
phosphorylation for the energy-dependent apoptosis, cyto-
toxic mitochondrial ROS production could sensitize butyrate-
treated cells to oxidative stress-mediated cell death (schema-
tized in Fig. 5, Cluster B).
HSPs and Chaperones—A temporal decrease in the ex-
pression of chaperones, such as heat shock 27-kDa protein,
HSP90, heat shock cognate 71-kDa protein, and thioredoxin,
was detected in butyrate-treated HCT-116 cells (Fig. 1). The
degree of down-regulation was shown to be reduced after the
36-h time point. HSPs act as molecular chaperones, thus
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playing an indispensable role in defense against cellular stress
such as chemotherapy-induced apoptosis (44). HSP90, one
of the down-regulated chaperones identified here (confirmed
with real time PCR and Western blot), was advocated as a
novel anticancer target (45), and its inhibitor 17-allylamin-
ogeldanamycin is currently in an anticancer clinical trial.
HSP90 is responsible for maintaining the stability of many
oncogenic proteins with biological functions in cellular prolif-
eration and apoptosis. HSP90 is known to be dysfunctional in
tumors (46, 47) and was detected to be up-regulated in trans-
formed cells. Inhibitors of this antiapoptotic protein triggered
cancer cell death synergistically with butyrate treatment (48).
The reduced expression of chaperones as shown here will
deter proper protein folding leading to protein aggregation,
ultimately resulting in cell death in cancer cells.
Ubiquitination-Proteasome Pathway—Proteasome activa-
tor subunit 2, ubiquitin-activating enzyme E1, and F-box-only
protein 2 are some of the proteins in the ubiquitination-pro-
teasome pathway that were also noted to be differentially
regulated by butyrate as shown in our results (Fig. 1). Degra-
dation of proteins via the ATP/ubiquitin-dependent pathway
mediates apoptosis (49). Targets of the 26 S proteasome
include proteins in heat shock response and cell cycle control
(50, 51); both systems were found to be down-regulated in
this study (Figs. 1 and 4). The butyrate-induced apoptotic
cascades are associated with the ubiquitin-degradation sys-
tem, and inhibitors of the proteasome act synergistically with
butyrate in anticarcinogenic therapy. In support of this, Pei et
al. (52) found that the simultaneous application of a protea-
some inhibitor and butyrate could induce apoptosis. Both Yu
et al. (53) and Giuliano et al. (54) showed similar synergistic
effects between proteasome activity and butyrate. Hence the
butyrate-regulated ubiquitination-proteasome pathway would
affect the levels of survival- and apoptosis-related proteins in
cancer cells.
Cluster C: Metabolism
Our data identified a repertoire of biosynthetic enzymes,
including those involved in the Krebs cycle and pentose phos-
phate pathway, to be up-regulated by butyrate in a time-de-
pendent manner (Fig. 1). The change in the expression levels
for most of these proteins was shown to be more pronounced
after 36 h of treatment. Examples of these metabolic enzymes
were malate dehydrogenase, oxoglutarate (-ketoglutarate)
dehydrogenase, transaldolase, and transketolase. This sug-
gested that butyrate altered the metabolic machinery of HCT-
116 cells. Most tumors including colorectal cancer depend on
the enhanced glycolysis instead of oxidative phosphorylation
for ATP production even in the presence of oxygen; this
phenomenon is known as the “Warburg effect” (55). The
metabolic enzymes found to be up-regulated by butyrate in
this study are involved in various glucose metabolic pathways
that thus promote glucose metabolism. However, unlike other
metabolic enzymes, -enolase was shown to be down-regu-
lated by butyrate. This may retard the rate of glycolysis be-
cause enolase catalyzes the formation of phosphoenolpyru-
vate, a precursor of the glycolytic end product pyruvate.
Furthermore several enzymes functioning in the oxidative
phosphorylation pathway were up-regulated by butyrate (as
discussed earlier).
Butyrate demonstrates phenotypical specificity whereby it
causes growth arrest followed by differentiation and/or apo-
ptosis in carcinoma cells but promotes proliferation in normal
cells (56). Colonic carcinoma cells derive energy via metabolism
of glucose, whereas normal colonic epithelial cells oxidize bu-
tyrate as the key fuel source for cellular proliferation (57–59).
Butyrate has been reported to induce apoptosis in the presence
of glucose and pyruvate but promote growth in the absence of
these alternative energy sources (60). Herein butyrate altered
the metabolic profile of cancer cells, resulting from an enhanced
expression of several metabolic enzymes. Metabolism of other
energy sources as fuel thus avails butyrate to effect its antican-
cer actions in HCT-116 cells.
In addition, proteins functioning in amino acids and lipid/
cholesterol metabolic pathways, such as ornithine amino-
transferase, asparagine synthetase, argininosuccinate syn-
thase, 1-pyrroline-5-carboxylate synthetase, and enoyl-CoA
hydratase, were up-regulated in this study. Leschelle et al.
(61) and Tabuchi et al. (62) have demonstrated stimulated
lipogenesis by butyrate. Ruemmele et al. (63) and Della Ra-
gione et al. (64) found that inhibiting protein synthesis by
cycloheximide blocked butyrate-induced apoptosis. In this
work, vesicular transport proteins (which function in protein
synthesis), such as vesicle trafficking protein SEC22b (verified
by real time PCR and Western blot), clathrin heavy chain 1,
and N-ethylmaleimide-sensitive factor attachment protein-
protein, were identified to be up-regulated. These pathways
were grouped under Cluster C in the proposed model (Fig. 5).
Cluster D: Metastasis and Cytoskeleton-associated
Proteins
In correlation to previous reports on cytoskeletal organiza-
tion of cancer cells (65, 66), the data here showed increased
expression of various cytoskeleton-related proteins by butyr-
ate (Fig. 1). The overall increase in the expression level of
these proteins was higher after the 36-h time point. The
concerted temporal up-regulation of these proteins such as
cytoskeletal 18, cytoskeletal 19, epiplakin, and filamins may
lead to a strengthened cytoskeletal scaffold and reduced
metastasis potential of carcinoma cells (Cluster D in Fig. 5).
Several of these identified proteins function as cross-linkers in
the intermediate filament network, modulating cell adhesion,
motility, and invasiveness. Real time PCR was conducted for
cytoskeletal 19 (Fig. 2). LIM domain and actin-binding protein,
also known as the elevated expression of epithelial protein
lost in neoplasm (EPLIN), identified by cICAT, diminishes the
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invasiveness of cancer cells. EPLIN is a cytoskeleton-associ-
ated protein whose down-regulation in cancer cells may fa-
cilitate motility of these cancer cells (67). Our results showed
that the antimetastasis effect was induced as a later event
after growth inhibition and apoptosis (Figs. 1 and 4). The
antimetastasis effect shown here corresponds to the in vivo
study done by Velazquez et al. (68) that demonstrated inhibi-
tion of seeding and growth of colorectal metastases to the
liver by intravenous infusion of butyrate in mice. Butyrate is
currently being evaluated in clinical trials and has shown
optimistic results (69).
Conclusion
A global quantitative proteomics approach was utilized in
this analysis of the temporal effects of butyrate in HCT-116
cells. Differentially expressed proteins identified from this
study were grouped according to their biochemical functions,
and a model depicting the integrated cellular processes initi-
ated by butyrate was proposed (Fig. 5). The temporal and
synergistic effects of each pathway would lead to the antipro-
liferative and proapoptotic properties of butyrate.
As shown in Fig. 4, our study demonstrated that butyrate
reduced expression of cell cycle regulatory proteins and nu-
cleotide biosynthesis proteins that led to growth arrest at the
early stage and tapered off after the 36-h time point. The
regulation of HSPs and the ubiquitination-proteasome path-
way by butyrate was less significant. On the other hand, the
expression levels of proteins that function in oxidative phos-
phorylation, in metabolism, or as tumor suppressors increase
on a temporal basis with a similar trend. Moreover there is a
greater increase in their expression levels after the 36-h time
point. The synergistic up-regulation of these proteins induces
apoptosis in HCT-116 cells. The antimetastasis effect of bu-
tyrate was most significant and strongly accentuated at the
late phase of treatment.
These signature clusters of butyrate-regulated pathways
could serve as potential therapeutic targets or proteomics
markers to assess the efficacy or toxicity of drug candi-
dates. Our data clearly showed that in addition to targeting
proteins involved in cell cycle blockage, apoptotic, and
antimetastatic pathways, butyrate also alters the metabolic
profile of the cancer cells to induce its anticancer effects. A
better understanding of the mechanism whereby butyrate
mediates its therapeutic actions would certainly aid in the
design of better therapeutic intervention. Thus, a multidrug
regimen(s) that has synergistic effects on these clusters of
pathways may be a promising pharmacological strategy for
chemoprevention of colorectal cancer.
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